Golden Gate University School of Law

GGU Law Digital Commons
California Joint Committees

California Documents

12-2-1988

The Human Genome Projects: Issues, Goals &
California's Participation
Joint Committee on Science and Technology

Follow this and additional works at: http://digitalcommons.law.ggu.edu/caldocs_joint_committees
Part of the Legislation Commons
Recommended Citation
Joint Committee on Science and Technology, "The Human Genome Projects: Issues, Goals & California's Participation" (1988).
California Joint Committees. Paper 92.
http://digitalcommons.law.ggu.edu/caldocs_joint_committees/92

This Hearing is brought to you for free and open access by the California Documents at GGU Law Digital Commons. It has been accepted for inclusion
in California Joint Committees by an authorized administrator of GGU Law Digital Commons. For more information, please contact jfischer@ggu.edu.

BEFORE THE JOINT COMMITTEE
ON
SCIENCE AND TECHNOLOGY

1

IN THE MATTER OF

2

THE GENOME PROJECTS:

3

ISSUES,

4

CALIFORNIA'S PARTICIPATION

~OALS,

Senutor John Garamendi - Chair

AND

5
6

7

.

8

9
10
11

12
13
14

TRANSCRIPT OF PROCEEDINGS
Friday, December 2, 1988

15
16
17
18
19

20
21

22
23
24
25

Molecular Biology Institute
Room 159
University of California, Los Angeles

Pike Court ReoortinQ

'

\

'

AGENDA

THE HUMAN GENOME PROJECTS:
ISSUES, GOALS, & CALIFORNIA'S PARTICIPATION
Friday, December 2, 1988
Molecular Biology Institute • Room 159
University of California, Los Angeles

8:30

9:00

REGISTRATION AND CONTINENTAL BREAKFAST

MORNING SESSION: NATIONAL GENOME INITIATIVES
JUUUS KREVANS, Moderator· UC San Francisco

9:15

THE NIH GENOME INITIATIVE
JAMES WATSON • Cold Spring Harbor Laboratory

10:00

THE DOE GENOME INITIATIVE
CHARLES CANTOR • Lawrence: Berkeley Laboratory

10:45

COFFEE BREAK

11:00

THE GENOME PROJECT: CONGRESSIONAL & INTERNATIONAL PERSPECTIVES
ROBERT COOK-DEEGAN· Office: of Teclmology Assessment

11:15

PANELDISCUSSION
KREVANS-MODERATOR
WATSON, CANTOR, COOK-DEEGAN

11:45

LUNCHEON
THE IMPORTANCE OF COllABORATIVE RESEARCH TO THE STATE'S ECONOMY
JOHN GARAMENDI - State Senator

1:00

AFTERNOON SESSION: CALIFORNIA'S PARTICIPATION
WINSTON SALSER, Moderator • UCLA

1:10

THE CALIFORNIA COMPETITIVE TECHNOLOGY PROGRAM
KENNETH GIBSON • California Department of Commerce:

1:25

PANEL 1: POTENTIAL IMPACT OF THE GENOME INITIATIVES ON BASIC RESEARCH
NORMAN ARNHEIM, Moderator • University of Southern California
DAVID COX· UC San Francisco
GLEN EVANS • The Salk Institute
WALTER FITCH • University of Southern California
ROBERT MORTIMER· Lawrence: Berkeley Laboratory

2:25

PANEL 2: DEVELOPMENT OF NEEDED TECHNOLOGIES, HARDWARE, AND SOFTWARE
ANTHONY CARRANO, Moderator - Lawrence: Livermore National Laboratory
NEBOJSA AVDALOVIC • Beckman Instruments
ELBERT BRANSCOMB - Lawrence: Livermore National Laboratory
TIM HUNKAPILI.AR - California Institute of Teclmology
MICHAEL WATERMAN- University of Southern California
NORMAN WHITELEY- Applied Biosystems

3:25

PANEL 3: UTILIZATION OF THE DATA GENERATED BY GENOME PROJECTS
ELIZABETH NEUFELD, Moderator- UCLA
A STEPHEN DAHMS - San Diego State University
MICHAEL ESPOSITO- Lawrence Berkeley Laboratory
MICHAEL KELLY • lntelligenetics Inc.
THOMAS MARR - Los A.Jamos National Laboratory
lARRY SIMPSON· UCLA

4:25

SUMMARY COMMENTS

4:40

ADJOURN

Sponsored by:

Joint Committee on Science and Technology
UC Systemwide Biotechnology Research and Education Program
Lawrence Berkeley Laboratory
California Department of Commerce

1

I N D E X

T 0

S P E A K E R S

2

3
4
5
6

7
8
9
10

11
12
13

14

15
16
17
18

Page No.
Dr.
Dr.
Dr.
Dr.
Dr.

Paul Boyer, UCLA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Julius Krevans, UCSF . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
James Watson, Cold Spring Harbor Laboratory ..... .
Charles Cantor, Lawrence Berkeley Laboratory .... .
Robert Cook-Deegan, Office of Technology
Assessment . . . . . . . . . . . . . . . . . . .
Senator John Garamendi, Fifth Senate District . . . . . . . .
Dr. Winston Salser, UCLA . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mr. Kenneth Gibson, California Department of
Commerce . . . . . . . . . . . . . . . . . . . . . . . . .
Dr. Norman Arnheim, USC, Los Angeles . . . . . . . . . . . . . . . . .
Dr. Glen Evans, Salk Institute . . . . . . . . . . . . . . . . . . . . . . .
Dr. David Cox, UCSF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dr. Walter Fitch, UCLA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dr. Robert Mortimer, Lawrence Berkeley Laboratory ... .
Dr. Anthony Carrano, Lawrence Livermore National
Laboratory . . . . . . . . . . . . . . . . . . . . . .
Dr. Nebojsa Avdalovic, Beckman Instruments . . . . . . . . . . .
Dr. Norman Whiteley, Applied Biosystems, Inc . . . . . . . . .
Mr. Tim Hunkapillar, California Institute of
Technology . . . . . . . . . . . . . . . . . . . . . .
Dr. Elbert Branscomb, Lawrence Livermore Laboratory ..
Dr. Michael Waterman, USC, Los Angeles . . . . . . . . . . . . . . .
Dr. Elizabeth Neufeld, UCLA . . . . . . . . . . . . . . . . . . . . . . . . . .
Dr. Lawrence Simpson, UCLA . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dr. Michael Esposito, Lawrence Berkeley Laboratory .. .
Dr. Michael Kelly, Intelligenetics, Inc . . . . . . . . . . . . . .
Dr. Thomas Marr, Los Alamos National Laboratory ..... .
Dr. Steven Dahms, San Diego State University . . . . . . . . .

19

20
21
22

23
24

25

Pike Court Reporting

l
2
4

29' 230
67
102
110
116
127
128
133
142
147
157
163
171
179
187
193
200
201
204
208
216
219

1.

1

Joint Committee on Science and Technology

2

December 2, 1988

3

9:00 a.m.

4

P R 0 C E E D I N G S

5
6

DR. BOYER:

7

I'm Paul Boyer, head of the University

8

of California Systemwide Program of Research and Education

9

in Biotechnology, one of the cosponsors of this meeting.

10

And I come with a perspective which in one way

11

is better than anyone else in the audience, and that is of

12

55 years since I received my Ph.D. in biochemistry.

13

at that time, the possibility that some half a century later

14

there would be a conference on looking at the possibilities

15

and problems of sequencing the human genome was just utterly

16

beyond my imagination.

And

What has been accomplished in our science has been

17
18

really a revelation.

19

to become a biochemist at the time that I

20

The wisest decision I ever m0de was
did.

But you don't want to hear about my background

21

and perspective.

22

most interesting challenges in biology, to examine the pros

23

and cons.

We're here today to look at one of the

24

We're fortunate to have as a chairman of an excellent

25

morning panel, Dr. Julius Krevans, Chancellor at the University

Pike Court Reporting
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1

of California, San Diego --

2

DR. KREVANS:

3

DR. BOYER:

San Francisco.
-- a fine clinician

University

4

of California, San Francisco -- Professor of Medicine for

5

a long time there, Dean of the college before he became

6

Chancellor, and who has had a keen interest in the development

7

of the biotechnology and related facets that come out of

8

our studies.

9

who will moderate the morning session.

10

11
12

13

And it's a pleasure to introduce Dr. Krevens

for moving you south.
DR. KREVANS:

I'd take your land, but I don't

want your science, Paul.
I would welcome all of you to this session on

14

the Human Genome Projects.

15

is a little disarming.

16

it going to be projects?

17

And I apologize

And the title right off the bat

Is it going to be a project?

Is

And what we're really here this morning and this

18

afternoon to share is a discussion of how and where we should

19

go in this exciting prospect of sequencing the human genome.

20

Now, I'm going to make the assumption that no

21

one in this audience thinks it would be a terrible thing

22

if we knew the sequence of the human genome.

23

that we should make the assumption, however, that there

24

aren't people in the United States or in the world who think

25

it would be a terrible thing.
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1

There remains a potent, and perhaps even growing,

2

group of intellectual Luddites who find the prospect of

3

new knowledge terrifying.

4

people are interested in finding out what the sequence of

5

the human genome to this logic is terrifying and awful and

6

something to be resisted.

7

And the idea that a group of

I grew up in New York City -- one of our next

8

speakers, we were talking about it -- and I recall reading

9

about what New York City was like in the 19th century.

10

We used to study history in those days in the public schools.

11

They've now given that up as you know.

12

And when I hear people railing against the internal

13

combustion engine as having destroyed the world, I would

14

say to myself that the little knowledge I have of the history

15

of New York that without the internal combustion engine,

16

given the means of transportation which preceded it, New

17

York would be at least shoulder high in the same substance

18

of which the logic of the nay-sayers is made.

19

At any rate, the interest of the University as

20

a partner in this symposium is a genuine and important one.

21

Biomedical science, biomedical research in the United States

22

is a result of a social contract between the people of the

23

United States as expressed by the legislature and the government

24

and a variety of institutions, independent research entities,

25

the National Institute

of Health itself and the universities
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1

of the United States to produce new knowledge.

2

So we have a stake, and an important one, in the

3

answers to the question as to how and when we might embark

4

on a project as exciting as knowing the sequence of the

5

human genome.
We're fortunate to have on the program today some

6

7

very interesting and, I think, informative perspectives.

8

And the first of those will be given by James Watson who

9

is formerly of a lot of places.
His office sent me an extraordinarily brief CV.

10
11

This is the James Watson CV.
Currently, Jim Watson is looking at the human

12

He has, of course, been

13

genome initiative for the NIH.

14

Professor of Biology at Harvard.

15

the Cold Spring Laboratories.

16

work at Cambridge and is one of the people who changed the

17

wa.y we even think in biology.

20

He did some interesting research

So, Jim, we're looking forward to hearing your

18

19

He's been the Director of

remarks.
DR. WATSON:

It's a pleasure to see such a small

21

group of people.

I got used to the fact that if I go to

22

a university that everyone in the audience is not there

23

to listen to me but to get my autograph.

24

inhibiting and makes me feel rather creepy.

25

now that I'm talking to people who actually want to listen
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1

to what I have to say.

2
3

Now I have the position of Associate Director
of the NIH for genome research.
And can you hear me all right?

4

5

I speak softly

and if someone could --

6

[At which time the microphone was adjusted.]

7

Is that better now.

Okay.

And if you can't hear

8

me in the back, please yell because I get lower and lower,

9

probably because I don't believe in what I'm saying so if

10

it doesn't go very far I won't get into trouble.
Anyway, I have now a position now at NIH.

11

I'm

12

also at Cold Spring Harbor.

And I have committed myself

13

to spending two days a week on the Genome Project which

14

probably won't be enough, but if I spent more, I'd have

15

to resign from Cold Spring Harbor and that would put me

16

in a bad position because it's very useful to have two jobs

17

because if you don't like what you're doing, you can say

18

that you'll resign and you'll have another one, which I

19

found useful when I was both at Harvard and Cold Spring

20

Harbor.

21

Those I have a little say because I found -- at

22

least at Harvard, not very often, and even at Cold Spring

23

Harbor -- that occasionally you had to threaten to resign,

24

not very often, but sometimes issues really count.

25

Now, I felt-- I mean there's the two talks, one
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by Charlie Cantor and one by myself -- and I feel slightly
2

weak because Charlie actually knows what he's talking about

3

and he's a pro in it.

4

really to make decisions as to which pro's to listen to.

5

So I don't know anything, and I'm going to try

6

and learn something.

7

done fast.

Eventually, we can get the project

Now, I felt -- to me it has always been pretty

8
9

And I've been brought in, I think,

obvious we should do the project.

But a lot of people,

10

at least to start with, felt it was a scandal, and really

11

intelligent people.

12

So a lot of things have been written which I think

13

we won't drag out to embarrass them later in the future.

14

I thought maybe I would give a history of sort

15

of where I see the genome project and why it's so necessary

16

and what are the phases of genetics, which I've been in

17

some form or another, I guess, now for 45 years, since when

18

I went to the University and decided I wanted to find out

19

what the gene was.

20

Now, if one looks at genetics, I think the first

21

phase was the classical Mendelian one, which was gene mapping.

22

At the turn of the century it became clear that hereditary

23

was controlled by discreet units, which got the names genes,

24

~nd

25

that these were located on chromosomes.
And really first through the work of the fly group
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1

at Columbia, it is clear that the genes were arranged in

2

linear order, which sort of made sense because the chromosomes

3

were linear.

4

on today.

5

in gene mapping, sort of the map of the nucleotide level.

And this phase of people mapping genes goes

And what we're talking about is the ultimate

But sort of showing the traits were controlled

6

7

by genes is the sort of dominant theme of genetics for about

8

40 years.

9

which genes were discreet objects, where you didn't think

And one could say that that sort of phase in

10

in terms of chemistry, we saw the banding of the Drosophila

11

chromosomes in the early '30s.

12

a complete map of the Drosophila chromosomes in the late

13

1930's at Cold Spring Harbor.

14

genetic map.

And Calvin Bridges made

So that was the first ultimate

And it wouldn't have been except that the director

15

16

had money from the Carnegie Institution of Washington.

Bridges

17

came to Cold Spring Harbor and laboriously did the banding

18

pattern.
Now, the second phase of genetics was really:

19

20

What is the genetic material?

What was it chemically?

And

21

that was interconnected with not only what the gene was,

22

but what did it do?

23

I became a student and I learned the slogan "One gene, one

24

enzyme."

25

was promoted the best, but the idea really goes back to

And that was going full blast when

And it was really at Cal Tech where I guess it
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1

the metabolic defects in man going back to around 1910,

2

and Haldane talked about it and other people talked about

3

it.
And when I was a student, it was -- I heard about

4

And then when I went to Indiana and took Luria's course

5

DNA.

6

on viruses, I certainly learned the details of transformation,

7

and that focused me on DNA.
Most people weren't focused on DNA at that time,

8
9

I guess for a variety of reasons.

One was that even at

10

that time one didn't know the chemical structure of DNA.

11

And suddenly about 1951,

12

to be a 3-5 linkage.

13

of DNA before '51 because the chemical structure wasn't

14

there.

'52, there was unambiguously established

So one couldn't have made the model

I think the number of people who were interested

15
16

in DNA at the time we found the double helix was at most

17

a couple hundred.

18

of different reasons.

19

is the gene DNA?

20

"Yes," and the biochemists would have said, "No."

And they were interested for a variety
And most people had a sort of:

What

I think the geneticists would have said,

The biochemists would have said, "No," because

21

22

they wen'

23

to be important.

24

sort of unspecific scaffold into which the interesting things,

25

the genes, were sort of attached.

il

11 protc,in chemists,

and they wanb'd proh•ins

So they preferred to think of DNA as a
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1

2

conventional viewpoint.
Paul, I guess, says that the luckiest thing for

3

him was that he became a biochemist.

4

say that the luckiest thing for me is that I didn't because

5

I probably would have become a protein chemist, very interested

6

in proteins whereas, in fact, geneticists knew that the

7

chromosomes were filled with DNA, and so they were more

8

likely -- I mean you could see Hermann Muller, he would

9

have taken the discovery quite seriously.

10

I guess you could

Anyway, that phase -- What is the Gene? -- ended

11

in '53 when we saw the gene had the complimentary double

12

helix, because if the DNA had the structure it should have,

13

it was going to replicate itself.

And that was the question

14

which the geneticists had raised:

How did it replicate

15

itself perfectly?

16

So there was Cold Spring Harbor symposium in 1953,

17

and everyone agreed -- there was only person, and it was

18

really odd, he didn't like it, and that was Barry Commoner.

19

He just was sort of mad.

20

So that phase of genetics ended as to what the gene was

21

chemically.

22

I think in more than one way.

And then the next phase was how the gene acted

23

and, essentially how you translated the four-letter alphabet,

24

four-letter messages of DNA into the 20-letter messages

25

of proteins.

And that went incredibly fast, from 1953 to

Pike Court Reporting

10.

1

1966 when the code was established and you could say we

2

had our Rosetta stone.

3

language to another.

You could translate it from one

There are still details being worked out, but

4

5

it was sufficiently a big event that people reacted to it

6

in several ways.

7

and so moved on to the brain or embryology.
And in retrospect, now you can say that they were

8
9

Some people thought the field was over

pretty silly.

But, in fact, if we come that DNA hadn't

10

come along, the DNA sequencing, you might as well be working

11

on the brain because we weren't going to get very far.
But the next phase of genetics, which really now

12
13

you see, was made possible only b¥ the discovery of recombinant

14

DNA and by working out the Sanger and Gilbert sequencing

15

methods was:

16

that's the dominant theme of genetics now.

17

function?

18

of protein factors.

19

competitive because now, in a sense, it's almost easy to

20

do because you can work out the sequence of DNA and do lots

21

of things.

22

What controls gene functioning?

What are their control?

And I guess

How do genes

And there are all sorts

And it's moving very fast and unbelievably

When we know these rules for gene functioning,

23

then we will now permit, you can say, the ultimate aspect

24

of genetics, that's really genetic manipulation and genetic

25

engineering.

And that's what many people in this room are
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1

interested in, and you could say it's the end of genetics.

2

I mean, if we know what the rules are.

3

go out and make new sorts of organisms.

4

And then you can

You could then, I think, go to the next stage,

5

whether you call it genetics or not, it is arbitrary.

6

guess I wouldn't.

7

I

Now one can actually approach the question of:

8

Really what is a cell?

9

for a cell comes from the DNA, if you can go to the DNA

10

level, you will see the instructions for how a cell can

11

divide, and you can go beyond that in embryology.

12

the DNA are all the instructions for embryologic development.

13

So if you can look at the DNA level, you actually ought

14

to be able to work out the way development occurs.

15

that will be very complicated.

16

I mean really if all the information

Within

And

And you have to -- if you say that a fly develops,

17

you have to know what is a fly.

And I guess you could look

18

at all its proteins and say that a fly is a sum of 20,000

19

proteins or something like that.

20

to the DNA level, if you wanted to find what a fly is, the

21

simplest thing is just to get the DNA sequence of Drosophila.

22

This will tell you how many genes there are.

23

to say that some are DNA binding proteins and others will

24

be any number of

25

of what a fly is.

But now that you can go

You can begin

anyway, you can begin to get an idea
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And if you have all the genes plotted out, you

1

2

can find which time they function during development, and

3

we can completely describe a fly.

4

nothing more than the instructions in its DNA.

5

that idea, maybe it's because I have no affection for flies

6

and the fact that there's nothing but DNA seeing that the

7

right proteins appear at the right time, and we'll understand

8

the fly.

9

And so there's really
And I like

It's complete reductionism.
And there probably isn't anyone who would say

10

there's more to the fly than its genetic instructions manifested

11

itself through development.

12

exiciting, but to really do it, you need the DNA sequence.

13

And if you go to humans and say, "We really want

But it will be extraordinarily

14

to understand ourself.

15

aspects of ourself," but you want the total picture, you

16

might as well go the DNA and say:

17

And it's really the instructions from the DNA.

18

We understand all sorts of different

What is man or woman?

Some people say that it's more than that.

I don't

19

want to get into any arguments, but I'll be satisfied to

20

know what's in the DNA.

21

So as a biologist, the prospect of now seeing

22

problems other than genetic problems, in terms of just the

23

instructions of the DNA, is to me very exciting.

24

could be more exciting than to

25

trying to say, "Well, how does the Drosophila brain function?"
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And nothing

you know -- if you were

13.

Well, you want to know all the proteins in it.
2

And you can lead to some people saying that they

3

are dull projects.

4

about it.

5

But I don't see any other way to go

So I think we have to go to the gene.
If we want to go to these big problems:

What

6

is a cell?

How does it divide?

7

a cell is.

In the same sense, we had to know what DNA was

8

before we could say what a gene is.

9

You've got to know what

So if you want to ask what human being is, well,

10

it's all these genes correctly functioning.

11

find out the genes.

12

ever to work on if we hadn't been able to go to the DNA

13

level.

14

your problem.

15
16

17

So you better

Cancer would be just still as bad as

When you can go to the DNA level, you can define

So if you want to define embryology, you just
better go the DNA level.
And so I think working -- and, of course, we've

18

done it in the case of viruses where we got the complete

19

sequence alligned.

20

unsatisfactory because lambda replicates in the coli cell,

21

and we don't have the sequence for coli.

22

have the coli sequence, you won't really be able to understand

23

it completely.

24

25

And it's only in the

you could say

And until you

So I guess that's my general reason for saying
we have to know the sequences if we want to, say, go on
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1

to embryology.
So if you want to say, "Well, who's going to control

2

3

the yeast world?

4

world?"

5

to own

6

have to get at it because I

7

and lots of surprises.

I would think that I wouldn't want someone else
sequence in the sense that I

th(~

think you

rc~ally

think we're going to get lots

And we ought to go forward.

Now, if you say, "Well, why until recently was

8
9

Who's going to be on top of the Drosophila

all this controversy as to whether we should do it?"
think common sense was that we should.

I

Well,

think the reason

10

I

11

was that we talked about sequencing the human genome.

12

no one can really sequence it today, so it's not really

13

a question of it's too expensive or we don't have the right

14

techniques.

15

see people wasting money, and knowing that the only people

16

who are going to do massive sequencing are sort of idiots.

17

And no one wants to see a group of idiots consuming a large

18

fraction of the national budget.

And

And so as long as you see the sequencing, you

So it was probably very bad public relations,

19

20

or at least confused the issue by saying that one is going

21

to sequence it; whereas, in fact, one should say, "Who's

22

going to map it?"

23

map.

24

who doesn't want the genetic map.

25

and really a good high-resolution genetic

And when you say that to people, I

can't see anyone

And that has to be done first, and it needs an

Pike Court Reporting

15.

1

organized program.

2

program to do the map; whereas you got into all this controversy:

3

Why spending all this money sequencing junk? which Joe Gall,

4

a very intelligent person, managed to waste his time by

5

writing that letter to Science saying that it was silly

6

to sequence junk.

7

So you're going to have to set up a

The only problem is that you don't know where

8

the junk is.

So whereas it sounds sensible, now that you

9

have introns and ectrons, and you don't know the borders

10

between genes, it would cost more money to find out where

11

the junk is than to sequence the genome.

12

be an even more ridiculous sort of effort, I think.

13

have to do the map.

14

So that would
You

And not all -- you could say -- why do we -- what

15

are the problems in getting the map?

16

are several

17

one is that we don't really know how to do it yet.

18

there are a lot of ways that might work.

19

sort of perspective that we should have is that we really

20

want the human map in roughly five years.

21

And I guess there

and Charlie will really talk about it -But

And I think the

If you said 10 years, really you will waste five

22

not making real decisions.

But if you say five years, then

23

we will then have to even organize it and you will be sensible.

24

And that says that if we get the map in five years, then,

25

hopefully, someone will have clever ideas on DNA sequencing
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,

which will reduce the costs so that we can do it.

2

That doesn't mean that we shouldn't try and sequence

3

a couple megabase fragments because that probably won't

4

inspire people to do it, and you'll actually find out the

5

true cost.

6

it's really two if you look at it closely.

7

it twice, it comes out to --you know-- you're up around

8

$10 billion.

9

I can't see the reasoning.

10

Everyone says a dollar a base pair, but I think
And if you do

And no one wants to spend that.

At least

The map -- if you can't do it for $200 million,

11

we're really in pretty bad shape, which means three to five

12

years effort.

13

will say-- and I'll just emphasize too-- we really need

14

the high-resolution genetic map.

15

And we have to do three maps.

And Charlie

And there we have to, I think most of us, rely

16

on Maynard Olson's experience from yeast; and he says you

17

have better have a mark for every million base pairs.

18

so to do that, there are various estimates that will cost,

19

say, $50 million based on how much it costs now, but maybe

20

we could do it for less.

21

And

What has happened so far has been fairly interesting.

22

It really got off the ground only because of the Howard

23

Hughes supporter, Ray White, in Utah.

24

Genetics spent some of their own money to do it in Boston.

25

And they spent their own money only because some stupid
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study section at NIH turned down the application to pay
2

for it out of NIH money under the theory that I guess it

3

was dull repetitive work and didn't show intellectual sparkle.
And so one has to have great respect and see the

4

5

need for peer review committees but also to be aware that

6

sometimes they make terrible decisions and generally don't

7

think heroically, and sometimes rather pedantically, I think.

8
9

So we're lucky that the Howard Hughes money was
there to support Ray White and lucky probably also that

10

Collaborative made the business decision and spent $10 million

11

getting it going.
The only problem is that we've got two competitive

12
13

groups.

14

And we're going to support both of these groups to go on,

15

and we hope that they will integrate their data.

16

And as everyone knows, we've got to get one map.

If they don't, then we have to in some way, I

17

guess, either decide to support one at the expense of the

18

other or withhold the money until they get together.

19

I think that we should just assume that they'll get together,

20

and we'll get the map.

21

But

And in five years, we'll have it.

Then we have to have the overlapping fragments

22

and those nodels.

And later whether that can be done by

23

clever tricks involving cosmids, or whether YAC's would be the

24

procedure is what we have to find out.

25

been given out, and I would think there's a time frame of
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1

about Wlthin one to two years, we're going to have to decide

2

what to push.

3

But at some point, I think it would be irresponsible if

4

you really think one method is much better than the other,

5

just to support the other because it happens to be in some

6

state.

7

to spread the money around, but on the other hand, we want

8

to get the job done, and there's got to be some balance

9

between actually seeing that someone can do it and then

10

And right now all you can do is push everything.

You want to spread the money around.

It's nice

putting your faith in them and getting it done.
Now, as to the organization of NIH, we have money

11

12

first in fiscal '88, and now we have money in fiscal '89

13

to the tune of roughly $30 million.

14

and hope is that it will be above $50 million in fiscal

15

'90, which should allow us to do quite a bit.

16

And the projection

Up to now NIH has just sent out -- sort of notified

17

people that will support genome studies, and a lot of grant

18

applications have come in and special study sections have

19

existed, and the money has been passed out in the absence

20

of any real plan for how to do it most efficiently.

21

Now there has been created an office of genome

22

research at NIH, and there's an advisory committee that

23

has been appointed, and we're to have our first meeting

24

on the 3 rd and 4th of January.

25

mc~mbPrs,

And I would tell you th(?

but T can't because until they've all accepted,
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1

there's some government rules that we can't announce them,

2

and some of them are obvious, and I think it's a very strong

3

and good committee.

4

And the function of this committee, I think, is

5

really to see that a plan is drawn up by the right people

6

for how to proceed and get the job done, so a real plan.

7

And at the NIH-sponsored meeting, and less than a year ago

8

there was talk that we should have a rolling five-year plan

9

and that we should update it every year.

10

And I think that's

a good idea.
Now, it would be very simple if it was only NIH,

11
12

but it's also parallel effort in DOE.

13

a memorandum of understanding between the two agencies for

14

a joint committee.

15

soon.

16

there should be a joint plan.

17

having two plans.

18

than the individual committees.

19

would indicate that we're working together.

20

And there's been

And I would hope we will meet fairly

And since there is really one genome, I think
I can't imagine the two groups

So this joint committee may be more important
I hope it is because that

The money of NIH is -- we have an advisory committee,

21

but there's no authority to give out the money, which now

22

has to go through General Medical Sciences.

23

increases, we would hope that the authority will be given

24

so that the genome office can make grants and contracts

25

itself.
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1

That's a big step because you really have to create

2

a new bureaucracy.

And you don't really want to get into

3

it until there is sufficient money to justify it.

4

the money goes up, then I think such an office will be created,

5

and then this office will begin to really look at the study

6

sections and probably give them more direction.

But if

7

And to use a term which frightens a lot of people,

8

I think we'll have to go to contracts because it's really--

9

we're not giving a grant for $1 million to do what you please.

10

We are saying that we're giving $1 million to get the coli

11

sequence or

12

a lot of people for whom the word contract sounds -- smells

13

of mediocrity.

someth~ng

like that.

I know that there are

But a lot of this work is going to be, hopefully,

14
15

routine.

16

is the best way.

17

controversy to start with as to whether we should go to

18

contracts or keep it all on grant money.

19

on your contract offices.

20

bureaucracy is good or bad.

21

And it should be managed, and probably a contract
So I'm sure that there will be a lot of

It all depends

So it depends on whether your

Besides the mapping, and something which really

22

is contract things, is going to be the whole question -- at

23

least to start with

24

supported in a variety of ways by General Medical Sciences,

25

by Howard Hughes.

of the data bases which have been

They were started when the problems were
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1

relatively simple.

2

going to have to be totally reorganized.

3

to handle them isn't clear.

4

National Library of Medicine considerable sums of money,

5

and in a sense they're a natural body to have something

6

to do with the -- at least the dissemination of the data

7

once it is collected, and I think that may be the area where

8

we're going to have to make firm decisions the soonest.

9

And everyone has agreed that they're
And who is going

A bill was passed giving the

On mapping, we don't really know how to proceed,

10

but in something like a GenBank

11

problem, which is how to give what is inherently very dull

12

work -- interest very intelligent people in very dull work,

13

which is sort of what data bases are.

14

it's too dull for me to be worried about," then it's almost

15

like nuclear power plants, they're in charge of people who

16

know what intelligent would be in the control room waiting

17

for a crisis which develops every 20 years.

18

and so on, I think a major

If you say, "Well,

And we have a separate data base system for the

19

protein sequences and for the nucleic acid and so on.

20

they have got to be put there, which means we somehow have

21

to get people that everyone generally respect to make the

22

decisions so that they will stick.

23

And

If the decisions are made by ad hoc committees

24

of people who really aren't that interested, but just show

25

up, and then you decide whether GenBank has another year,
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1

and on and on, and I think a lot of -- we could waste a

2

lot of money.

3

And I think that we have two things that we want

4

to ask for and need a lot of money, but we really have to

5

realize that it would certainly be irresponsible to other

6

people if it could be pointed out that our research -- we

7

give money to grants to people who wouldn't get it through

8

an R-01 system.

9

That's why I'm actually pleased that we have such

10

a good advisory committee for NIH because I think that we

11

can't stand as the conscience to see that this dull work

12

is not done wastefully.

13

Now, maybe the last thing I should say is that

14

all our discussions of the relative roles of NIH and DOE

15

all sounds like we're the only

16

but, in fact, the project has excited enormous interest

17

throughout the world, and we don't own the human genome.

18

And other nations are go

19

to have to collaborate with a lot people.

20

who are doing it;

to be involved, and we're going

And toward that end, we've set up a human genome
And it's

organization.

22

aim, I think, will be certainly to keep everyone informed

23

of what everyone else is doing through holding meetings

24

and, hopefully, actually to have an even more greater world

25

Johns

s is the head of it.

21

for how to do

t so that we don't get totally in a
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1

competitive situation.

2

I see no reason why within the United States there

3

really has to be competition, I mean in a sort of nasty

4

sense.

5

and they will be rewarded by having bigger roles.

But in

6

the world we really have to somehow get together.

And the

7

first place that we're going to have to do something is

8

on the data bases and seeing that they're set up.

9

Naturally, some groups will work better than others,

So I expect that I and I'm sure Charlie will spend

10

more time than we want to going to meetings about seeing

11

that the data bases are done correctly.

12

Ideally, the cost of the project could be shared,

13

one-third by Japan, one-third by Europe and one-third by

14

the United States, or roughly some sort of thing.

15

this will happen, I don't know.

16

Whether

We both, I guess, have a sort of fear, unless

17

we act intelligently at least, that the whole sequencing

18

end of the project will be done by the Japanese.

19

other hand, when you get near them they say, "We don't have

20

any money to do anything, much less help pay for anything."

21

On the

So I don't know what the final answer should be,

22

but I think that if we're going to provide data to the other

23

parts of the world that it should be reciprocal at least

24

in terms of cost.

25

maps across the Pacific at the expectation that it's a free

We just shouldn't send all our genetic
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1

I'm sure that there will many tortured negotiations,

2

But I

3

which always have some reason for not succeeding.

4

can just

5

of individual scientists, the Japanese that we know, we

6

like and they're a

7

that we

ther.

an work

sure to be with.

It s just that everyone sort of expects that the

8

United Sta tcs has paid for science, and

9

science, and they he

10

rest of the world is

11

I think we've

12

support.
think, will come together.

I

15

be the body that would final

of ethical issues, which

18

l

19

11
f

i

them wil
of

a battle of

25

There's

ly, I would guess, would
some money.

Now, as to my last thought, it's on this sort

16

24

But the

s wealthy as we are and, therefore,

an initiative in the EEC and

23

has paid for

the rest of the world.

14

2

NIH

to work to try and actually get some real

Europe,

13

17

And at the level

I

think are

-- we

work

thi

ion is go

rema

t because the
to educa

them as

to tell us.

Many

matter how we try -- essentially
And

go

to have to constantly fight

who don't understand what we are doing

or really don't want us to do what we are doing.
And I think that we should, at the level of the
nome program, pass out money, and I think it should be
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1

one of the functions of our advisory committee as to how

2

much, under the circumstances, to discuss the ethical issues

3

through the holding of courses, through the writing of books,

4

through mass meetings in one which talks genetic screening

5

and what it means and doesn't mean.

6

belong to, the police or to yourself?

7

issues.

And who does your DNA
These are important

Actually, at Cold Spring Harbor this week, we

8

9

are having a meeting that I had to miss on DNA fingerprints

10

with joint funding partly from legal bodies, or the police,

11

and partly from the companies who are selling the fingerprint

12

methods.

13

some legal types to really come in to the question.

14

I think we're going to have to fairly soon have laws that

15

at least define that if some of your blood is taken what

16

rights someone else has to look at your DNA, not only to

17

see whether you are actually the son of your parents, which

18

could be great mischief if in the wrong hands.

And we have a federal appeals judge and we had
And

It would be silly to go under the assumption that

19

20

since we now can screen for things, we won't be able to.

21

And I feel very strongly that no screening should be done

22

without someone's consent.

23

seems because many people give consent knowing not what

24

they are doing. And, in fact, should you be asked to give

25

consent?

And that's not as easy as it
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If we found that schizophrenia was due to some

1

2

transposable ailment or something which gets such high frequency,

3

and we could really detect it, then you don't want someone-- you

4

don't want the right before you hire someone to look at

5

the person's DNA to spot the things that your group health

6

insurance doesn't cover.
We raised the ethics

7

it was fairly interesting -- the

8

ethics question in front of HUGO, and I was really amazed

9

at some of the clinical geneticists, ethics was terrible.

10

I mean really it was sort of a pain because you had to deal

11

with ethicists, and they're a phony lot.
But maybe we don't have to deal with ethicists.

12
13

We have to become one ourselves.

I think maybe rather than

14

passing it off to other people, we need to become part of

15

the discussions instead of thinking that we can hire ethicists

16

who are going to solve the problems.
The people in the room, I don't think that you're

17
18

going to have to spend much of your time talking about ethics

19

or thinking about it.

20

better think about it a lot because we certainly don't want

21

to mislead Congress.

22

we're going.

23

correct.

24
25

But I think that at my level I'd

We'd better be very frank with where

And I think that what we're doing is completely

But just the thought of all the complications
of a national register of DNA, it sounds very good.
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1

apparently the time on that is running down, Charles, so

2

you better make up your mind quickly.

3

Dr. Cantor had the good sense to be born also

4

in New York City, and then had his education at Columbia,

5

undergraduate, and then took his Ph.D. at the University

6

of California in Berkeley.

7

as a geneticist, and brings to the problem -- and the exciting

8

initiative of the human genome project/projects, et cetera -- an

9

extraordinary record of accomplishment and a promise of

10

an exciting colleague for those of us at the University

11

of California.

12

Charles.

13

DR. CANTOR:

He has had a distinguished career

In trying to figure out what to say

14

to you this morning, I called Jim last week in New York

15

and asked him what he was going to say, and he said that

16

he didn't know.

17

I think, as you'll see, I've guessed at least partly right

18

in figuring out how to follow him.

19

So that made it a bit of challenge.

And

Jim has really painted a beautiful overview of

20

the history of this project and stressed sort of really

21

way into the future some of the ethical implications.

22

What I'm going to try to do is to fill in the

23

middle ground and try to give you a feeling, in a little

24

bit more detail, for the scope of the project.

25

is the Humane Genome Project?

What exactly

What does it entail?
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If we actually look at such a chromosome by electron

1

2

microscopy, rather than by a light microscopy, what you

3

see is shown here.

4

up the sort of core of the metaphase chromosome, covering

5

almost the entire rest of the slide, probably not visible

6

to anyone over the age of 40, but younger people can see

7

little hints of single DNA fiber on the left.
I estimate that on this slide, you're looking

8
9

This is the protein scaffold that makes

at somewhere between 50 and 100 million base pairs of DNA.

10

So these are really incredibly large molecules by anybody's

11

standards.

12

like this.

Our goal is to learn the structure of a molecule

We can't work with these molecules today.

13

The

14

kinds of molecules that

15

are shown here.

16

This is a single molecule of lambda DNA.

17

pairs long, give or take a factor of 2 or 3.

18

kind of material that we really can manipulate biologically

19

today.

20

as much of as we want to, understand the genetics of and

21

so on.

22

we'~e

much more comfortable with

Jim actually mentioned bacteriophage lambda.
It's 50,000 base
This is the

This is the kind of stuff that we can clone, have

Now the problem in trying to describe the Human

23

Genome Project is that we're crossing many, many orders

24

of magnitude and size and dealing with a number of different

25

descriptions on the human genome.
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order.

And this is, I think, the area where the technology

2

is in the greatest state of flux at the moment.

3

return to that theme a few times.

4
5

And I'll

But this is still a physical map because you're
dealing directly with DNA molecules.
Now, the other type of map, which is really totally

6

7

different, is a genetic map which for a human is a linkage

8

map.

9

where the two inheritable markers -- Huntington's disease,

You measure biotic recombination, that is you measure

10

blue eyes, or what have you -- where they are coinherited

11

and passed from a parent to a child where they can separate.

12

And we know, as Jim already mentioned, that the order of

13

the markers on such a map is linear and must correspond

14

to the same order as their gene on the physical map.
Unfortunately, the relative distances along these

15
16

two maps in the human, and in other mammals, is variable.

17

It is the meaning of this that prior to gening things in

18

base pairs can vary by a factor of 100 on different regions

19

of the human genetic map.

20

which will have to be dealt with.

And this is a very serious complication

A second problem is that recombination does not

21
22

occur uniformally throughout the human genome.

And so,

23

in fact, the genetic map in many respects is a discontinuous

24

map.

25

to discriminate between genetically, followed by other clusters.

It will have clusters of genes that are rather difficult
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1

That's a major problem, and we need new technology to try

2

to deal with that, and people like Dave Cox in the room

3

are really in the process of developing that technology

4

which could produce maps that are sort of almost hybrids

5

between genetic maps and physical maps.

6

Now, one of the other problems in thinking about

1

these different types of descriptions of the genome is that

8

they occur on very different size scales, and that's summarized

9

for you here.

The Human Genome Project overall, the goal,

10

is to get a fine genetic map, complete your physical map,

11

acquire the genome as a set of samples in freezer, clone

12

DNA, or amplify DNA and determine the complete sequence.

13

Find all the genes.

14

There are somewhere between 50 and 100,000 genes
in the human genome.

16

half of these, as far as we know, are brain specific.

17

we probably have no other way to get those genes except

18

19

20
2

Each one codes for a protein.

Roughly

15

this type of global approach.

And

It's rather difficult

to do biochemical ,p_xperirnents on the human brain.
The goal is to find all the genes, and really
the most important goal, and I think the goal that many
of us have stressed since the onset of this project is in

23

addition to getting all this information to develop the

24

tools to use it for interesting biology in medicine.

25

And that really means two things.
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1

to have improvements in technology that allow us to do rapid

2

comparative studies and to have parallel records on a series

3

of different organs because a human is not an experimental

4

animal.

5

do direct experiments to test what it does.

6

parallel studies

7

is probably less interested in those organisms, or less

8

excited anyway, than they are in the human.

9

the goal of the project.

10
11

If we have a human gene, it's very difficult to

o~

So we need

the mouse, Drosophila, even though Congress

And that's

And this project covers almost

10 orders of magnitude in scale.
And I want to quickly give you a feel for that

12

because I'd like to convince you that the

13

the types of information we're likely to get, and the types

14

of technology that we need to work across these different

15

areas vary tremendously because we're covering such a wide

16

size range.

17

types of thinking,

So you'll find a model of the human genome as

18

the earth as seen from outer space.

19

the whole genome.

20

It's an aerial view of the city of Chicago, which I don't

21

know if you can see these.

22

It's very interesting, but it's still fairly coarse.

23

That corresponds to

On this scale, this is the genetic map.

So this is the genetic map.

The physical map is about a factor of 20 in higher

24

resolution.

And you're now looking at Soldier Field in

25

part of Lake Michigan.

This is the physical map, but you
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1

can't sequence directly from such a scale.

2

correspond to a typical clone, at least that's ready for

3

sequencing.

4

base pairs, and the actual sequence itself is represented

5

by this, which is a lOx magnification of man's hand.

6

the problem with this project is that it covers a very large

7

range of size scales.

We're now down to the scale of about 5,000

So

Now, there are several things about this project

8
9

This could only

that I think are unique.

And this slide is really made

10

to -- more or less for a different audience, but I think

11

it's -vmrth going through.
Unlike most other large -- first of all, I should

12

13

say this is biology's one large science project.

14

most large science projects, this one is basically closed-ended.

15

It's feasible, and we know where the stopping point is.

16

Unlike many large physics projects, I think that we can

17

guarantee that the results will be interesting, no question

18

about it.

19

all large accelerators, right?

20

Unlike

And that, unfortunately, has not been true for

I think we could also guarantee that an important

21

new technology will emerge as the project proceeds.

22

the reason for this is that I think all of us have accepted,

23

and Jim has really underscored already, that we're going

24

to do this project as an evolving technology model.

25

is that rather than try to slam into the project with today's
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1

technology, even though it is feasible, we're going to basically

2

develop new technology over half a decade, and maybe the

3

one percent of the overall project with at least sequencing

4

with today's technology.

5

in order of magnitude better do about 10 percent of the

6

sequencing project.

1

from now, start the completion of the project with technology

8

that we can't even anticipate today.

9

And then, hopefully, with technolgoy

And then finally, maybe in 10 years

The other thing that is unique about this compared

10

to most other large science projects -- and this is really

11

a challenge -- is that coordination of work at this first

12

location is necessary.

13

do all of this project in one place.

14

make it politically unsalable.

15

There is no particular reason to

So we have to coordinate it.

And I think it would

And I think scientists

16

are, by and large, individuals and not terribly used to

17

being coordinated.

18

mechanisms of doing this.

19

biggest challenge for the project.

20

And we need to develop some effective
And I think that's probably the

Let me give you a scorecard of where we are and

21

where we are going.

22

about how far we have to go.

23

six months ago.

24

I think this is helpful in thinking
This slide was made about

It's out of date.

The largest continuous DNA sequence now known

25
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1

it's 250 kilobase.

It's about the same size as the smallest

2

chromosome that has more or less all the goodies we think

3

of when we think of what a chromosome is biologically, which

4

is roughly a quarter of a million base pairs.
The largest genome where we have a complete contiguous

5

6

library and a fine restriction map, where we really have

7

a good description, and probably the first genome that will

8

be sequenced is the E. coli, which is .46 megabases.

9

largest autonomous piece of DNA, where we have any kind

10

of complete map at all is just a little bit bigger than

11

that.

12

6 million base pairs and, in fact, we have a complete map

13

of the S. pombe genome.

14

also has a complete map.

15

size scale.

It's the largest S. pombe

chromosomes,

The

just under

And I think Maynard also virtually
So mapping is feasible on this

But the human genome is 3 billion base pairs,

16

17

and it's not so easily subdividable.

The smallest human

18

chromosome is 50 megabases.

19

is a quarter of a billion base pairs and, unfortunately,

20

these don't grow individually.

The largest human chromosome

A number of groups in the national labs have developed

21

22

methods of sorting individual human chromosomes to hand

23

you this.

24

it wouldn't be that much more romplicated than the yeast,

25

but you can't get very much of it, unfortunately.

And if you could get enough of such material,
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And people -- many people have developed methods

1

2

basically of cloning human chromosomes in hybrid cell lines

3

so that you have a single human chromosome living in a rat

4

cell, or a hamster cell, but the problem is that you still

5

have the rat or hamster's background so that these numbers

6

don't look very much bigger than those numbers.

7

like almost a factor of 3, a stretch from yeast to human.

8

But that's very misleading because this purified and this

9

is contaminated with all of that.

It looks

And working on human

10

maps is much more difficult than working on yeast maps.

11

And I'll come back and show you that.

12

Now, the human genome is three gigabases, in the

13

physicist's language, but that number doesn't impress physicists.

14

If you want a really large number, our goal in the long

15

run is not to understand simply a single-reference human

16

being, because that's basically almost useless, but we want

17

to be able to compare human beings because that's how we're

18

going to learn about interesting human diseases.

19

And if you realize that there are 4 billion humans

20

on the earth, and we differ each of us from another, at

21

the average of 3 million base locations, if you multiply

22

3 million by 4 billion, you get 12 x 10

23

That's the size of the data base we really need to describe

24

human diversity.

25

to get.

15

, 12 picabases.

That's ultimately the information we want

And that is really tough.
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That's a large data base from anybody's point

1

way off.

2

of view at the moment.

3

acquisition, we need to have vastly superior technology.

And to even dream about such data

Now, let me spend a few minutes just showing you

4

5

how vlC: make maps to give you a fee ling for what's invol V('d,

6

and why a human is much harder than bacteria.

7

There are basically two approaches.

8

called in slang top down and bottom up.

9

and conquer.

'l'hey are

This is the divide

This is the constructionist approach.

In the top down approach you take a chromosome,

10
11

you cut it into pieces, you figure out the order of the

12

pieces.

13

you subdivide it again, reorder it and so on.

14

pretty feasible, but it works at relatively low resolution.

15

If you want more information, you take each piece,
This is

The bottom up approach, you take a principal randomly

16

selected piece of DNA, you try to fingerprint them in one

17

way or another, you find identifying marks on them, you

18

look for correspondence between identifying marks, and you

19

link up by finding such correspondences, adjacent clones.

20

Such maps can be extremely detailed; at least in the beginning,

21

they are very, very efficient to construct, but they are

22

almost impossible to complete, probably impossible to complete

23

for any higher organ.

24

now feel that a combination of these two approaches is going

25

to be what is effective for human mapping.

And, in fact, most of qs, I think,

Pike Court Reporting

(805)658-7770

41.

Let me show you just what this looks like at two

1

2

extreme levels to try to convince you that humans are not

3

bacteria.

4

If you take the E. coli genome and you cut it

5

into pieces, the genome is small enough and the pieces are

6

big enough so, in fact, we actually can fractionate -- what

7

you're looking at is separated DNA pieces ranging in size

8

from 50,000 base pairs up to about l million base pairs -- we

9

can separate every one of those pieces -- in this case the

10

genome has been cut into just 22 fragments -- and making

11

a map is simply determining the order of those pieces.

12

critical thing is that you can see all the pieces.

13

know how many there are.

14

to be relatively simple.

The

You

Putting them in order turns out

If you do the same experiment with the human genome,

15
16

the human genome is cut in the same way into 3 to 5,000

17

pieces.

18

that would allow us to subdivide the genome into a smaller

19

number of discreet fragments.

20

working on such techniques, but they're not functional today.

21

And this is an area where great technology development is

22

needed.

23

And right now we don't have existing techniques

People like Dave Sigman are

Unless we have it, we're faced with the fact that

24

we have to do a jigsaw puzzle with 3 to 6,000 pieces, and

25

we can't see the pieces.
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challenge.
2

How do we do it?

Well, we do it slowly and painfully

3

at the moment.

4

already exists.

5

points for us that is based on the average about 10 million

6

base pairs apart.

7

genome are average about 1 million base pairs in size.

8

We start with the genetic map because that
And today's genetic map provides anchor

The pieces that we can cut from the human

We can take each gene whose location we know on

9

the genetic map and use it as a physical DNA probe to identify

10

the corresponding large DNA piece on which that gene resolves.

11

And the trouble

12

what happens is we link up the physical map, and it's complete

13

because the genes are close together.

14

when we do such an experiment in coli,

In the human genome, the genes we know of today

15

are far apart, and so these fragments are very distant

16

from one another, and we have to somehow bridge the gap

17

between them.

18

And this slide is meant for a fairly technical

19

audience, and I'm not going to go through it in detail.

20

Some of the methods are easy to understand, some of them

21

are difficult, but they all work.

22

a simple one because I think it really does represent where

23

the future is going.

24

25

But I'll show you just

These are large pieces of DNA that have been generated
by cutting the genome with a particular enzyme.
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1

out that it's possible to get now quite efficiently small

2

small pieces of DNA that overlap to large pieces of DNA,

3

that is they contain on them the same cutting site that

4

generated two adjacent large fragments.

5

can be used as analytical tools to identify the two large

6

DNA fragments and prove they're adjacent.

7

to be a rigorous and relatively effective method of making

8

maps.

Such linking probes

This turns out

I'll show you one example here for the human which

9
10

I like particularly because it deals with molecules that

11

are very, very large.
This is data from chromosome 21.

12

These are two

13

adjacent DNA fragments on chromosome 21.

14

by the same DNA probe.

15

base pairs, the other one of them is about 2.7 millibn base

16

pairs.

17

fragments are the same in most cell lines, but not all.

18

And this single probe then actually makes a map of two fragments

19

that cover 5 million base pairs over more than 10 percent

20

of the whole chromosome.

21

making a very low resolution map.

22

These are illuminated

One of these fragments is 2.5 million

These are a different set of cell lines, and the

So this is a very easy way of

Now, they probably need to think about over the

23

next couple of years is how not just how to make a restriction

24

map but how to actually make it in the order of a library,

25

how to actually possess pieces of DNA in order in a form

Pike Court Reporting

(805)658-7770

44.

1

where they amplify, where we have as much of them as we

2

want.

3

strategies to do this.

And a number of people have been thinking about effective

4

And many of those strategies boil down to this

5

type of an approach in which you try to make a yeast artificial

6

chromosome library of DNA fragments and make n complimentary

7

small library of ordinary size clones, but these are linking

8

clones, and so they overlap two adjacent yeast clones, and

9

then in principle such linking clones could be used efficiently

10

to tell you that two larger clones are adjacent.
And if anybody could get this strategy to work

11
12

in practice-- there's not at the moment-- then it would

13

probably be a very efficient way to put a genome together.

14

And a number of people are developing alternative ways to

15

do this.

16

fingerprinting methods for DNA fragments.

17

and Sydney Brenner are both worried about efficient ways

18

to actually do this step, which turns out to be very time

19

consuming at the moment, and Bob Mortimer and Mike Esposito

20

at Berkeley are looking at alternative ways to do some of

21

this.

22

Jim that in the next year or two we're going to see explosive

23

developments, and then we'll be able to make an evaluation.

24

25

Tony Carrano in the room has been developing effective

So I

Cassandra Smith

think that this is an area where I

But there's a problem, and it's this:

agree with

In any

mapping project, and it's also true for sequencing, it's
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1

very easy to start but very hard to finish.

2

this question for you:

3

a map that somebody has erased 20 percent of the lines?

4

It's very difficult, right?

How do you navigate if you have

What do we do about that?

5

And so I pose

Well, we don't have

6

any answers at the moment, but I'll show you what the problem

7

is.

8
9

One of the major justifications for doing the
Human Genome Project, for doing whole chromosome maps, whole

10

genome maps, is an economy of scale.

You have a chromosome,

11

and you want to make a complete map, any piece you get from

12

it, any clone you get from it to start with is as interesting

13

as any other one.

14

You don't have to do sorting.

So you have a tremendous economy of scale.

15

The moment that you are forced-- let's say we

16

have a map that's complete except we have a hole in this

17

region -- the moment you are forced to focus on one region,

18

unless you have an efficient way to go into this region and

19

cut it out, you're back to facing the fact that you have

20

to sift through large numbers of fragments, most of them

21

are uninteresting, but you've done the Hork anyway, and

22

so the economy of scale is lost.

23

which even for mapping are too expensive to be realistic.

24
25

And you're back to problems

So what we desperately need is some new technology
that will allow us to focus, let's say, on a region of DNA
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1

that's of particular interest.

2

Now, this is a realistic problem.

This is a serious

3

problem today, and it's because of the following:

4

out that a certain fraction of the human genome -- we don't

5

actually know what that fraction is, but we know it's

6

significant -- is not clonable.

7

it in any vectors that we have today.

8

And so in any attempt to make a map, there are going to

9

be segments that are simply not represented.

10

It turns

You cannot immortalize
It's not clear why.

Nobody has

probes, nobody has clones.
So how do you get into such regions and work

11

12

with them?

Well, I think the seeds of the technology arc

13

there, but they need to be developed.
One of the things that I'm interested in trying

14

15

to stimulate at Berkeley is the development of methods for

16

working with single DNA molecules because, in principle,

17

if you had this molecule, and that was the region you wanted,

18

and you had the appropriate micromanipulation methods, you

19

would just go in and cut out that piece.

20

use the PCR technique

21

that technique are in the room -- to actually amplify this

22

material even if you couldn't clone it, you could at least

23

have some of it to work with.

24

that we're going to solve the problem of completing maps,

25

but thZI t

And then you could

and several of the developers of

So that's one possible wa;r

is just a speculation at the moment, zmd it remil in[;
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1

to be seen.

2

Well, let me turn now from the science to the

3

organization.

And these are the major players and how I

4

see them in the U.S; NIH and DOE.

5

is unclear to me at the moment.

6

it.

7

in the Human Genome Project, or will be.

8

to me that a lot of the large pharmaceutical companies are

9

interested in this.

The role of private industry
I'd love to hear more about

I'm sure that the instrument makers are heavily involved
But it's not clear

There is tremendous foreign interest.

It is my impression that thus far that interest

10
11

is mostly intellectual.

12

commitment on the part of most European countries today.

13

Italy has probably been in the most advanced position in

14

investing money except for the U.S.S.R., which apparently

15

has in this fiscal year allocated 15 million roubles for

16

the Human Genome Project.

17

corresponds to in dollars, but it's a lot.

18

fraction of the U.S. genome project.

19

the U.S.S.R. has a significant fraction of the U.S. talent

20

to go along with that funding right now, but we shall see,

21

and HUGO is going to attempt to coordinate all of this.

22

There has not been a large financial

I don't know exactly what that
It's a significant

I don't think that

Let me spend just a couple of minutes giving you

23

a sort of view of what DOE is doing.

24

charts.

25

major things.

DOE loves organizational

And I just really want to point out to you two
DOE is supporting research today at both
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1

universities and industry and at the national laboratories.

2

Roughly, at least in the future, the support ratio between

3

these two types of projects is estimated at about somewhere

4

between 1-2 and 40-60.

5

go to the national laboratories, but not by much.

6

fraction will be in extra

7

So the majority of the funding will
A significant

[inaudible.]

The work at both the national labs and universities

8

is judged by peer review panels, a slightly different mechanism.

9

All this is coordinated by the Office of Health and Energy

10

Reseach which has an advisory committee somewhat affluent

11

as far as

12

slightly different about the DOE organization today is something

13

that needs, and I hope will be coordinated with NIH, is

14

something called the Human Genome Steering Committee.

15

is actually a committee made up of some of the major contractors,

16

and it is designed to actually try and coordinate the science

17

at a very intense level.

18

be seen, but it is just beginning to function, and in a

19

moment I'll show you what it consists of.

20

I

can tell to an NIH council.

vvhat is new and

That

How it will function remains to

And it's going to mostly function by setting up

21

specific task forces to try to deal with problems like data

22

bases.

23

coordinated intimately with NIH activities, Hughes activities,

24

and foreign activities.

25

And I suspect that most of these will wind up being

I want to stress what Jim has already said.
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1

really is only one genome project.

There are many players.

2

And the major challenge is how to coordinate all of these

3

efforts.
Now, I thought I'd just show you what DOE is actually

4
5

supporting today.

The large support at the national labs

6

is mostly at three, Los Alamos, Livermore and Berkeley.

7

There are smaller levels of support at Oak Ridge and Brookhaven.

8

There is support at a number of universities, one foreign

9

grant in Yugoslavia, and all the rest in the U.S., and then

10

a number of companies, a number of small businesses have

11

some smaller levels of support.

12

That is the current program.

DOE's budget for the Genome Project in FY '89.

13

It was $18 million.

14

$28 million in fiscal 1990, we hope.

15

It will probably be something around

This is the Human Genome Steering Committee, which

16

I chair for the first two years.

17

from

18

from Livermore, myself.

19

from OHER, that's EOE, Elke

20

at NIH, and Diane Hinton from Hughes.

21

It consists of representatives

George Bell of Los Alamos, Tony Carrano who is here
It has ex officio representatives
Jordan who is Jim's assistant

And its charge ... ~ and it remains to be seen whether

22

it can live up to this charge is to coordinate at least

23

the DOE funded effort striving for the same degree of cooperation

24

and efficiency that would occur if everything was in a single

25

location; obviously, it isn't.
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This committee actually exists.

And to prove

2

that, it has met once.

3

just last week by Tony Carrano, who I'm sure never thought

4

I'd shmv it.

5

national labs.

6

they have always had great photography.

7

It's just getting started.

8

things look quite frightful.

This slide was kindly sent to me

This shows one of the great strengths of the
I think it's important to keep in mind that
That is the committee.

We're in our infancy, and obviously

Now, let me spend a couple of minutes first seriously

9
10

and jocularly talking about the differences between NIH

11

and DOE.

12

project different points of view, and that there really

13

is in the true Hegelian sense, that the opposites will actually

14

complement and make a stronger project overall.

I think that both agencies are bringing to this

I think one of the

15

thihgs

to stress

Jim

16

didn't say it, so I will

17

people who by and large are waiting with bated breath for

18

some of this data are mostly supported by NIH.

19

say theirs is a retrospective view.

20

suggest that NIH will change and move a lot closer to the

21

DOE view.

22

is NIH really represents the

And I should

And Jim's comments really

But NIH, at least in the past, has distributed

23

most of its resources in relatively small aliquots, individual

24

research grants.

25

strongly committed to study a number of different organisms,

There is no question that NIH is very
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1

and not just human.

2

supporting extensive high resolution human mapping.

3

And there's no question that NIH is

DOE is very comfortable with long-term large projects.

4

It has mechanisms to coordinate efforts tightly, particularly

5

those in the national labs.

6

in engineering, which I think turn out to be major parts

7

of the Genome Project in terms of technology that needs

8

to be developed.

9

totally limited to human physical mapping and sequencing,

10

And its emphasis at the moment is almost

not genetic mapping, not parallel studies in other animals.
Both agencies, I think, are strongly committed

11

12

It's very strongly computing

to supporting technology development, which is the future.
This is one way, I think to try to summarize what

13
14

I've just said.

DOE is strong in engineering and NIH is

15

strong in biology.

16

that.

I think that no one would disagree with

This is another way, I think, to try to illustrate

17
18

both the organizational problems and the differences.

19

is putting a large amount of its funds into interdisciplinary

20

efforts at the national labs, or relatively large programs

21

in other places.

22

and smaller programs which may combine instrumentation and

23

materials.

24

combine all of these at a single location.

25

DOE

NIH is supporting a lot of terrific biology

But it was unlikely, at least in the past, to

And there are advantages to this.
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1

a much higher probability of innovation.

And there again when

2

you're trying to get a boring job done, it helps to have

3

a structure like this to do it.
Let me turn back to science for a second.

4

I'm

5

trying to decide one piece of science to highlight, and

6

naturally I will choose something that's related to something

7

that we're working on.
But this starts from,

8
9

I think, one of the most

interesting things which has emerged in the Human Genome

10

Project in the past year is a discovery by Bob Moyzis

11

Los Alamos of a DNA probe that detects the end of the chromosome

12

of all higher organisms, that's both its strength and

13

weakness.

14

cell, in a mouse cell, a hamster cell or what have you.

15

Unfortunately, in the hamster it also detects centromeres,

16

which makes it not so useful in the hamster.

17

. .._

l t.-S

It detects the ends of the chromosomes in a human

Now, this is a great probe, but the trouble was

18

that it looked at every organism.

19

And to actually take advantage of this for human studies,

20

it was necessary to try to find a probe like this that would

21

be human specific.

22

in the last few months by using Bob Moyzis' approach.

23

It was not human specific.

And we were able to find such a probe

And the scheme which we used is a very simple

24

one.

We gambled that if we took half a yeast artificial

25

chromosome and demanded that it lie in a free-living form
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1

that we could compl~ment its missing head with the end of

2

a human chromosome.

3

of the human chromosomes then we could select these out

4

of the bottle and clone them in yeast.

5

correctly as it turns out, the human genome telomeres would

6

be functional in yeast.

7

If we had a bottle containing the ends

And so we've actually

Because we gambled

fished out clones, and

8

this is one of them which have on their end Bob Moysiz's

9

repeating sequence still in yeast, so we know where it came

10

from.
Fortunately for us, the first clone had a human

11
12

ALU repeat, the kind of thing that Carl Schmid studies here,

13

so that we knew it had to be human.

14

not exist in yeast, and we were very lucky because this

15

region turned out to be a human specific -- at least in

16

most, if not all, human chromosomes

17

DNA sequence, which we're beginning to characterize in some

18

detail.

19

Why is this so important?

This sequence does

the human specific

Well, if you're going

20

to make maps, one of the biggest problems that you get into

21

is not knowing left from right.

22

molecules, as you start to map you don't know \vhat direction

23

you're

going in.

Since we can't see the

The only way that you would know what

24

direction you were going is by starting at one end.

25

you start at one end, the maps are unequivocal, and in roughly
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1

10 percent of the effort you can at least creep about 20

2

percent of the way down a chromosome.

3

such clones we now have the ability to start from chromosome

4

ends.

5

And, of course, the ends are biologically interesting.

And so by having

And I think it's going to make things much simpler.

6

Now, in the last few minutes let me start with

7

why we do this, what's coming out of it and where we are

8

going in the future with this project.

9

The most interesting reason to have high resolution

10

physical maps is to find genes.

11

if we actually possess the DNA in this region.

12

genetic map tells us is that Gene B is between Gene A and

13

Gene C; if we're lucky, we can combine some information

14

about where in between.

15

We have a physical map

But, frankly, in those cases as you really bump

16

the resolution up, it doesn't tell you where.

17

you that it's in between.

18

What the

It just tells

But with the physical map, which after all is

19

10 or 100 times more detailed, you begin to know where to

20

look for Gene B.

21

in where this is.

22

like those that Dave Cox is developing may start to cut

23

down on that uncertainty considerably, but right now it's

24

a real mess.

25

The problem is that there's a lot of uncertainty
And as I mentioned earlier, techniques

How do you know when you've found the gene you're
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1

looking for?

2

you have that correspond to that gene.

3

there will be disease alleles that represent cataclysmic

4

rearrangements of the DNA of the genome, translocations,

5

deletions,

6

Well, that depends on what disease alleles
If you're lucky,

insertions, something major.
This shows,

for example, the case of Duchenne muscular

7

dystrophy where roughly half of the known disease allele

8

are large deletions; and,

9

It's 2 million base pairs.

furthermore,

the gene is gigantic.

So the gene is of the same order

10

as the resolution of the qenetic map.

11

Duchenne dystrophy once you're in the neighborhood of the

12

gene, you're in the gene.

13

alleles, or deletions, the material in the region is missing,

14

and you know that you are there.

15

case, and I

16

remains to be seen.

17

So in the case of

And you know it because the disease

That's the great fortunate

fear it's not going to be all that common.

It

The more usual case, the case we're almost truly

18

up against is Huntington's disease, cystic fibrosis, with

19

many of the others that we're interested in is that the

20

disease represents a single base change.

21

This presents the following problem:

Genetics

22

will locate if we are today to within 10 million base pairs.

23

If we're lucky, eventually to within 1 million base pairs.

24

Maybe if we're extremely lucky, and there's not too much

25

linkage to [inaudib~]within the region, to 10 percent of
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that, but that's it.
2

You just can't get any closer by anything

that we know of today in genetics.

3

Jn this reqion, there will be 100 to 1,000 DNA

4

polymorphism.

5

that there is a sort of super genetics, which is potentially

6

available from the recent work that Norman Arnheim has done.

7

And if that proves to be generally applicable, it may allow

8

us to go from 1 million base pairs to a tenth million base

9

pair resolution providing that linkage to

Actually,

I shoulcl mention

10

does not get in the way in that region.

11

possibilities of technical advances here.

bcfon~

<JO on

l

[inaudible]
But there are real

But even so, even if you shrink it to a tenth

12

13

of a megabase, there will be 100 to 1,000 DNA polymorphisms

14

1n that region of the genome because we vary, 1 in every

15

1,000 bases.

16

only one of them is responsible for the disease.

17

are just noise.

And of these 100 to 1,000 DNA polymorphisms,
The others

To actually prove that we found the disease allele,

18
19

the only sure way to do it is to sequence the region and

20

look for the single base variation that correlates with

21

the disease.

And what you have to do is sequence lots of

22

individuals.

There will be many, many differences.

23

particular difference will show a 1-1 correspondence with

24

a disease.

25

you don't every time you don't.

You have the 'c' every time you have the
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1

At the moment, we have two options.

One

I

2

mean this means that you're doing millions or tens of millions

3

of base pairs of sequencing every time you're trying to

4

find a disease gene.

5

much cheaper sequencing technology.

6

forces,

7

can't do this kind of thing -- I mean with cystic fibrosis

8

we're actually in this position.

9

me personally -- people have the gene localized to about

And that either requires much faster,
It's one of the major

I think, which is really driving this project.

We

We have the gene -- not

10

800,000 base pairs, but nobody can conceive of doing 8 million

11

base pairs of sequencing right now to try to prove that

12

we've got the gene.

13

There is another approach -- and Rick Meyers in

14

the room has been one of the innovators of it -- and that

15

is that you may not have to sequence all of this region

16

if you have specific ways of trying to look just at the

17

bases which vary, you might be able to focus in on those

18

one at a time, or in groups, and not have to actually repeat

19

this kind of massive test.

That remains to be seen.

Now, what's going to happen from the Human Genome

20
21

Project?

22

base pairs of sequence.

23

because it's a very large amount of information.

24

25

At the end of it we're going to have 3 billion
And I want to dwell on that a bit

To put it into the scale for you, perhaps tangible,
if you wrote it out in the same size type as the Manhattan phone
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1

book, it turns out that it would fill 200 volumes of 1,000

2

pages each.

3

a single human sequence.

4

today, the whole world supply of DNA sequence is one telephone

5

book, or roughly equal to the yeast genome.

That is what it actually takes to write out
And all of the available sequence

So we have to expand our data base by a factor

6

And, clearly, in doing that, we have more than

7

of 200.

8

just a managerial task, we have an analytical task.
And I think that one of the areas where enormous

9

10

advances need to be made -- and there are a number of people

11

in the room who worry about such problens already -- is

12

~n

fast multiple text matching.

13

What's going to happen progressively through the

14

Human Genome Project is someone will sequence a region and

15

want to know whet. her it's interesting, vmn·t to know whc· t \tl' r·

16

somebody r;hould immediately follow it up biologically or

17

just store it into an archive and forget about it for the

18

moment.

19

And the way we do that is we compare it with all

20

of the known text.

We compare it with all the known sequence

21

that we understand and ask:

22

we do that is tremendously crude.

23

tv10 at time without any regard for their meaning.

24

need methods which will do that faster, will make multiple

25

comparisons, and will consider the meaning of the text and
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1

not just the raw text itself.

2

methods to do this, which are not so simple, these methods

3

will have a major impact on other problems where a large

4

amount of text has to be analyzed rapidly, problems having

5

nothing whatsoever to do with biology.

6

And I think that as we develop

Now, let me talk for a moment about the meaning

7

of the text.

What do I mean by that?

Well, raw sequences,

8

just alphabets -- a, t, g, g, c, c -- but we know several

9

things about it.

We know that sequence is expressed in

10

DNA structure.

11

bends, it rides, it does all kinds of things.

12

Dick Dickerson in the room have been making their living

13

on this for the last few years.

14

types of bending or arriving may be important in control

15

of gene expression.

16

DNA is not a constant bordering helix.

It

People like

And we now know that certain

But nobody has really developed a methodology

17

yet for combining our understanding of DNA structure and

18

this text matching.

19

At the much more sophisticated level, we know

20

that genes come from proteins that follow up in three dimensions.

21

And three-dimensional structures are much more conserved

22

than the text itself.

23

what those three-dimensional structures would look like -- that's

24

a very, very difficult problem -- we'd be able to analyze

25

this text much better.

And if we had better ways to guesstimate
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Let me show you an example now -- a practical

1

2

example -- of what I mean, and this is a very partisan example.

3

It was made for a different audience.

4

message literally.
These are three texts.

5

So don't take the

Text 1 and Text 2 differ

6

or have 23 out of 35 units the same.

Similarly, Text 2

7

and Text 3 have 25 out of 35 units the same.

8

way that we score text comparisons today, we would say these

9

two are as similar as those two.

So in this

And if you read the text

10

it says,

11

"I feel DOE should be the lead genome agency.

12

DOE should study lead genome toxicity."

13

two are related in a way that those two are not.

11

I know NIH shouldn't be a lead genome agency.
11

I feel

Clearly, these

I really want to stress though that we can't do

14
15

this today with DNA sequence information.

16

hovl

17

to go.

18

11

11

to do this kind of comparison.

We don't know

So we have a long way

In the last two minutes, or three minutes, let

19

me just turn to a little bit more of the technology.

I

20

believe that in the next five years these kinds of advances

21

will be made in terms of technology; essentially, automated

22

genetic mapping rather than the type of manual techniques

23

that are being done today.

24

is rapidly upon us.

25

image scanning and analysis, protein structure prediction,

Automative high-speed DNA sequencing

Automative physical mapping, computerized
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1

at least better than we do today, improvements in manipulating

2

and cloning large DNA and multiplexy tricks that will enable

3

us to analyze many samples in the same tube rather than

4

one sample at a

5

time by George Church's sequencing technology.

What's this going to do for us when we have this?

6

Well, DOE I should say is supporting work in all these areas;

7

and to be perfectly honest, NIH is also supporting work

8

in all of these areas.

9

Data bases and clone maps.

We're going to get

10

two types of things from the Genome Project, and it's important

11

to realize that we get them both.

12

vast improvements in technology.

13

applicable to all living species, not just to humans.

14

I think one of the major fallouts will be in agriculture,

15

and that will also lead, I think, to substantial improvements

16

in handling data and samples which probably will have a

17

major impact in places like supermarkets, as well as the

18

Genome Project itself.

19

We're going to get technology,
Once we have it, it's
So

The samples and the data are key because once

20

we know the sequence of a single human genome, it allows

21

us to have access instantly to any region of the human genome

22

we want using the ability to amplify with PCR, any piece

23

of sequence gives us the gene, gives us the material to

24

do experiments with in humans.

25

genes in other animals if they're there.
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So this is really an enormous resource, and it
2

will form a basis of probably the next 100 years, or part

3

of the next 100 years, of research and development.
To say it in a slightly different way, the instruments

4

c;,~nomo

5

that are qoing to be developed as part of the Human

6

Project will be instantly usable in diagnostic testing.

7

The methods development will be applicable to a host of

8

plant and animal species of commercial importance.

9

data base design

The

the major problem that we have to start

10

with and coordinate -- I

agree with Jim completely on this,

11

it's where we have to begin.
Designing a data base and implementing it with

12
13

the peculiar needs of the Genome Project requires solving

14

a number of problems in computer science and informatics

15

which are going to be broadly applicable to other fields.

16

And, finally, to clone DNA samples will eventually

17

to,

18

to understand the gene involved in many serious diseases,

19

we \lOUld be able to develop better therapy for them.

I

20

le~d

believe, improved pharmaceuticals because if we were

Let me close with one specific example which gets

21

very much to the heart of the first problem that faces us

22

because today we pretty much have a Tower of Babel.

23

are a whole bunch of different data bases.

24

to each other.

25

on

di

They don't talk

They run on different hardware.

ffen•nt soft_ware.

Some of thc•m --God
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1

2

not documented.

It's a mess.

We need to have what I think probably Tom Marr

3

in the room first called a human genome work station.

4

need to have a package of software and hardware that sits

5

on everybody's desk who is interested in this project, can

6

address any data base regardless of what it looks like,

7

contains all the tools you need to integrate and manipulate

8

a variety of genome data.

9

to be monopolistic, this data base has to run on a wide

10
11

We

And since none of us are going

variety of different hardware.
We would like it to allow the user to see the

12

same screen wherever in the world he or she is.

13

because we're all individuals, we would like it to allow

14

the user to be able to customize it.

15

And also,

And the typical problem that we get into -- it's

16

a marvelous problem in the Huntington Disease Collaborative

17

Research Project, which a couple of us in the room are involved

18

in -- every lab uses different nomenclature.

19

own names for your own DNA samples.

20

together in a room and discuss the work that you're cooperating

21

on, you're talking a different language.

22

You use your

When you try to get

And it's extremely difficult when you-- it's

23

very easy if you have two DNA probes.

24

When you have 40 DNA probes, or 400 DNA probes, and you've

25

been working with them for three or four years, it's very
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difficult to get people to learn a new language.
2

So we need the types of data bases that will automatically

3

translate from our local language, that we're not going

4

to give up I fear, to a global language that can communicate

5

between laboratories.

6

in order to be able to work with them.

We almost need computer translators

And there are two aspects to this.

7

The first

8

is that someone needs to take this very coarse description

9

and firm it up.

In terms of writing the specifications,

10

\lhat do we all want?

11

be created a joint DOE, NIH, Howard Hughes committee to

12

try to do that, which would be a very great start, at least

13

for the U.S.

14

so it will sort of encompass the world at the same time.

And I hope that group will have foreign representation

That's the easy part.

15

16

And it looks like there is about to

It's just politics.

People

have to decide what they want.

17

Once we get past that part, then there's a much

18

more difficult challenge -- and you may hear about that

19

later from other people this afternoon

20

actually implement it?

21

easy.

22

I think the answer is, "Yes," but it's not a trivial problem.

23

but how do you

Because to say "I want this" is

To say "Can we do this with current computer technology?"

Finally, I want to close with almost the same

24

way that Jim closed -- not quite -- the Human Genome Project,

25

what do you do about the 90 percent which is garbage, the
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1

90 percent of the text that we can't interpret today?

2

I love this quote from Sydney Brenner-- I think that's

3

correct to attribute it to him -- and that is that this

4

extra stuff in the human genome is not

5

because garbage you throw out and junk you keep.

6

human genome has kept all this stuff, so it must be there

7

for a purpose.

8
9

g~rb~ge,

Well,

it's junk
So the

First of all, there are some people interested
in this garbage.

The human genome has 500,000 copies of

10

a short-repeated sequence.

11

been studying that for many, many years.

And it contains

12

interesting clues about human evolution.

So it's not just

13

junk.

14

Carl Schmid in the room has

I agree with Jim, today we don't knou enough to

15

be sure what's junk and what's not junk.

16

to simply throw all this 90 percent aside.

17

It would be reckless

Furthermore, even if we knew for sure, we don't

18

really have easy methods right now to sort the junk from

19

the good stuff.

20

I think nobody is going to sequence 500,000 repeated sequences

21

that are all the same except for a few bases.

22

no one that is going to take on that project voluntarily.

23

And so at today's cost, in terms of sequencing,

There's simply

But as sequencing becomes much more automated,

24

I think people will become more enthusiastic about prowling

25

through the junk.

And I think that when they do so, there
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1

will be some interesting surprises.
I think with that I'm going to stop.

2

3

I hope I

have given you a fair overview of this project.

4

Thank you.

5

DR. KREVANS:

To show you the effect of the adv,1nccd

6

technology that is a part of anything we do about the Human

1

Genome Project, unbelievably, we're right on time.

8

have a 15-minute break.

We'll

We'll reconvene at 11:00 o'clock.

9

10

Recess 10:45 a.m. to 11:00 a.m.

11

DR. KREVANS:

12

The final paper this morning

lS

13

on the status of federal legislation and appropriations.

14

7\nd we arc

15

knows something about it as opposed to someone who will

16

criticize it.

11

criticisms of federal policies and appropriations available,

18

but relatively few who know something about it.

19

n~ally

very lucky that. we rwve sorn(•onc: who <tetually

There are plenty of people available for

Robert Cook-Deegan is currently a Senior Associate

20

with the Office of Technology Assessment.

21

you also do something else.

22

DR. COOK-DEEGAN:

23

DR. KREVANS:

As I remember,

I'll get into it.

Yes, he's got two jobs.

Everyone

24

has two jobs.

25

undergraduate school, and took his medical school degree

He was educated at Harvard College in his
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1

at the University of Colorado, was trained in the clinical

2

specialty of pathology and then was a post-doctoral student

3

with Erikson on the molecular biology of retroviruses, and

4

did some interesting work in the early understanding of

5

the biochemistry and the enzymes in the energy systems of

6

the oncogenes.

7

Following that, his career has taken him more

8

in the direction of an analyst and someone who understands

9

and studies public policies, ethics, the interaction of

10

those, working at the Kennedy Institute, as well as in the

11

Office of Technology Assessment.
So it's a great privilege to introduce Dr. Robert

12

13

Cook-Deegan.

14

DR. COOK-DEEGAN:

15

Again, my name is Bob Cook-Deegan.

Thank you.
And for the

16

rest of this week I work at the Office of Technology Assessment,

17

OTA.

18

The reason that I'm here really is principally

19

because OTA did a study of federal policy relating to human

20

genome initiatives that began about two years ago and culminated

21

in the release of a report in April of this year.

22

We get into the act, typically at OTA, when there

23

is a policy question relating to either science or technology

24

that is clearly going to be a congressional concern.

25

usually means that it's going to last for a couple of years
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1

and that it's likely to be fraught with some controversy

2

with lots of different opinions about how some things should

3

be done or how much of some things should be done, or questions

4

of that nature.

5

It became clear in the middle of 1986 that the

6

Human Genome Project meant many different things to many

7

different people, and it was causing a lot of controversy

8

since there were two federal agencies involved already at

9

that point.

10

In what was by then already beginning to become

11

a major topic of discussion in biology, it was immediately

12

apparent that Congress was going to have to get involved

13

because Congress is where budget decisions are made.

14

when there are two agencies in separate departments of the

15

federal government, there are only two places where those

16

can meet, one is in the Executive Department, which is essentially

17

the President, and the other is in the Congress.

18

And

And in recent years, in fact, most science policy

19

decisions have been made by a combination of the Office of

20

Management and Budget, which is under the President, and

21

the Appropriations Committees of the U.S. Congress.

22

The history of biomedical research, in fact, is

23

very largely the history of Congress kind of forcing money

24

down the throats of the executive agencies.

25

as a congressional employee.
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There's a second reason that I'm here that grew

1

2

out of the OTA project, and that's that I'm currently doing

3

a kind of-- it's not an informal-- but it's almost a

4

verbal history that will soon be written down into a book.

5

The Sloan Foundation has given me a grant to record the

6

politics and the science of the early genesis of Human Genome

7

Projects.

8

half time.

9

So I've been doing that since June of this year

And relating some of the questions that both

10

Dr. Watson and Dr. Cantor have raised earlier this morning,

11

sometime next week, I'll be starting a new job.

12

the Biomedical Ethics Advisory Committee and the Biomedical

13

Ethics Board.

14

mandate is to look at ethical questions in biomedical research

15

and in health care.

16

It's for

This is a new congressional entity whose

One of the topics that that committee has to deal

17

with initially is the topic called "human genetic engineering,"

18

which is being interpreted by the committee to include gene

19

therapy, use of genetic diagnostic tests -- both medically

20

and nonmedically --and also following what's happening

21

in the Human Genome Project because a lot of people in Congress

22

are interested in it but are concerned about the ethical

23

implications of mapping the human genome.

24
25

What I would like to do

I was going to show

some slides, and I'm not going to do that now since I think
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1

most of what I was going to say on the slides has already

2

been said more eloquently by somebody else.

3

What I think is probably the most useful for me

4

to do now is to talk about kind of the national context

5

for human genome projects.

6

point of view or the technological point of view because

7

I think those have already been articulated to some degree.

8
9

And I won't take the scientific

What I would like you to do is transport yourselves
into being a member of the U.S. Congress or into being a

10

high-level administrator in NIH or DOE or some other executive

11

department that has something to say about genome projects,

12

and think about:

13

or set of projects?

14

Why would you be interested in this project

It seems to me that there are principally five

15

things that you'd be worried about on the one hand, or very

16

supportive of on the other hand.

17

The first thing -- I think the first reflex of

18

most people in Congress is to support the science.

19

don't fully understand the scientific implications, but

20

they hear from the experts, the best experts, that having

21

a map of the human genome is very important to understand

22

the human genetic disease and, in fact,

23

other diseases that are not necessarily genetic.

24

25

They

just to understand

That has obvious implications.

That's the main

basis for the rather generous support of biomedical research
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in the United States compared to any other country in the
2

world.

3

thing to do."

4

NIH budgets have been relatively unscathed in the last couple

5

of years in times of great fiscal austerity is testimony

6

to the fact that people in Congress and in the executive

7

agencies think this is very important.

8

9

So there's a reflex to say "Yes, this is a very important
And I think the fact that both the DOE and

There's a second line of support for anything relating
to biotechnology.

And that is the economic implications

10

of human genome projects.

The thinking there seems to be

11

that work on human genetics is related to biotechnology.

12

And biotechnology at least eventually is going to be related

13

to jobs and wealth.

14

care about your district, you care about what you're paid

15

to do is to represent the people in your district.

16

they care about most is how they're doing.

17

wealth are the things that are on the top of that list.

18

The linkage is not very direct, but that is something that

19

is in the front of most people's minds as they're making

20

decisions about human genome projects at the federal level.

21

There's a third issue, and that's national pride.

And if you're a member of Congress you

And what

And jobs and

22

And this is, in fact, driven some of the decisionmaking in

23

Washington; that is, there are lots of arguments about if

24

we don't do it then the Japanese are going to beat us or

25

the Europeans are going to beat us.
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1

actually play relatively well for short periods of time.

2

Generally, you eventually get down to making judgments about

3

the technical feasibility and the actual pragmatic applica ions

4

of something you're

5

to necessari

ing money on.

do that initially.

The fourth

6

But you don't have

concc~rn

relates to

i:hE~

other three.

7

And this is that obviously the very No. l dominant issue

8

in Washington for the next year is going to be the deficit.

9

And now that the election is over

I shouldn't say election,

10

the multiple elections -- members of Congress also worry

11

about things on a two-year cycle.

12

about things on a four-year cycle.

13

stopped simultaneously now.

14

in the next year is that people will worry less about

15

elected and more about managing the government.

16

is going to thrust the deficit problem right to the top of

17

the list.

18

The President worries
And all the cycles have

So what you're going to see

in it's coming out of its embryogenesis and real

20

fetal s

21

s

22

federal spending.

23

to happen.

25

And that

The human genome initiative is somewhat unfortunate

19

24

ng

right now, I think.

into its

And it's coming to that

at a time when there are tremendous pressures to restrain
And I, frankly, don't know what's going

But that is a major concern for anybody in Congress.
The fifth area is the social and ethical implications

of human genetics research.
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1

a lot of the things that people in Congress are worried about.

2

They're worried about people being able to get insurance,

3

the use of genetic information for insurance purposes for

4

hiring and firing decisions for eligibility for federal programs

5

or non-federal programs, the criminal investigation uses -- that

6

is forensic applications.

7

of the medical uses of a new technology.

8

important than all of those is the spotty history of the

9

use of genetics in politics.

10
11

They also worry about the costs
And perhaps more

And here I'm referring to

eugenics.
Most people in the audience think that the issue

12

of eugenics was something that happened early in the 20th

13

century and went away.

14

are people in prison in Malaysia right now that because of

15

their beliefs relating eugenics.

16

of Malaysia right now is a -- what would at the turn of the

17

century have been classified as a classical eugenecist; that

18

is, he bases theories of race and justifies those in kind

19

of a pseudo-scientific jargon.

20

That is, in fact, not the case.

There

In fact, the Prime Minister

But that history does overlay human genetics, and

21

it's something that people in Congress worry about.

And

22

I think that what you're going to see in the next few years

23

is that all these five major interests are going to be thrown

24

into the same pot.

25

something will come out at the other end.

And in the usual chaotic American mode
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1

not sure what that's going to be.
My guess is that the projects -- well, let me finish

2
3

one thing on the social and ethical implications before I

4

go on because I don't want to leave it on a negative note.
Frankly, most of those social and ethical implications

5

The Genome

6

have nothing to do with the Human Genome Project.

7

Project is the creation of information.

8

those issue relate to the use of that information and are,

9

in fact, things that are part of the normal social fabric,

10

and they are things that legislatures are well prepared to

11

deal with.

12

this or that thing?

13

are legal questions.

14

pretty well prepared to deal with questions of that sort

15

once they are understood.

And almost all of

Who has access to this or that thing?

Who owns

Those are legislative questions.

Those

The system of government is actually

The creation of the information is really on separate

16

17

track.

18

is:

19

we create it in the first place?

20

of argument doesn't go very far because most people in policy-making

21

positions understand the distinction between generation of

22

information and its use.

23

discovery and application.

24

25

And the only question that has been raised to date

If this information is going to be abused, why would
But, generally, that sort

That is, again, a distinction between

The final thing I wanted to talk about -- although
it has nothing to do with the legislative status these days -- is
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1

the management prospects for genome projects.

You've heard

2

about the DOE and NIH efforts to organize the projects.

3

think, actually, if you compare development of the genome

4

projects in the United States to development of any other

5

biomedical research program.

6

frankly.

I

It's been remarkably efficient,

Two years after the beginning of discussions about

7

8

how much controversy there was about genome projects, NIH

9

and DOE seemed to be living somewhat compatibly on the same

10

planet with the same budget mechanism and, in fact, have

11

a piece of paper that you can point to and it say, "This

12

is how we're going to cooperate."

13

in things happening in the real world.

And that has resulted

If you follow the history of a project within NIH,

14
15

that's not always the case.

16

agency.

And that's within a single executive

There are, nonetheless, going to be lots of complicating

17
18

factors.

And Dr. Watson and Dr. Cantor referred to this.

19

So far France, Italy and the U.S.S.R. have got pieces of

20

their federal budget, their national budget, devoted to genome

21

work.

22

of trying to formulate its policy.

The Japanese government is now kind of in the stage

There's a lot of talk from people in the four major

23
24

research agencies in Japan about who's going to take the

25

lead.

It's kind of the debate that was going on here two
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It's going on right now in Japan except that

1

years ago.

2

in the United States it's done on the pages of Science and

3

Nature magazine.

4

it when the results are pretty well established.

In Japan we'll probably only know about

One overarching comment about the level of effort,

5
6

however, is in order.

The U.S. effort right now is at $50

7

million this year, and it sounds like it will be somewhere

8

around $80 million next year, and maybe even higher than

9

that.

That totally dwarfs all the other efforts put together
It's probably more than double

10

from all the other nations.

11

that all other nations are going to put together in the next

12

years.

Perhaps it will change over time.
But one thing about the international efforts is

13
14

they are much more difficult to coordinate because there

15

is no point where all decisions converge as there is in one

16

government.

17

that role.

18

and has some sort of agreement from the various governments

19

to cooperate with its planning efforts, I'm not sure how

20

that's going to work out.

21

in biology that there would be a concerted well-planned effort

22

involving more than one nation.

23

sciences, but the history of their success is somewhat spotty.

24

25

And HUGO is, I think, the only hope for fulfilling
But I'm not sure that unless it's fiscally healthy

This is totally unprecedented

There are examples in other

A final comment on the international aspects of
the genome project.

I think the key issue there will data
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1

sharing.

And I think there is widespread agreement among

2

the scientists of all nations that data should be shared.

3

There are problems, however, in implementing that very traditional

4

scientific value.

5

It's very clear that scientists left to their own devices

6

would share journal articles and the sort of normal pieces

7

of scientific communication.

8

share data base structures, but that has been done with some

9

success in the cases of GenBank and, in fact, in the RFLP

And there is a tendency to blur distinctions.

It's less clear that they would

10

mapping efforts, the efforts of CEPH have been really pivotal

11

in keeping the groups doing RFLP mapping unified at least

12

to some extent.
So there is some hope for cooperation at the data

13
14

level.

15

the degree that they see investment in genome projects as

16

an economic investment see this as a way of creating new

17

instruments, new technologies, new ways of making products.

18

And that's going to be an area where economic nationalism,

19

I think, will be the norm.

20

It's equally clear, however, that governments to

And the game will be to try to separate the data

21

gathering and data sharing from the commercial aspects of

22

the human genome projects because it's clear that on one

23

hand there's going to be competition; on the other hand,

24

there's an agreement that there should be cooperation.

25

But the decision-making apparatus in the United
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1

States are very different from what it is in most other

2

nations.

The people in this room today are -- as I look

3

around

principally scientists.

4

have a great deal of power over the decisions over spending

5

money for science in the United States.

6

greater degree of control over spending in the United States

7

than in most other nations.

8

of the role of the government is in influencing private corporations

9

spend their money.

And, in fact, scientists

They have a much

And particularly in Japan, most

It's an indirect role rather than a direct

10

role.

11

Japan much more difficult to explain some of the difficulty

12

of the Japanese government being able to say, "Yes, we'll

13

pay for this or that thing."

14

And it makes the process of formulating policy in

They don't do that in any area.

And, in fact, the research budget in the United

15

States is about 50/50 private/public.

16

more highly private research money in the biomedical area.

17

So it's going to be a difficult impedance match among the

18

various nations, particularly between the U.S. and Japan,

19

because there's so much room for trade fiction.

In Japan it's much

20

I'll end there and just open it up for discussion.

21

Thank you.

22

DR. KREVANS:

Thank you very much.

23

I'd like to ask Dr. Cook-Deegan and Dr. Cantor and Dr. Watson

24

to please come to the table.

25

comments, discussion, questions for our panelists.

Pike Court Reporting

We have now a free time for

(805)658-7770

And they

79.

can question one another or you all can comment and question
2

them.

And I'd like to just start out by calling on people

3

for questions and comments.

4

Could you please identify yourself so that you

5

can be recorded, and 10 years from now you can point out

6

what a mistake you've made.
DR. SHANKAR:

7

8

Robert Shankar, University of Southern

California.
I haven't heard any participation from the United

9
10

Nations such as UNESCO or the World Health Organization.

11

Is anybody -DR. WATSON:

12

I would hope that we would have none

13

in the sense that they're large bureaucracies, and I don't

14

think they'd bring any expertise.

15

more time in meetings if we had to bring them in.

16

think that the reason for forming HUGO is to keep an organization

17

run by the scientists instead of, essentially, civil servants.
DR. KREVANS:

18
19

20

And we would spend even
And I

Do other analysts want to comment

on that?
DR. CANTOR:

UNESCO has been sending observers

21

to some Human Genome meetings recently, but they've been

22

keeping a low profile.

23

DR. COOK-DEEGAN:

They're very interested in following

24

the projects.

They're particularly interested in if there

25

are data generated in the Human Genome Project promoting
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1

Third World applications of that information; for example,

2

sickle cell disease, or something like that, the diseases

3

that are highly prevalent in Third World countries.

4

want to make sure that their data are rapidly made applicable

5

for the needs of Third World countries.
And they have been quite interested

6

They

in fact,

1

at the Valencia meeting about a month and a half ago, there

8

were three representatives there.

9

enthusiastic; more so, I think, than the scientists were

10

And they were extremely

about having them involved.

11

DR. KREVANS:

Next.

12

DR, NEUFELD:

Elizabeth Neufeld, UCLA.

13

Dr. Watson, what proportion of resources does the

14

NIH plan to put into genomes of other organisms versus the

15

human genome?

16
17

DR. WATSON:

I don't think we've made any decision.

I think

18

DR. NEUFELD:

19

DR. WATSON:

Would it be minor?
No, I think it would be major.

I

20

mean in any sense of the word, we want to get the coli sequence

21

out as fast as possible, and then you want yeast, and then

22

you want to really see that we get the Drosophila sequence,

23

I mean certainly a map of it.

24

25

And I think one thing is that we hope that bodies
will appear which say, "We want to do something."
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1

go a long ways away from the human.

2

sequenced in Europe because they actually put their act together.

3

Or will some group from the United States say, "We really

4

want to find out what a plant is"?

5
6

We won't end up being

So I would hope that there would be bodies in the
United States, or groups, which will have rather heroic objectives.

7

DR. CANTOR:

Let me add to that because I sit on

8

the GenomeCouncil, and so I have seen what has thus far come

9

through and been funded with genome, I mean even before Jim

10

was on board.

11

budget thus far has been spent on organisms other than human.

12

Some direct attempts to explore those organisms, some using

13

them for model systems to develop technology.

14

how that pertains to the future.

15

thus far, which is very reasonable.

16

And I think, roughly half of NIH's genome

DR. WATSON:

I don't know

But that's what has happened

Maybe, I think, we sort of want to

17

put a lot of money in the mouse.

18

to find people who really can do it well.

19

a problem of finding people who can do it than the desire

20

to do it.

21

saying, "We want to do it," and then we're saying, "Well,

22

we're not interested."

23

DR. KREVANS:

But you're going to have
I think there's more

And I think there are going to be a lot of people

Is the extensive, fairly extensive,

24

data base on mouse genetics a reason you say we should use

25

the mouse in terms of one of the manmals?
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DR. WATSON:

1

2

Well, you want to compare the mouse

sequence just really to identify genes in nonsense regions.
DR. CANTOR:

3

The mouse is really, I think, especially

4

useful for comparison because as expensive as transgenic

5

experiments are on mice, they are more expensive than probably

6

almost any other animal, and they will be more expensive

7

in any other animal you can think of.
And the problem that you're going to be faced with

8
9

in so many cases is:

You have a gene, whether you've originally

10

gotten it from human or a mouse almost doesn't matter, you

11

want to know what it does.

12

to do is create a nullmutant in most cases, and knock it

13

out.

14

years from now probably efficiently.

15

a human ever probably, and you can't do it in larger organisms

16

because no one will pay the bill.

17

The first experiment you want

You can do that in the mouse today inefficiently; three

DR. WATSON:

You can't do it in

The mouse world now -- and maybe I

18

shouldn't say this -- is rather mouselike.

19

don't expect to get much.

20

of the mouse >mrld who really think big and have the same

21

ambition as the human people.

22

the center of the mouse world has to be in Bar Harbor which

23

is so far removed from everyone.

24

in recruiting such molecular types.

25

been the natural center for it.
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1

in fact, it would be the place where --

2

DR. KREVANS:

Those of us who summer in Maine think

3

that Bar Harbor is much more attractive than Cold Spring

4

Harbor.

5

DR. WATSON:

I think it is in the summer.

But

6

I think that we're going to find a way to encourage major

7

groups working on it.

8

Yes.

9

DR. LAKE:

Jim Lake, UCLA.

I wanted to ask -- a lot of people seem to think

10
11

that one of the most informative organisms for comparison

12

to put us in the proper background would be the chimpanzee.

13

Is this the sort of thing that you would perceive as following?

14

DR. WATSON:

15

DR. LAKE:

16

some political ramifications?

17

must be central --

You wouldn't.

DR. WATSON:

18

No.

that you can do on the mouse.

20

organism.
DR. LAKE:

22

DR. WATSON:

I think scientifically it

We really can't do the experiments

19

21

You think it might have

So it's not an experimental

But in terms of comparative questions?
When someone gets all the costs down,

23

then we can look at the chimp.

24

personally think

25

working on chimp DNA.

But I think right now --

I

I wouldn't think vle' d develop a big group
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1

DR. CANTOR:

rtve heard that the chimp is also

2

a little too close evolutionary to the human.

3

you could ever afford to do :the experiment, some more distant

4

related monkey might be a better choice.

5

debatable.

6
7

DR. WATSON:

DR. KREVANS:

9

DR. WATSON:

,,

12

I mean that's probably

The way things are going it would

be harder to do experiments on the chimps than on humans.

8

10

And that if

Certainly more expensive.
So I really shudder at the thoughts

of the problems.
MR. HURST:

Steve Hurst, UCSF.

I'm a patent counsel with UCSF, and one of the

13

areas that I have noticed a deafening silence on is the issue

14

of patent rights related from proprietary technologies developed

15

by the participants in the Human Genome Project.

16

I see it as being anything from a minor nuisance

17

to a major problem within the project in terms of how those

18

rights are going to be coordinated.

19

that industry will at least have some interest ln.

And I think it's a question

20

I wondered if the three of you could comment the

21

coordination efforts in that area, any thinking other than

22

the proposed solution of putting all patent attorneys on

23

a boat and sending them off to China?

24

to the potential problems associated with having to fuse

25

proprietary rights?
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1

DR. KREVANS:

I don't want to discard that solution.

2

Do you want to take that on, gentlemen?

3

DR. COOK-DEEGAN:

We thought long and hard in connection

4

with OTA project about what we were going to say about patent

5

rights.

6

straight forward.

And, frankly, the federal policies on it are fairly

7

The Institution of Human Research get the rights,

8

whatever the rights are.

9

we don't know what those rights are because there's no case

10

The problem as I see it is that

law in the area.
For international stuff, I don't think it's a problem,

11

12

frankly.

It's very clear who gets a patent.

13

problems in harmonization of patent criteria among nations,

14

and procedures and things like that.

There are serious

But in terms of a federal effort involving DOE

15
16

and NIH or NSF, it's very clear of how they're supposed to

17

distribute the patents.

18

very --- from the federal perspective -- as being all that

19

important.

20

are doing the research, but then it's going to be up to them

21

to negotiate who owns the patent.

22

people doing the research would make those decisions now.

23

That's federal policy.

24

DR. KREVANS:

25

And I don't see that as being a

It's going to matter a lot to the people who

The Institution and the

Charles, do you want to comment on

this?
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DR. CANTOR:

1

I just want to second what Bob said

2

about harmonization because already a significant fraction

3

of the effort in the Human Genome Project are international.

4

And the differences in the patent laws and constraints about

5

disclosure in different nations is really cumbersome.

6

mean that's a problem that transcends this enormously, but

7

it's a mess.

8

one day straighten this out.

And I would hope that patent attorneys can

DR. KREVANS:

9

All the way in the back, please.

UNIDENTIFIED SPEAKER:

10

There was no mention of

11

the Department of Defense in the funding role of this.

12

there implications to DOD?

13

was inaudible.]
DR. WATSON:

14

I

Are

And if so -- [Rest of the question

I don't really think that their help

15

is needed.

You know, at a different level, I think they're

16

very interested in the DNA fingerprint for body identification,

17

and you can get that sort of a question.

18

DNA fingerprint everyone who enters the armed services.

19

I don't really feel qualified to make any comment on that.

20

DR. KREVANS:

And

Charles.

DR. CANTOR:

21

Do they want to

Well, they're also interested in autorr.atic

22

pattern analysis.

And that technology is relevant to the

23

Genome Project.

24

from DNA sequences to automatic analysis of photographic

25

images.

There's no question about it.

Patterns anywhere

But, again, I agree with Jim; I don't think that
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they're needed in this project.
2

DR. KREVANS:

I just want to pursue that.

Hasn't

3

a lot of the advance in pattern analysis come out of DOD

4

research on how to analyze patterns from satellites; the

5

other direction, if you will?

6

DR. CANTOR:

As far as I know, yes.

7

DR. KREVANS:

8

DR. COOK-DEEGAN:

Do you want to comment on this, Bob?
No, that's absolutely right.

9

The DOD has got some interest in this.

They've got a few

10

little bits and pieces here and there.

They've got the world's

11

best treasure house of odd pieces of the human body at the

12

Armed Forces Institute of Pathology.

13

that probably will eventually be quite useful to their genetics

14

and things like that.

15

It's a wonderful resource

And I think that at the hardware end, their artificial

16

intelligence is in large part supported b7 DOE.

17

relevant to these projects.

18

think it will probably trickle down from DOD.

19

would probably be a little worried about being perceived

20

as getting into this because everybody would immediately

21

think that this was pretty nefarious purposes.

22

DR. KREVANS:

23

DR. LONGERBEAM:

24
25

It's highly

But I think at that level, I
Frankly, they

Yes, right here.
Gordon Longerbeam, Lawrence Livermore

National Lab.
I have a question about technical data rights excluding
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1

patents, perhaps from Dr. Cook-Deegan, but the others may

2

respond.

3

Do you see any progress at the federal level on

4

differentiating between technical data which has economic

5

value and technical data which is principally scientific

6

value which should be open to share?

7

very sticky question?
DR. COOK-DEEGAN:

8

9

Or is that still a

That's a mess.

tied up also with the question:

And it's all

Who owns the data and all

10

that?

11

soon not talk about it too much.

12

about it, and it's undoubtedly going to change in the next

13

two or three years.

14

15
16

And that's a total mess right now, and I'd just as
We don't know very much

Access to technical data and who owns it and all
that is very unclear.
DR. KREVANS:

But this, I think, is the question

17

that Mr. Hurst was trying to get at.

18

in cooperative studies where we talk about ways in which

19

to make data accessible, then when something comes from it,

20

who owns it?

21

22

23
24
25

DR. COOK-DEEGAN:

As these things evolve

If that was the point of your

earlier question, I missed the point, and I apologize.
MR. HURST:

If I could maybe elaborate just a little

bit on the issue.
DR. COOK-DEEGAN:
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1

MR. HURST:

I think you'll see within the industry

2

that there is a lot of -- I think the relevant point of the

3

whole project is that at some point the Genome Project will

4

translate itself into a technology transfer effort that will

5

ultimately benefit people not just of this country but the

6

world.

7

Those technologies are expensive to develop and

8

require some incentive.

And usually the industry will perceive

9

incentive as being exclusivity, or maybe even free competition

10

where someone can't come in and close them down, all of which

11

is relevant.

12

And I think that if you find that in a project

13

as profuse as this, those patent rights rest in 40 or 50

14

or 60 different places, I think you're going to at some point,

15

maybe not in the basic research, but certainly where the

16

tech transfer efforts take place, I think you're going to

17

find a real bottleneck that, hopefully, will straighten itself

18

out.

19

that all the patents expire at some point in time.

It will eventually straighten itself out in the sense

20

But I wonder, perhaps, should we wait 30 years

21

after the technology is developed for all the patents to

22

be out of the way before the industry can really take off?

23

And I think if you don't have a coordinated effort within

24

a project of this scope, can look at exactly what you've

25

cited, which are the federal laws on ownership and the fact
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1

that each institution can elect ownership, and in a project

2

of this scope I'm not sure that sounds reasonable.
And I think that's what I was getting at because

3
4

you're going to find an impedance in progress at some point

5

along the way by virtue of proprietary rights in data, techniques,

6

products.

7

And I think the law is clear that gene sequences,

8

protein probes, et cetera under the U.S. patent law are clearly

9

patentable right now.

10

This is a real issue.

DR. COOK-DEEGAN:

Yes, I think just to make sure

11

that I understand where you're going with this, I think the

12

real issue is not:

13

Although, that's still in question.

14

What's patentable and what's not patentable?

It's also clear that if you've got something that's

15

patentable, it's clear who owns the patent.

16

is what you do with information that goes into the process

17

of documenting that you have an invention.

18

What is unclear

And I think that patent laws as they're currently

19

construed do have -- it is a serious problem for the project

20

in the sense that people will be reluctant to disclose sequence

21

information; for example, that is relevant to a patent they

22

found until they file it.

23

And that could lead to a delay.

But if you aggregate it over hundreds of labs where

24

you're trying to pool data, it does matter a lot.

25

things by years if you add it all up.
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1
2

problem.
There are things that the federal agencies could

3

do to encourage data sharing if they just had explicit policies

4

saying that this sort of information needs to be shared as

5

a condition of accepting this grant.

6

going to have to be a clause in there.

7

to be inevitable uncertainty because the agencies can't cross

8

that line if it gets in people's way when they're filing

9

patent applications.

10

But there's always
And there's going

It's against the law for them to put any impositions

11

on recipients of grants if it's going to interfere with their

12

intellectual property rights.

13

So there's a gray area there, and it's just going

14

to have to be thought about a lot by the federal agencies.

15

And I think it's going to be muddled through, frankly.

16

DR. SALSER:

Winston Salser, UCLA.

17

Regarding the earlier question about the interaction

18

of the Department ofDefense, it seems to me there's more

19

likely to be an interaction and a problem with the intelligence

20

community because one of the things that they do is analyze

21

huge amounts of communication to sift through, trying to

22

sift through it.

23

And they must have contemplated for at least 10

24

years the various kinds of data analyses that will also be

25

needed here.

And, presumably, they could tell us a lot about
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1

how to do it.

I don't think they will.

2

But more problematically, if we look at the basic

3

researchers on breaking codes, they really interfered a lot

4

by classifying a lot things on code breaking.

5

have them really interfering when someone gets a powerful

6

outgrowth in decifering DNA and picking up things.

7

may feel that that's very threatening to them, and that would

8

be unfortunate.

9

DR. COOK-DEEGAN:

And we may

They

The Cal Tech chip that is being

10

used with that style finding is based on one of the chips

11

that was developed -- so there'sa big area of overlap.

12

I think the biologists only got access to it after it was

13

no longer the first generation technology.

14

UNIDENTIFIED SPEAKER:

And

I understand that the [inaudible]

15

of automated instrument in DNA sequencing is important for

16

this program.

17

In Japan, companies where [inaudible]

instruments

18

are developing the instruments [inaudible] is support from

19

government.

20
21

22

Is there any federal support for the development
of instrumentation in this sequencing effort?
DR. CANTOR:

Really that's one of the things that

23

has changed as a result of the Human Genome Project is the

24

fraction of the money at both NIH and DOE is now being spent

25

on instrumentation development.
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1

before the Genome Project.

2

kinds of projects to get funded in a conventional way.

3
4

It was relatively hard for those

UNIDENTIFIED SPEAKER:

The money is spent in [inaudible]

or with companies?
DR. CANTOR:

5

Some of the funds are used

6

for SBIR

7

companies are quite successful in competing for standard

8

research grants of NIH or DOE.

9

of the funds have gone along those directions.

or direct grants.

We have a lot of the biotech

And so a reasonable fraction
I mean I

10

can't name names, but I know of at least one major company

11

which has totally new ideas for sequencing and is seeking

12

federal support for it, and I imagine will get it, based

13

on quality.

14

15
16

DR. COLE:
Pre~ident's

Belle, Cole, University ·of California,

Office.

Dr. Watson, you mentioned that -- you discussed

17

the ethical issues that confront the project, and mentioned

18

the role of this advisory committee.

19

that Congress will be hearing from many different groups

20

about the project.

21

interest groups out there that will develop and that might

22

be adverse to the project.

23

And also you mentioned

You also mentioned there may be some

What are some of the things that NIH is thinking

24

about to deal with these issues, ways of educating the public,

25

ways of just being prepared?
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,

I think we really don't have a program,

DR. WATSON:

2

but I would think that within six months we vlill announce

3

one.

4

advisory committee.

5

I would hope that we would form some subcommittee to deal

6

with these matters and to deal with things like with the

7

Human Genome Office at NIH to issue proposals for grants

8

in this area, but at what levels I can't say.

9
10

I think we have to --we haven't had a meeting of our
And when that occurs early in the year,

But I would think there should be a level of several
million dollars, a fairly sizable sum.

11

DR. WHITELEY:

12

In response to:

Norman Whiteley, Applied Biosystems, Inc.
Does the federal government support

13

instrument development?

They financed the purchase of a

14

lot of the equipment.

15

of that money goes back into research.

16

support a great deal of research.

Something like 10 or 12 or 14 percent
So indirectly they

17

I'd like someone to explain the role of HUGO.

18

DR. KREVANS:

19

20

Charles, do you want to handle that

one?
DR. CANTOR:

The role of HUGO will depend very

21

much on how successful HUGO is in fund raising.

22

if it's very unsuccessful at raising funds, it's likely to

23

be in discussion forum and very little else.

24

25

At one extreme,

If it's quite successful at raising funds, it sees
itself modelled after an organization called EMBO, which
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1

1s the European Molecular Biology Organization, which has

2

a substantial budget which it gets from participating nations.

3

And in addition to being very active in training various

4

post-doctorals of workshops and so on runs a gel.

5

important, it runs one large international laboratory called

6

the European Molecular Biology Laboratory.

And most

At least some of the major participants in HUGO

7

8

at the moment are very enthusiastic about trying to have

9

the latest stages of the project -- a discreet number of

10

international laboratories -- that \JOuld do the real predominant

11

efforts in a way that will allow a lot of foreign nations.
Whether that fantasy ever really becomes a reality

12
13

will depend on whether the governments are willing to give

14

substantial amounts of money to a truly international organization.
Other people in the room may know more about EMBL

15
16

than I do.

17

year-by-year political negotiation of participating nations

18

to try to keep a budget going.

19

It's my impression that EMBL is a very delicate

It's very, very tricky.

And what I'm worried about with HUGO is that since

20

it's the whole world, and not just a small European nation,

21

it's going to be even more complicated.

22

23

So I've given you two extremes.

I think the reality

is likely to be somewhere in the middle.

24

DR. WATSON:

25

DR. KREVANS:

Right now HUGO has $75,000.
It's certainly not going to do a
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1

lot of harm with that, Jim.

2

DR. WATSON:

I would just like to say that I think

3

it will need roughly $1 million a year to really have a real

4

secretary and to be able to hire someone who really has this

5

function of really trying to integrate the activities in

6

different parts of the world.
I think if Charlie and I try and get bogged down

7

8

in bilateral discussions with all the different countries

9

involved, it would be a mess.

And we would like to in the

10

United States interact with HUGO and not have to, but that

11

means a secretary.

12

a year, which means that the United States itself would have

13

to make a contribution to it, that is our government.

And I think that's about $1 million dollars

And I would simply be 1n favor of -- if the means

14

15

can be found -- of NIH making a contribution to HUGO when

16

we really know what HUGO is going to be.
The thought, I think, was that for a year or two

17

18

you should get foundations to give money to put together

19

a secretary so that the governments would know what they're

20

buying.

21

DR. KREVAN:

One last question, please.

22

MR. HUNKAPILLAR:

23

And I was going to real quick follow up on what

Tim Hunkapillar of Cal Tech.

24

Bob said about the TRW.

This is an idea.

25

so far -- so far there haven't been any real difficulty.
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In fact, they come looking for people to put the technology
2

out into the world.

3

or another, not just NSF but those people, don't seem to

4

care a whole lot.

5

And NSF doesn't seem to care one way

Where is the NSF in this?

NSF obviously is a major

6

contributor to funding for instrumentation and large data

7

bases.

I know they do a lot of data bases all over the world.

8

And why do we never hear the NSF in these discussions?

9

DR. KREVANS:

10

Gentlemen?

That's the question that

I asked as you were gathering together.
DR. COOK-DEEGAN:

11

NSF in terms of budget has life

12

sciences budget that's roughly in the same ballpark as DOE's.

13

And they have probably the largest -- it may not be as of

14

now

15

biology instrumentation development.

16

but it used to be the largest budget for viewing

So, in fact, they are de facto in the game.

And

17

they've had a big role as you know.

18

only federal agency that ever supported the DNA sequencing.

19

So they do have a big role here.

20

I mean they were the

I think that they've been out of it just because

21

DOE and NIH both identified genome projects.

22

a conscious decision not to do that same thing.

23

is that eventually they're going to have to consolidate their

24

efforts so that they can have a match to what's going on,

25

and that's DOE and NIH.
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1

So I think it's a political answer; that is that

2

it made a conscious decision not to have that sort of an

3

approach to genome projects.

4

5
6

DR. KREVANS:

I'd like to close this with one question

and an advertisment.
The National Academy Press has just released a

7

committee report on which both Charles Cantor and James Watson

8

were members of the committee, and which v7as chaired by a

9

colleague of mine in San Francisco, Bruce Alberts, and it's

10

on mapping and sequencing the human genome.

11

from the National Academy Press.

12

San Francisco

13

And it's available

And the University of California,

gets a small royalty on copies sold.

In this book the question is raised:

Why sequence

14

the entire human genome<

And then it says that we hope everyone

15

agrees that it's a wonderful idea.

16

were only three major things that sort of stand in the way.

17

And the third one is -- and I'll read it:

And it says that there

18

"Even if the project is worthwhile, the

19

intensive effort required will divert

20

funds from other research aimed at

21

understanding the structure and function

22

of genes in all organisms and, therefore,

23

there will be a net loss rather than a

24

net gain of important biological information."

25

Now, the narrative goes on and destroys that argument,
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2

Cantor say something on that in closing this morning's

3

session.

4

DR. WATSON:

Well, I think the sum of money, if

5

you add together the NIH support of biomedical and NSF and

6

DOE and Agriculture Department, it would only be about two-and-a-

7

half percent of the total biology -- I think in terms which

8

are buying as [inaudible] it would be a bargain if we can

9

actually deliver.

10

The other is, I think, the breadth of the program

11

that we hope to have.

12

things which a lot of people would have wanted to support

13

out of our lungs of program projects even if this program

14

didn't exist.

15

At least at NIH, we would be doing

So I think our -- as I said before -- our aim is

16

to see that when we pass out the money, outsiders can't say

17

we're passing out money to second-class people who --· that

18

are just supported because we have a lump sum of money which

19

is of a certain size, and we can't fill it with good people.

20

So I think we really have to -- if we believe in

21

the project -- really work hard to encourage good people

22

to come into.

23

And if I could say one thing, I think right now

24

the program is structured, for the most part, at NIH in terms

25

of almost on a one-type grants.
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1

in rather large program project.

2

at universities like the University of California and otherwise

3

would come together and put together sort of genome centers

4

which we could fund because I think we're going to need a

5

variety of diverse talents, and by forming centers, you'll

6

be able to, I think, get more done than individually.

7

8
9

And I would hope that groups

DR. KREVANS:

Charles, do you have anything to

DR. CANTOR:

I think Jim has really said it all.

add?

10

I would just add as a postscript that that criticism was

11

leveled at and was valid at the original concept of the project.

12

That current technology, the moment you broaden the project

13

to the model which exists today, the criticism is really -- it

14

just doesn't apply.

15

DR. KREVANS:

What I was hoping our panelist.s would

16

say is that it's better to spend the money on this than particle

17

physics, but they're very ecumenical.

18
19

20

I'd like to thank our panelists very much and turn
the program back to Paul Boyer.
DR. BOYER:

We appreciate very much the fine panel

21

we've had this morning.

22

mention what our program will be.

23

some mistakes.

24

tried to give Julius two jobs, both at San Diego and here.

25

That was a mistake on the thing.

And I would like to continue to
Let me just quickly correct

It won't take 10 years.
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I need to take 10 years off my own time since a

1
2

Ph.D.

I want to say that in terms of biochemistry, the area

3

of proteins and enz:rme molecules uould have been far ahead

4

if Jim Watson would have chosen to be in that area.

5

it would have been a disaster for genetics if I would have

6

chosen to try to do Jim's research.

I think

I want to also say something about how this meeting

7

8

developed.

And it developed out of an interest of Senator

9

Garamendi's office and Senator Garamendi.

And what's going

10

to be the role in the future of the activities related to

11

the Human Genome Project.
And the people who put it together, I want to just

12

13

take brief recognition of and introduce Masako Dolan from

14

Senator Garamendi's staff.
Are you here Ms. Masako?

15
16

17

Would you stand up just

briefly.
And I was going to introduce Dr. Sue Huttner of

18

my biotechnology staff, but she just disappeared with

19

Dr. Watson.

20

But I would like to at least say these and their

21

staff have done a fine job of bringing all the money together,

22

and a round of applause would be in order for them.

23

I would like to mention just briefly our technical

24

plans now for lunch.

We will have a lunch available on the

25

terrace in which we can pick up lunch.
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1

tables on the terrace where you can sit.

Others can proceed

2

with this meager lunch that you will have out through the

3

opening of the building and compete for space in the eating

4

S8rvice called the bomb shelter, which is just across from

5

the front of the building.

6

Are there any other technical plans I need to mention?

7

[No response.]

8

And we're also very pleased that we can have Senator

9
10

Garamendi here to comment on just a bit about the importance
of collaborative research to the state's economy.
Now, I mentioned that Senator Garamendi here has

11

12

a strong interest in the University of California; although,

13

he took his Bachelor's Degree at Berkeley, he has learned

14

to appreciate at UCLA, San Diego, San Francisco, Sacramento,

15

Riverside and so forth.

16

He is a very successful cattle rancher, but is also the Chairman

17

of the Senate Committee on Revenue and Taxation and the Joint

18

Committee on Science and Technology.

19

on his background, but we're more interested in hearing his

20

comments.

21

He had an MBA for Harvard University.

And I could say other

And Senator Garamendi, if you would tell us a bit

22

here while we have a few moments before

23

it would be greatly appreciated.

24
25

SENATOR GARAMENDI:

vJe

move for lunch,

It's good to be with you.

I'm

delighted to see the size of this audience and the participants
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that are here.
2

We, in California, like to pride ourselves as being

3

on the top of the scientific and technology of the world.

4

And indeed we have been.

5

certainly the Joint Science and Technology Committee, is

6

to see to it that we remain at the top.

7

And our goal in the state legislature,

There are no guarantees that simply because we're

8

in this golden state and get to enjoy this marvelous weather

9

when the rest of the country is freezing that we deserve

10

to be at the top.

11

every single day.

12

We have to earn it.

We have to earn it

You don't get there, and you don't earn this ranking

13

by letting opportunities pass.

We have lost many, many major

14

research projects in the last six or seven years here in

15

the State of California.

16

opportunities.

We don't intend to lose future

17

The project, the Human Genome Project, is a huge

18

one, and it involves -- it will involve the entire nation.

19

And as we were hearing a few moments ago, it involves many

20

other parts of the world in the process of figuring out what

21

human beings are all about.

22

California is ahead.

We need to do some things

23

to stay ahead,

just in the pure research.

24

I want to make to you are not just that area.

25

you are scientists, most of you.
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1

and you provide certain tools to the scientific community.

2

It is that part of the linkage that I want to spend a few

3

moments on with you.
The scientific efforts of the State of California

4

5

in the past have invariably been translated into an improvement
the soc

6

in California, in our economic status, in

7

the distribution of wealth to the many citizens of this state,

8

and to opportunities for every individual in the state to

9

prosper, to benefit directly from that scientific endeavor.
We have to see that that continues to occur.

10

I

11

think that anyone that looks at the future economies of the

12

world have come to the conclusion that those economies are

13

going to be based on a large extent on the issues of biotechnology.

14

It is a field that is growing and blossoming and holds tremendous

15

potential, certainly in the area of human health.

16

all of you are aware of that, and certainly the Chancellor

17

is.

18

I think

In the areas of pollution, in the areas of dealing

19

with -- you name the problems that are out there in front

20

of us -- feeding people, dealing with the environmental problems

21

that exist today.

22

come back to the issues of biotech and biology.

23

a tremendous potential here.

24
25

All of those things can be reduced or
There is

We have to make sure that the economy of California
has in its foundations for the future a very strong scientific
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1

program in biology and biotechnologies of all sort.

2

particular project, the Human Genome Project, being funded

3

by the federal government gives us the opportunity in California

4

to maintain our leadership and to advance our leadership

5

in this area.

6

carry on the kinds of research that are fundamental in this

7

area, we see a tremendous potential for all the citizens

8

of this state and beyond that, the nation and the world,

9

to benefit from our efforts here.

10

This

Out of that, if we're able to position ourselves,

We see our industries providing the tools necessary

11

to sequence the gene and all the other scientific tools that

12

are going to be necessary, not only to do the research but

13

then to take that research on into products or into medicine

14

or whatever it happens to be.

15

In order for us to make each of those steps, we

16

need to have a very, very close collaboration between the

17

scientific community, the government and the private

18

secto~.

One of the primary goals of this conference is

19

to pull together all of those elements so that they are all

20

working together right at the outset.

21

First, to see to it that we in California have

22

a reasonable share of the federal research dollars that are

23

coming out.

24
25

Secondly, to encourage our state government and
policy makers in state government to provide the necessary
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1

state funding to backfill, to fill in wherever the research

2

dollars at the federal level are inadequate or insufficient,

3

and also to provide a base of support so that those research

4

dollars can be used here to provide the facilities, the research

5

grants for the scientists and the others that are going to

6

be necessary to conduct that research.
So we're trying to build that coalition in the

7

8

governmental area, to build the knowledge in the governmental

9

area so that the policy makers, those of us that put together

10

the budgets for the state and set the priorities are ready

1,

and willing to provide the money.
We've also brought together here major players

12

13

in the private sector who have a very, very significant role

14

and opportunity to provide, as I said earlier, the tools

15

and also later to use the research to develop products, and

16

in terms of our whole society develop the economy, to add

17

value, to add wealth to this economy so that it can go back

18

and do something in the next round of research in moving

19

and advancing the citizens of this state and this natiori.

20

So our hope out of this conference

and I believe

21

that there will be subsequent conferences -- is to move this

22

process along.

23

progress.

24

I think the first meeting we had we started with three or

25

four of us, and now and then it went about to 20 or 30 at

We've already made, I think, very substantial

The fact that so many of you are here today
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1

Berkeley,

and now we're well over a 100 here -- that kind

2

of growth and understanding, collaberation, communication

3

is going to be essential in building in the State of California,

4

whether it's at the University of California or Stanford

5

or Cal Tech or any of the other laboratories or private industries,

6

the opportunity for this state to carry on this kind of research

7

and to benefit directly from the research that's going to

8

be conducted.
We know that we can do it in this state.

9

Challenge

10

is one of those that comes to us every day.

Fortunately,

11

we have the leaders here among us that will carry it out.
I want you to know that the California State Legislature

12
13

is aware of this project.

14

make it a priority and to fund where appropriate.

15

your input and information to help us in that process of

16

trying to determine where our resources should be spent.

We need

Now that I have sufficiently wet your appetite,

17

18

We will be doing what we can to

let's go have lunch.

19

Thank you very much for being here.

20

DR. BOYER:

Let me just comrnEont, Senator Garamendi,

21

that had we opened this for full attendance, we would not

22

have had 100 people, we would have had 500 people at the

23

meeting.

24

SENATOR GARAMENDI:

25

DR. BOYER:

Good.

What you have are the people that are
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1

really the most interested.

2

field.

3

things.

You have the leaders in the

These are the important people to carry out these

4

Thank you very much for your pertinent comments.

5

We're adjourned for lunch.

6

7

Recess 12:00 p.m. to 1:00 p.m.

8
9
10
11

12
13
14

15
16

17
18

19

20
21

22
23
24

25
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1

Afternoon Session:

2

December 2, 1988

3

1:00 p.m.

California's Participation

4

5

PROCEEDINGS

6
7

DR. BOYER:

I'd like to welcome you again, but

8

now to the afternoon session, after what to me was a very

9

interesting and intriguing morning session posing many promising

10

11

prospectives and problems which come ahead.
In the afternoon session, we're going to be looking

12

with three panels on the impact of the genome initiatives

13

on basic research, the need in technologies and hardware

14

and the utilization of the data.

15

And let me comment that in the organization here,

16

we've had so much interest in participation by capable people

17

that we may have put too much into the pie; that is, we may

18

have more participants that could tell us interesting information

19

than we have time on the panel.

20

So I need to comment briefly here of how we would

21

like the panelists perhaps to proceed would be to take the

22

information that they have gained in the morning and what

23

they know themselves about the problems that they want to

24

address and in a way of self-introduction speak for five

25

and not longer than 10 minutes each about what their perspectives
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1

are of the issues that face this on the Human Genome Project.

2

Then that will allow the audience to know what

3

the panelists' viewpoints and perhaps areas of interests

4

are, and then have the balance of the time open for discussion

5

from the audience among the panelists or with the audience

6

because otherwise if we were to get all of the information

7

that would be really useful, our talkers would need to extend

8

far beyond this afternoon.

9

Now, Winston Salser, Professor of Molecular Biology

10

at UCLA who I found had an understanding of the implications

11

of DNA long before most people in the field, not earlier

12

than Jim Watson, who also himself has been a student and

13

contributor to the area is going to chair our afternoon session.

14

15
16

And I will not try to introduce the moderators
of that, but I will turn it over to Winston at this point.
I will mention one other thing.

I think this morning

17

that I mentioned our other sponsors.

18

Laboratory and the California Department of Commerce as well

19

as the Joint Committee on Science and Technology with Senator

20

Garamendi and the U.C Biotech Program.

21

out, I thank you anyway.

22

DR. SALSER:

The Lawrence Berkeley

If I left anyone

I remember as a young kid driving

23

from a farm that we farmed in western Kansas to Wichita

24

where my dad was also a school principal hearing on the radio

25

a popular program about -- it must have been right after
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1

the discovery of how DNA replicated.

2

by that.

3

And I was really intrigued

I guess I was a teenager.
Let me tell you a little bit about my perspective

4

on DNA sequencing because I'm going to make a couple of comments

5

that I hope will stimulate discussion.
During the past year I've been -- among other

6
7

things -- setting up a DNA sequencing facility which will

8

provide automated sequencing for the more than 60 labs here

9

at UCLA that have need of that.
And we were very pleased that we were quickly able

10
11

to get highly accurate sequences out beyond 500 nucleotides

12

per run.

13

in the near future that machines should be able to do all

14

of UCLA's current DNA sequencing needs with a very cost-effective

15

manner.

16

And we think that things are going well and that

So we are very pleased with the technology.
But also I've become aware in doing that about

17

how much further the technology can be taken with some further

18

automation.

19

sequencing newsletter that now goes out to about more than

20

700 people that are connected with automated DNA sequencing.

And to facilitate that I've organized an international

21

So from these perspectives and from exchange of

22

information with quite a wide number of people, I think I

23

have a little bit of insight into how the actual sequencing

24

part of the genome sequencing initiative might go if it was

25

based on an extrapolation of the current technology, things
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1

that are now in at least prototype form without involving

2

some new things that no one has discussed yet.

3

happens here, it's another area of magnitude, that really

4

would be delightful.

A miracle

How would

5

But I think it's useful to consider:

6

it work if we just extrapolated things that we now have?

7

In the transparency I've broken things down into

8

four areas, and the top is the human genetic map.

9

my own laboratory in collaboration with Dr. Gatti, was one

And actually

10

of the 20 original labs in the CEPH consortium that's put

11

together a number of genetic maps of the human genome, and

12

I think it's very fair to all of us that that works.

13

technology is working very well, and undoubtedly it will

14

be improved and so on.

That

15

Incidentally, here at UCLA we've just succeeded

16

in mapping the gene for Ataxia telengiectasia, which is a

17

disease probably unknown to you, but it's turning out to

18

be more important than the disease Ataxia itself since in

19

the past few years it's become clear that that Ataxia gene

20

is responsible for an estimated 20 percent of breast cancer

21

and a large number of other cancers appearing in the heterozygote

22

carriers of the gene rather than, of course, the patients

23

with the neurological disease.

24

25

But similarly in the second area of physical maps,
Charlie Cantor has pointed out to you the things thore that
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we don't know how to do and the problems.

But from the fact,

2

the success in the Ceanorhabditis elegans case one can take

3

encouragement that a great deal can be done, and that ultimately

4

that will be-- one sort of has a picture of how that's going

5

to be worked out.

6

There's also the problem of converting cosmids

7

or YAC's, whatever the physical maps are made of, to sequencing

8

clones -- sometimes referred to as the subcloning problem -- and

9

this is a really important technical problem.

And I guess

10

we'd like to have perhaps automation of the Henikoff deletion

11

procedure, or something like that, to solve it in a really

12

powerful method.

13

But what I want to talk just briefly about is the

14

four step, the actual sequencing.

15

NRC report, put it this way:

16

in scaling up automated techniques that are already at the

17

prototype stage, or does it lie in revolutionary new methods

18

which may as yet undiscovered?

19

I think the report, the

Is the future likely to lie

Well, as of six months ago when I did a survey

20

as part of the intersequencer's newsletter, I think I can

21

say that currently the best machines are actually working

22

at a rate that would require about 4,000 machine years to

23

sequence the human genome to a depth of 1.

24

that's the kind of thing that Jim Watson was speaking about

25

when he said that currently sequencing is very expensive;
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1

although, this may already represent an advance, probably

2

does, over what he was talking about.
But the encouraging thing is that it's clear that

3
4

the machines could go a lot faster.

And if we had automation

5

of template preparation and automation of the sequcncinq

6

reactions, we could go at half of 10 to

7

per machine per year.

8

sequentures, we could go at about 10 to the 7th nuc1eotides

9

per machine year.

th<~

7th nucleoti dPs

And with minor changes in the existing

Now, that means that 300 machine years would suffice

10
11

to sequence the human genome to a depth of 1, but, of course,

12

that's not adequate.

13

300 machines to sequence both strands to a depth of 2.

Or you could take four years with these

But on the second one, which repeats a little bit

14
15

of that and goes further to a depth of 2, and the capital

16

costs turn out to be not totally unreasonable.

17

But 300 machines would cost around $30 million whether you

18

bought them from ABI or Dupont, and I don't know if any other

19

machines are out, and if you have to build new space to house

20

them.

21

$200 million roughly.

22

would cost to staff it.

23

part, not the other parts.

24

equal the capital costs, you could supply about 15 man years

25

for each of these 300 machines.

It's expensive.

So your total capital expenditure might get up to
It's more problematic how much it
This is just for the sequencing
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1

So I think this is perhaps doable, but I think

2

that Jim Watson really put it very well when he said, "The

3

question is:

4

dull work?"

5

How do you interest intelligent people in very

What we're doing now is extremely exciting because

6

we're pushing it ahead.

We're improving the technology.

7

But now we're talking about -- well, supposing you got the

8

technology, and you said that we now want to replicate this

9

and have 300 machines.

I don't know at what stage you'd

10

make that decision.

11

immediately a very different ball game.

12

people to think about that in more concrete terms than I've

13

heard of being done before.

14
15

16

But if you did make that decision, it's
And I just wanted

And with that, I will turn it over to the first
talk this afternoon which will be by Kenneth Gibson.
He was appointed by Governor Deukmejian in 1987

17

to head the California Department of Commerce.

18

was trained at Princeton University.

19

us the perspective of big business because he served as Senior

20

Vice-President for Kaiser Steel Corporation before he joined

21

the state government.

22

Ken Gibson

And he also brings

And as Director of the Department of Commerce,

23

he's the administrative official in the state most directly

24

concerned with his topic this afternoon which is the California

25

Competitive Technology Program.
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MR. GIBSON:

1

After hearing Winston's comments,

2

I hope the group will forgive me if I revert back to English.

3

It's always helpful.

4

supPrconductivity symposium a coupln of monthn aqo,

5

had exactly the same feeling.

6

know they were English.

7

sequence that I've always heard them.

g€d.

invite~(!

Inf'

down to

Most of the words

<1

c~nd

were~

···· l

They just weren't exactly the same

Anyway, I appreciate being here, and I'm sorry

8
9

Sey S

that I missed this morning's session.

I understand that

10

it was very helpful.

What I've been asked to do is describe

11

to you a new program which is just being initiated on the

12

state level that we think should very definitely be material

13

and certainly to our state's technology development.
And I'd like to give you, if I may, just a brief

14
15

background as to the philosophy of how this program came

16

about in the first place, and then to bring you up to date

17

on the status of it.
First and foremost, the Competitive Technology

18
19

Program in its initial conception and really the basis for

20

it throughout is that for us it's an economic development

21

program.

22

It has always intended to be that.
And I've quoted a couple of phrases out of Simon

23

Ramo's

24

this across.

25

recent book, The Business of Science, to bring
He says:

"As a nation we can't raise our average
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1

personal income by shifting a constant

2

total of assets around among our own

3

people, nor can we count on discovering

4

huge deposits of gold, oil, or diamonds

5

on our land.

6

States to raise its living standards is

7

to excel in technology.

8
9

A sure way for the United

"Technology can be applied to increase
the resources of a nation, to generate

10

wealth that would not exist if the

11

technology were not employed."

12

Well, I think that obviously what is true in the

13

United States is even more true in California.

14

as rich in natural resources as we have been, we've pretty much

15

run out of those.

16

attest to that.

17

And even

Coming from the steel industry, I can

But what we have now is the cold hard fact that

18

there's really only one natural resource remaining in California

19

vJhich can be converted into finished products to the degree

20

anyway that it will ultimately increase our standard of living,

21

and that's to convert our ideas and our brains into finished

22

products and processes for our state.

23

So our whole idea, obviously, with this program

24

is hopefully to bring the resources of our campuses and our

25

national laboratories into the commercial marketplace in
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1

the private sector.

2

Our challenge, as we see it, is to be more efficient

3

and a lot more prolific in converting these resources into

4

world-class products and jobs and manufacturing excellence.

5

And it is this realization really that brought around this

6

program and its ideas.

7

All the elements were here when we looked at what

8

this program should be.

9

doing.

We looked at what other states were

And other states have been very successful with programs.

10

And we determined that we had a unique situation in California

11

though that allowed us to not have to do some things that

12

some other states are doing.
We didn't feel that we had to go into the venture

13
14

capital business as some other states are.

15

that we had to get into a position of taking equity positions

16

in companies, which other states are doing.

17

really the components are here.

18

of this state are incredible.

19

in this state that are already here.

20

had is a vehicle to help them bring all these resources together.

21

We didn't feel

We felt that

The technological resources
We do have the entrepreneurs
But what we have not

We've achieved a great deal in this state, and

22

our topological excellence doesn't have to apologize to anyone.

23

But we're at a point in a global economy where we simply

24

have got to do more and do it better than we ever have in

25

the past.
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So Governor Deukmejian introduced this program
2

in

3

the program actually with one of his Saturday morning radio

4

shows.

5

that to give you a bit of the flavor for the idea and philosophy

6

behind the program.

of 1987.

He issued an executive order, and he introduced

And in that -- and I'd just like to read you from

He said that with this new partnership, that is

7

8

the private sector, the academic sector, and the state government,

9

we will encourage and support technology breakthroughs that

10

will have commercial potential through matching funds.

We

11

will stimulate industry to take these discoveries and turn

12

them into high-quality products that will generate new markets

13

and jobs for California.
We have neither the need nor the intention to wait

14
15

until the federal government or some other entity develops

16

a selection process to establish these

17

a process over which California has little or no control.

18

proble~s

-- projects,

So the point of this program, hopefully, is to

19

allow California to take better control of its own destiny.

20

And that's certainly what part of this program is intended

21

to do.

22

The funds that are available from this program,

23

as far as we're concerned, are for the benefit of California

24

companies.

25

to California companies as an incentive to -- as a challenge

We don't look upon them so much as an incentive
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1

to California companies.

The point is that the program will

2

provide an opportunity for the private sector which it really

3

has not had before.
We've had some excellent examples on a smaller

4

5

basis, the micro programs with the University, of course,

6

we think has been very successful, a couple of other pilot

7

programs, RIMTECH as another example.

8

very narrow framework, and we simply need a much more broad--based

9

program.

10

But they are in a

And I think we're at least on the right track right

now.

11

As I said, the governor introduced this program

12

in May.

Subsequent to that, Senator Garamendi introduced

13

a bill and Assemblyman Chuck Quackenbush introduced a second

14

piece of legislature which were passed in August and signed

15

into law in September.

16

legislation that had now made this new program a reality.

So those were the two pieces of enabling

17

What it does is that it creates, first of all,

18

an Office of Competitive Technology in the Department of

19

Commerce.

20

current fiscal year that runs through June of next year.

21

The governor has stated that he will be asking for $20 million

22

a year from then on.

23

We are funded at a level of $7 million in this

I have to tell you that with the passing of Proposition

24

98, none of us are sure what our budgets are going to look

25

like.

I won't get into an argument with anyone here over
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the merits of Prop. 98, but I can only tell you that the
2

cold hard fact is that it is going to wreck havoc with other

3

budgets, not the least of which is the University of California.
But in any event, we'll have to just see what that

4

5

$20 million next fiscal year looks like.

We think it will

6

be substantial.

7

program.

8

and it has been a very, very successful bipartisan effort.

Certainly the Governor is dedicated to this

It has the very strong support of Senator Garamendi,

So it is not for lack of support that the program

9
10

may have less funding than what we had anticipated, but that

11

remains to be seen.

12

significant funds here for us to get started.

In any event there are some reasonably

As I said, the legislation was signed in September.

13
14

Since that time, we have been writing the regulations to

15

the program.

16

basis, which means the regulations are also being written

17

on an emergency basis and should be completed in about two

18

weeks.

19

virtually completed.

20

The legislation was passed on an emergency

We have a final draft.

And so the regulations are

The application process for the program is coincidental

21

to this so that if everything continues to go well the next

22

two to three weeks, we should have the regulations in place

23

and the application process ready to distribute by very early

24

in January.

25

The program is obviously a technology transfer
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1

program.

It is intended to bring the private sector to the

2

labs and to the campuses.

3

very few exceptions, private sector participation.

4

for the benefit of California companies.

5

be done in California.

6

either a public agency, a university, a national laboratory

7

or a nonprofit organization of some other type.

8
9

Any given project requires, with
It is

We want this to

And the funding will flow through

It also comprehends intra-industry collaberation;
obviously, that would be applicable to the biotechnology

10

industry in some areas where discussions with probably three

11

or four different discreet industries at this point who are

12

interested in putting together intra-industry consortia that

13

we think would fit the requirements of this program very,

14

very well.

15

The program requires participation from the private

16

sector and from California companies.

17

involvement from companies outside of the state as long as

18

there is a California company or companies that are involved

19

in the project.

20

the project work, if you will, does have to take place in

21

California.

22

It does not prohibit

But the majority -- the great majority of

The purpose of the program again is to address

23

the competitive needs of our state.

24

policy issues of our state such as environmental concerns.

25

We intend to see this program -- at least hopefully see this
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1

program addressing environmental concerns, environmental

2

technologies that hopefully will help companies who are already

3

here who are suffering from environmental concerns of one

4

type or another, and find the technological wherewithal

5

to stay in the state.

6

So it's going to be heavily emphasizing healthy

7

companies who are already here, addressing the issues that

8

companies have existing in California today and, obviously,

9

serve as an inducement to bring other business and other

10
11

companies into California.
That's the rudiments of the program.

The program

12

was written and the statute was written hopefully in a reasonably

13

general manner so that we haven't locked ourselves in it.

14

It is intended to be nonintrusive, if you will.

15

attempting to dictate the policies of any given institution.

16

We simply are trying to create a catalyst and a program that

17

will induce collaboration.

18

who see their way to apply for them and to use them.

19

We are not

And the funds are there for those

If there are any questions about this, or if we

20

have time for a question or two, I'd sure be happy to answer

21

any if anyone else has anything they'd like to ask.

22
23

UNIDENTIFIED SPEAKER:

Is one of the industries

that you're talking to the biotechnology industry?

24

MR. GIBSON:

Yes.

25

DR. SALSER:

What kind of a generic kind of a
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1

proposal -- I know that you wouldn't want to discuss specific

2

ones -- do you see coming from the biotechnology industry,

3

especially related to the Human Genome Project?
MR. GIBSON:

4

I don't know that I can answer that

5

right now.

I think that's exactly what this kind of conference

6

is there to tell us.

7

from here to there.

8

for hoping to achieve the incremental steps to the end result.

Obviously, there are so many steps
And the program would certainly be available

So in other words, if we're talking about computer

9
10

processing or a process achievement along the way, the

11

program-- in other words --we don't see it as always being

12

on the tail end where a product is going to cough out and

13

we can go buy it at Sears.

It's not intended to do that.

On the other hand, it is intended to provide funding

14

15

for projects that do have in mind the eventual commercialization

16

or a product-oriented end result, or a process-oriented end

17

result, if you will, for the good of the state and the companies

18

in it.

19

But it would be hard for me to answer that question

20

because I'm not sure where you are on that.

21

more up to this kind of a group and the industry to tell

22

us what they need out of this program.

23

UNIDENTIFIED SPEAKER:

That's really

Does your program have anything

24

to say about or do with the public education of new technology,

25

or have any interest in it?
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MR. GIBSON:
2

address it directly.

3

that.

4

if you will.

5

It has interest in it.

It doesn't

Again, I think we'd be very open to

But there is no concrete records of that in the statute,

But, again, to the degree that it facilitates the

6

kind of project that we're looking for, we're open for suggestions.

7

And that's really the key point of this is that the concrete

8

is still wet on this program.

9

have input from a very wide variety of sources.

And we're very anxious to

UNIDENTIFIED SPEAKER:

10

Could funding for your program

11

serve to attract federal funding for a large project like

12

this?

13

HR. GIBSON:

That's an excellent question.

When

14

the Governor said and when we say that we're trying to go

15

our own way here and not be dependent on federal projects

16

or federal funds that doesn't mean that we don't want to

17

attract federal funds.

18

And we really feel that if our program is successful

19

it should tend to attract federal funding.

And a major part

20

of the project is to leverage private sector dollars, federal

21

dollars, whatever there may be.

22

DR. SALSER:

23

By the way, I've been told that there's not going

Thank you very much.

24

to be a coffee break this afternoon, but there will be a

25

few minutes between each of the segments for people to put
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1

slides in the projector trays and so on.

And I'm told that

2

there is coffee on the tables out there, and so you can come

3

in and out.
Our first panel this afternoon is chaired by Dr.

4

Dr. Arnheim is California trained, having

5

Norman Arnheim.

6

received his Ph.D. in Berkeley in 1965.

7

he has been chair of the Department of Biological Sciences

8

at USC.

9

And since 1985,

Many of you also know him, however, from his stint

10

as the Senior Scientist at the Cetus Corporation where he

11

played a major role in developing the polymerase chain reaction

12

approach that many of us are using.

13

More recently, he's also played a major role in

14

extending the usefulness of this powerful technique.

15

group has shown, for instance, that you can work with very

16

difficult but very useful material such as thin sections

17

of human tissue, of parraffin embeded tissue, or even single

18

spermatazoa.

19

His

And as Charlie Cantor mentioned this morning, related

20

to that technique, this technique for analysis of single

21

sperm sounds rather obtuse, but may become one of the most

22

powerful techniques for fine structure of genetic mapping

23

with human chromosomes which is a very important part of

24

what we're discussing today.

25

Dr. Arnheim will introduce the members of this
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1

panel who will discuss the potential impact of the genome

2

initiatives on basic research.
DR. ARNHEIM:

3

As was just mentioned, the purpose

4

of this panel is to discuss the impact of the human genome

5

initiative on basic research.

6

there are at least two fundamental principles that we can

7

rely on.
One is that there clearly will be a technology

8

9

And I think it's clear that

transfer, that is all the technologies and technologies that

10

we can't even possibly dream about perhaps will have an impact

11

on people who are interested in doing basic research.

12

I think there's no question about that.

And

It's also true that one of the major driving forces

13

~enome

14

for the human

15

some basic fundamental principles of biology.

16

equally clear that the kind of data that is going to be coming

17

out of the mapping and sequencing part of the initiative

18

is going to absolutely require -- in order to understand

19

the data

20

initiative is the need to understand
And it's also

some applications of basic biological research.
So I think each of the basic biology and the quest

21

for fundamental information about basic biological principles

22

is going to drive the human genome initiative, and at the

23

same time the human genome initiative in order for it to

24

understand its data is going to be driving the basic research

25

community at the same time.
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Now, three of our panelists this afternoon will

2

be discussing how the human genome initiative will impact

3

on general cell and developmental biology in animal models

4

of disease in human genetics and also evolutionary biology.
And, finally, our fourth speaker will more or less

5
6

bridge this panel to the next one by discussing some basic

7

research that's needed to help in some new technology developments.

8

I'd like Glen Evans, who is an Associate Professor

9

at the Salk Institute to perhaps start off this afternoon.

10

And he's going to be talking about areas that are related

11

to generating animal models for human disease.

12

DR.

EVANS:

One of the -- there are actually from

13

my point of view two major important things to come out of

14

the human genome initiative

15
16

One, of course, is simply this

sequence of nucleotides that make up human chromosomes or
the human genome.

17

But as Francis Crick is always very quick to remind

18

us, we don't really care what the structure of the genes

19

are.

20

And one can anticipate that knowing the complete sequence

21

of the human genome is likely to give us a vast amount of

22

information but, in fact, in many cases won't answer that

23

last question:

We want to know what they do, what their function is.

What do

the genes do?

24

To approach that and, in fact, to approach what

25

is probably the most important question in biology at the
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1

present time, which is:

2

development such that a single cell can turn into an individual

3

human being requires another step in biology?

4

How does the genome control or program

And while what I'll talk about in just this few

5

minutes is not directly under the auspices of the Genome

6

Project, it's something that will be evolving at the same

7

time as the Genome Project in terms of technology and techniques.

8
9
10

11

Genetics has really undergone a major change these
days in that one can now do experiments.
were not possible several years ago.
Could I have the slides?

12

are they controlled from there?

13

four slides or five, I think.

14

Genetic experiments

Do we control that, or

And you need to skip forward

One of the ways that we might begin to approach

15

what genes do having determined them is, in fact, to reimplant

16

them into an organisrrt, either in its normal configuration

17

or after making some changes.

18

in a large number of laboratories with a technique knmm

19

as producing transgenic animals.

20

This is now fairly routine

This is a selection of mouse embryos at a very

21

early stage, essentially a one-cell stage.

22

microscope, one can essentially hold that using micro tools

23

and introduce back into that embryo a small amount of material,

24

a gene, either a gene when it's cloned from a human being,

25

from a mouse, from another organism in its natural state
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1

or one in which one has expressed one's creativity and made

2

a number of changes.

3

Those embryos can then be reimplanted back into

~

a pregnant animal.

5

later one has mice.

And the next slide shows that 21 days

This mouse looks completely normal from the outside.

6

7

On the next slide though, we can demonstrate by looking at

8

the DNA that it has been genetically modified, and that it

9

now has material present in its genome which was not there

10

before.
The animals that show the extra bands here are

11
12

the ones where we had planted an extra piece of genetic material,

13

and that genetic material can be from a large number of sources.
One way that one might go about understanding what

14
15

some of the genes do that will be uncovered by the Genome

16

Project is essentially to reimplant those, having made a

17

mutation in that, then ask:

18

have?

19

What effect does that mutation

This can take a wide variety of

can use a wide

20

variety of different approaches which can go from simply

21

inactivating the gene using techniques which are just nnw

22

becoming available, that is turninq if nff, and

23

is the effect of that

24

final organism?

25

be turned on somewhere that it's not normally expressed.

~h~ence

aski~q:

of the gene product on the

Or, in fact, one can ask that that gene
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1

A gene that might normally be exprP-ssed in the liver, one

2

could perhaps turn on in the brain, and ask:

3

be the consequence of that?

What would

4

Both kinds of approaches are important because

5

many of the genes that one might imagine being important

6

to development if inactivated would be lethal.

7

not allow the animal to survive and develop.

8
9

It 'dOU}_d

The next slide shows that this can actually be
taken quite far, in fact,

~o

the extreme in that one can
This approach

10

model animals to simulate certain human diseases.

11

is now in its very infancy, but it has the potential of being

12

extremely valuable fer making models

13

we really can't imagine the underlying cause.

o~

diseases for which

This is an animal on the right which is completely

14

This is an animal on the left in which we've modeled

15

norma~.

16

a genetic defect in the development of the eye.

17

been done by implanting a plant gene from the castor bean

18

in the genetic compliment of the animal under the control

19

of elements which turn on at a specific time in development

20

and kill certain cells that are responsible, in fact, critical

21

for that developmental process.

This has

22

And a large number of labs are in the process of

23

doing those kinds of studies to derive models for diseases

24

such as Huntington's disease or neurodegenerative diseases

25

in which certain cells may degenerate or die at particular
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1

times in development but, in fact, we have no idea what the

2

underlying causr: is.

3

Eventually, as the Genome Project progresses, one

4

can imagine a lot of the genes responsible for those diseases

5

might be uncove=ed, but we may have no idea how they function

6

in the animal.

7

us to go a little bit further along that.

8

And these kinds of approacheG might allow

The next slide, I believe is the last one, is to

9

emphasize the point that these modifications are not only

10

the individual in which the gene is introduced but all of

11

the progeny of that; that is it's a true genetically engineered

12

situation where not only the initial animal but all of the

13

subsequent progeny are also modified.

14

can then be bred and extremely useful for a large number

15

of studies.

And those animals

16

One final word which addresses a couple o:: comr1ents

17

made this morning is that it is not possible to do experiments

18

in human beings, particularly genetic experiments.

19

it is possible to do those kinds of experiments in animals;

20

therefore, it's very important that as one begins to understand

21

the human genome that in parallel one begins to understand

22

the genomes of other animals in which one can do those experiments,

23

in particular the mouse which is a ,.,onderful genetic system

24

and becoming a model for manipulation.

25

Yet,

Many of the regions of the human genome are, in
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1

fact, colincar with the same regions in the mouse genome;

2

that is if one finds a gene in a particular place in man

3

and one looks in a similar place in the mouse, one finds

4

the same gene.

5

That's one way to anticipate that almost anything,

6

aleost anything, one would find in the human genome, a similar

7

gene would be present in the mouse, and that would allow

8

one to, in fact, approach it in an experimental sense rather

9

than in a descriptive sense.
I think that's all I want to say.

10

11

And I think

we' 11 lead into David Cox.
DR. ARNHEIM:

12

Yes, our next speaker is David Co:::

13

who is a human geneticist, and he will give us some insight

14

about what he feels the consequences of the

15

in that area.

16

DR. COX:

proje~t

to he

Let me just say that my comnents will

17

sort of be focused more specifically on one aspect of what

18

Jim Watson and Charles Cantor talked about this morning which

19

was the overall broad-brush stroke of the Human Genome Project.

20

But right now we're not waiting until we know where all the

21

genes are before we start trying to apply some of the technologies

22

and some of the approaches that we all hope to use in the

23

future.

24

25

And in the next couple of minutes what I'd like
to do is show you at least one apsect of that that's being
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1

done in my lab and in Rick Myers' lab in collaboration in

2

San Francisco, but just as an aspect of what's going on by

3

lots of different human geneticists around the country.

~

Where do we stand now over the past five years

5

with respect to recombinant DNA technology in human genetics?

6

And it's no mystery to this audience that it's been a revolution

7

in human genetics by the use of RFLP analysis allowing us

8

to identify where in the genome various human

9

lie even though we know nothing about the protein products that

10

dise~se

gen~s

codes for those mutant genes.

11

Just a minor list of examples:

Huntington's disease,

12

a gene for schizophrenia, a gene for manic depressive illness,

13

a gene for Alzheimer's disease; it goes on and on.

1~

truly remarkable.

It's

But just as though that's remarkable, it's been

15
16

equally dismal how in some of those situations where we've

17

known where the link gene was and on which chromosome it

18

lay, how difficult it's been to get the mutant gene product

19

out.

20

And so while we think about developing ways to

21

sequence the whole human genome, our approaches for coming

22

up with that development, I think in human genetics, is being

23

applied to present day problems.

24

it's how to get those genes out and what kind of technologies

25

cuuld then be developed for those specific problems. but
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1

also in more general ways.

2

So what's the experimental strategy?

3

such possible experimental strategy that one might take.

4

The first is specifically with regards to the Huntington's

5

disease gene, a simple dominant gene for a neurodegenerative

6

disorder.

7

4.

8

9

This is one

It's knovvn to map to the distal short end of Chromosome

If you simply take purified Chromosome 4 and try
and isolate DNA probes from that, the chance that you're

10

going to be close enough to show genetic linkage to the Huntington's

11

disease gene is very, very slim.

12

So what's an approach that will give you an order

13

of magnitude boost -- as Charles and Jim said today --- an

14

order of magnitude boost of getting probes in the region

15

that you vlan t?

16

Well, a simple approach would be to isolate the

17

region of Chromosome 4 in a somatic cell hybrid so that it

18

was the only human material there.

19

then the next thing you could do is isolate human probes

20

from that hybrid cell, and you'd be very close to the gene.

21

If you could do that,

So the very first step is a simple minded one,

22

how you just crack off a piece of chromosome that you want.

23

Once you have those probes though, you have a pot

24

of full of probes, but you don't know what their relative

25

order is to one another.
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1

Cantor pointed out -·- the real magnitude of the problem of

2

getting real fine structure genetic

3

relative to one another.

~aps

What you'd like is a genetic

4

to order those probes

~ap

that wasn't

5

1 million base pairs per 1 percent recombination, but you'd

6

like a genetic map that was much closer to the physical distance

7

so that 1 percent of a genetic unit would be like 100 kilobases.

8

So that's the second thing if one could come up with that.
The third thing is that once you've ordered all

9
10

the probes, you still don't know where the disease gene is.

11

You have to go back into the affected families.

12

probes that you think off of the ordered probes are the nest

13

likely to be flanking markers, but then they have to be polymorphic.

14

They have to be informative in the families that you're interested

15

in.

16

probe.

17

One needs a better technology

~or

You take

that for any particular

How does one approach that problem?
And,

finally, once you find the flanking markers,

18

hmv you clone all the DNA out bet\veen those flanking markers,

19

one needs a better technology for that.

20

These are the problems that are posed by our embarrassment

21

of riches; that is knowing where all these mutant genes are

22

but having difficulty getting them out because of those four

23
24

25

come back to identifying candidate
genes at the end.
So here's Chromosome 4.
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1

way up at that light band on the tip of the chromosome.

This

2

is to scale, so it shows you the magnitude of the problem

3

because the band is just 10 percent of Chromosome 4.

4

Can I see the next slide, please?

5

So one approach that we've taken js to start off

6

with a cell line that has a single human chromosome and a

7

hamster cell with a single human Chromosome 4, and that's

8

shown in Panel A there with the little arrow, that's Chromosome

9

4.

And over to the right in Panel B is that same cell line

10

stained just specifically for human chromosomes.

And so

11

you can see that fuzzier chromosome there, that's a whole

12

Chromosome 4.
If you take that hybrid, you expose it to radiation,

13

14

and in a nonselective way isolate hybrids that have just

15

pieces of chromosome in them, you can enrich be a factor

16

of 10 for getting probes out around the Huntington's disease

17

gene.

18

If you have two pieces of DNA in that hybrid that it greatly

19

enriches.

20

And that's illustrated down in the bottom of the slide.

It increases by a factor of 10.
Step No. 1.

Now, once you've got those probes,

21

how do you order them?

22

alluded to earlier today is an approach that's analogous

23

to meiotic mapping, but using just somatic cell hybrids.

24
25

And what we intend to develop wa3

With somatic cell hybrids then, put a single human
chromosome in that are irradiated, can be used like individual
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1

hybrids as though they're individual meiotic products.

2

you use breakage by radiation as a measure of how far apart

3

two genes are to one another.

4

this to you, but I wanted to show you a slide of what the

5

result is.

I don't have

ti~e

And

to describe

On the right is the meiotic map for region of Chromosome

6
7

21 that is in the vicinity of an Alzheimer's disease gene.

8

On the left are additional probes that are put on the map,

9

plus the ones that are also on the meiotic map.

And it shows

10

you that with this radiation hybrid approach the map is expanded

11

20-fold, and you're able to order probes relative to one

12

another.

13

a medical student vvorking two months in the .summer.

14

No. 2.

15

This is with the 100 somatic cell hybrids with

Step No.

Step

3 I don't have time to have a slide for,

16

but that's once you've had these probes ordered, then you

17

want to make them polymorphic to go back into the disease

18

families and make sure that you're able to tell one chromosome

19

from another and really know what your flanking marker is.

20

In the past that's been done by simply looking

21

at restriction enzymes and hoping that you find the single

22

base change, a single base change that changes ·the restriction

23

set.

24
25

My collaborator Rick Myers has pioneered ways of
identifying single base changes in human DNA.

Pike Court Reporting

(805)658-7770

You think

139.

1

that can't apply very much to human genetics?

It's remarkable

2

on human genetics, not only for identifying point mutations,

3

but specifically in this problem for taking any probe that

4

you want and identifying the single base change that allows

5

you to map it meiotically.

6

Can I see the next slide, please.

7

The fourth problem, which is how to clone the DNA,

8

Bob Mortimer will tell us about.

The closest flanking markers

9

are likely to be no closer than 1 million base pairs, as

10

Charles alluded to today.

If you have 1 million base pairs

11

and you clone 50 kilobases 50,000 base pairs at a time,

12

don't need to be a higher mathematician to figure out that

13

that's going to take you a long time.

14

million base pairs a time, or 300,000 base pairs at a time,

15

and yeast artificial chromosomes, then one will be able to

16

another order of magnitude --- speed up the possibility of

17

getting all the DNA between the flanking markers.

~ou

But if you can clone 1

So far I've talked about three technological advances

18
19

that allow us -- and not all of which have completely come

20

to fruition yet, but which are on the horizon so that they're

21

not just dreams.

22

that allow us in a general way to begin isolating human disease

23

genes and solve these problems.
Now, are they going and mapping the whole human

24

25

They're really going to happen, three ways

genome?

No, they're dealing with one specific gene at a
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1

time, but they're general and will be, I think, very useful

2

to the whole Genome Project, but they're very directed to

3

human genetics problems.
In the final 30 seconds or so I'd like to address

4

5

what I think is going to be the real problem.

6

and bolts.

7

the genes out.

8

genes, it's really finding out what they do.

9

find out what they do until we find the gene in the million

We need these orders of magnitude boosts to get
But the real interesting thing is not getting

10

or so base pairs of DNA.

11

future.

12

This is nuts

But we can't

That's the real problem for the

One of the things from my point of view and

13

for right now, we could sequence 1 million base pairs of

14

DNA easily.

15

identify all the genes in that million base pairs.

16

probably 20 or so genes.

17

doing that.

18
19

20

We could go and very directly with better software
There's

Right now there's no easy way of

I would think that that could be a major impact
of the human genome initiative on human genetics.
What are the approaches the people take now?

Glen

21

already alluded to it.

22

try and find sequences that are conserved in one organism

23

from those in another.

24

25

It's using comparative mapping to

This is an example that HSA-21 is -- a cartoon
of the human Chromosome 21.

Pike Court Reporting

And what it illustrates is that

(805)658-7770

141.

there's conserved sequences of human Chromosome 21, large
2

numbers of genes.

3

16, but not all on one mouse chromosome.

4

Chromosome 17 as illustrated to the right, three genes.

5

four genes are on mouse Chromosome 10.

6

To the left

are on mouse Chromosome
Some are on mouse
And

So this is very crude comparative mapping, but

7

it illustrates the humps of the genome in other organisms

8

that you can use to identify genes that might be in the region

9

that you want.

10
11

This is the area of technology development

that really needs to come about to get better.
But identifying the mouse sequences, then from

12

my point of view, one can go and make the animal models that

13

Glen just talked about and get two birds for the price of

14

one; and that is using them as models not only as assays

15

for the mutant genes you're looking at, in the case of Huntington's

16

or Alzheimer's disease, if you're lucky.

17

phenotype, then you're able to study the biology in those

18

animal models.

19

So to sum up, what have I said?

But if you get a

I've said that

20

I think that we don't have to wait for the impact of the

21

human genome initiative on basic biology.

22

though we don't know exactly how to approach and do the whole

23

human genome, approaches that are stimulated by thinking

24

about that are having major impacts on human genetics right

25

now, and I think that they're only to get better, largely
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1

in terms of helping us figure out where the genes are in

2

the large pieces of DNA that we isolate, but more importantly

3

constructing animal models or cell models that allow us to

4

understand the function of the genes.
DR. ARNHEIM:

5

Our next speaker is Walter Fitch

6

from the University of Southern California.

7

tell us a little bit about how he thinks the initiative is

8

going to affect evolutionary biology.
DR. FITCH:

9

And Walter will

I'll stick to evolution, but I hope

10

I'm less technical, that was my intent.

11

a little broader, perhaps over generally.

And I may be thinking

But I want to start off by first of all saying

12
13

that

14

as a process akin to a family tree.

15

family is not all that different from the genealogy of organisms

16

and really can ask about the relationships of animals and

17

plants and plants to bacteria and all of that.

18

well, most of you understand evolution, I think,
The genealogy of your

With the sequencing of the genome, there's another

19

kind of family tree that I'd just like to bring to your attention.

20

Our chairman in his youth studied a protein from eggs of

21

birds, but humans have this tOOi it's called lysozyme, and

22

it breaks down bacterial cell walls and is part of our ability

23

to resist infections.

24

25

Now, one of the things that can happen in the course
of the history of a group is that a gene can duplicate, and
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1

this gene has done it.

2

and sister here.

3

changed in such a way that while we can clearly recognize

4

that this is a brother and sister, the sister is really quite

5

different and is absolutely required for the lactating female

6

to synthesize milk.

7

be:

8

that breaks down bacterial cell walls and making mille for

9

human lactation?

10

And so you have sort of a brother

And in this case the sister evolved and

And your first reaction is likely to

What possible relationship can there be between something

Well, I won't go into why it's there, it's

obvious if you get into the details.

11

But this process of creating a family is something

12

that goes on continually in the genome.

13

of these.

14

them clans.

15

in the case of the duplication that I just described, not

16

surprisingly that gene duplication that led to this lactating

17

gene, lactation gene, occurred right at the origin of the

18

mammals.

19

present in birds, unlike lysozyme which is in both.

20

There are lots

Some families are larger, perhaps we should call
And asking:

What happened?

When did they happen?

And it's present in all the mammals, but it's not

So we can ask questions like this.

And there are

21

some clans in which there are hundreds of copies of genes,

22

the duplication has occurred many times in this spread.

23

we can ask:

24
25

How are they related to each other?

Searching for these is a simple problem in the
first place.

If you've got one pattern, you look to see
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1

if there's anything like it, and that's how this lactation

2

gene was found.

3

base looked like what you already had, and that's how it

4

vvas found.

You look to see if anything in your data

That process, of course, will continue.
But in terms of the future

5

and here's where

6

I'm going to be a little nebulous -- in this case, we had

7

a simple problem.

8

to match, and that's easy computationally.

9

going to be fun is to search for patterns that are meaningful

We knew the pattern that we were trying
What's really

10

because every time you look at something there's a pattern

11

there.

12

knowing the pattern you're trying to look at.

13

you can do that by things like restricting it.

14

The question is:

Does it have any significance? -- without
And, of course,

Supposing you would just look at pituitary cells,

15

that is brain cells of some sort.

16

things do I know that occur only in the brain and nowhere

17

else are present in my sample?

18

about those that are not characteristic of things that are

19

turned on in other kinds of cells like the liver or the lung?

20

And you start looking then for things that you don't know

21

what you're looking for, but you know that if you find it,

22

it's going to be a great help in terms of answering questions

23

like development, answering questions maybe about disease

24

and a lot of other things.

25

And then you ask:

What

And are there characteristics

So part of the problem is unsolved, but there will
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1

be a real cottage industry out there of people looking for

2

techniques for finding these patterns.

3

about searching for them, whether they're at the protein

4

level or at the gene level?

5

And how can you go

Another thing about this is trying to find out

6

these relationships that I've just described.

We'll be doing

7

that across species, of course, because we're going to be

8

learning a lot at the same time about genes from other animals.

9

So we will be getting that classical kind of evolutionary

10

relationship that I mentioned.

11

them for the duplications of the genes within the genome.

12

And finding those relationships is rather a tiresome process.

But we will also be getting

It turns out that if you had 100 different genes

13
14

that were all related to each other, and you wanted to know

15

their ancestory, the number of possible histories is greater

16

than the number of stars

17

than the number of protons in the universe.

in the universe, maybe greater

So you've got to have good efficient ways of attacking

18

19

those problems, and that's going to be a part of what's going

20

on in developing new methods.

So that's another new thing.

I think it's going to have an impact in the following

21

22

sense:

23

in order to brouse through this large volume of material

24

that we have.

25

What I've said up to here is what we sort of need

What's going to happen in the future, I think,
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1

is that scientists, especially in molecular biology, are

2

going to start doing the research rather differently, that

3

the first thing you do before you write an NIH grant is go

4

search this large encyclopedia of material to see how much

5

of what needs to be known is already there before you screw

6

up on your grant application and get rejected because its

7

been done or it's obviously there and you just didn't look

8

for it.

9

And so we're going to have a whole generation of

10

scientists who are going to be looking at this kind of prospect

11

before they even do any work.

12

people like me who, in fact, will never leave that encyclopedia

13

to go into the lab and do any wet chemistry.

14

to spend their life browsing through this looking for the

15

patterns that maybe the people who did the hard work and

16

got the sequences --- although it maybe it won't be so hard

17

when everything has been done here -- maybe have missed.

18

And, in fact, there will be

And so I see that there will be a whole new pattern

19

of the way that research is done.

20

are very strong for that.

21

They're going

DR. ARNHEIM:

I think the implications

The next talk will be by Bob Mortimer

22

who is from Berkeley and is the Chairman of the Department

23

of Biophysics.

24

DR. MORTIMER;

25

DR. ARNHEIM:

Former chairman.
Former chairman of biophysics.

Pike Court Reporting

(805)658-7770

He's

147.

1

go

to talk to us about YAC vectors.
DR. MORTIMER:

2

Well, just by way of introduction,

3

I'm not a human geneticist.

My specialty is working with

4

yeast genetics.

5

far away from humans.

6

on genetic mapping, developing the genetic map of yeast.

I'll make a point that yeast is not that
But I have spent a lot of time working

We have not had the audacity yet to compare the

7

8

order of genes in yeast to that of a human, but maybe it's

9

not an unreasonable thing to do.
I want to talk about YAC cloning, yeast artificial

10

11

chromosome cloning, which is one of the approaches that is

12

being considered for developing physical maps of the human

13

genome.

14

that after I'm through, you'll see that there's reason that

15

both of these are still being considered and possibly other

16

approaches.

The other principle is cosmid cloning.

And I think

17

Could I have the first viewgraph, please?

18

The procedure was described by Burke Carle Olson

19

a couple of years ago.

And basically there's a special vector

20

which they constructed that contains two telemeric sequences,

21

and if one clones into this exogenous DNA from any source

22

and transforms it into yeast, these will behave as extra

23

chromosomes in yeast, that's in principle.

24

vector, and then the two arms, and then basically the chromosome

25

here.

And this then can be human DNA.
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And Olson developed this method and has had a lot

1

2

of success cloning human sequences into yeast.

And several

3

other groups, including our own, have been working on this

4

as well.

5

Can I have the next one, please.

6

One of the technologies that needs development

7

is making viewgraphs that have a sufficient range of grays.

8

This is all just black and white, and there should be some

9

in between.

But the point is that the size of YAC's can

10

vary anywhere from about 50 kilobases up to the order of

11

a megabase.
This is a total [inaudible] digest of the human

12
13

genome.

14

is several megabases.

15

group and I understand most groups, is that we're not obtaining

16

any representative sample of the restriction map -- restriction

17

fragments from not one.

18

to obtain such a representative sample for developing a proper

19

physical map.

20
21

22

The bottom is about 50 kilobases.

Up at the top

And the experience, at least in our

And I think it would be necessary

I guess this indicates that it would take a large
number of these YAC's to cover [inaudible.]
If you want end in a particular chromosome -- can

23

I have the next one, please -- it will be necessary to separate

24

from this large library of YAC's those that come from a particular

25

chromosome.

And this will either by standard techniques
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will involve some form of hybridization with human-specific
2
3

or species-specific DNA probes.
If one can obtain purified or semi-purified chromosomes

4

either from the human cells or from rodent human hybrid cells,

5

then the job is much easier.

6

is interested in Chromosome 21, if one could have a large

7

sample of Chromosome 21, and make YAC's from that, then the

8

job is much easier.

9

In other words, if one in principle

Current technology -- the best technique is [inaudible]

10

activated cell sorter technique, and it can purify chromosomes

11

but not in sufficient quantity for YAC cloning.

12

I wanted to now just discuss some areas that I

13

think call for additional research, and the first one is

14

related to this.

15

Can I have the next one, please.

16

Related to the last point would be to explore new

17

areas for separation of large numbers of specific human chromosomes.

18

Several years ago it was shown that it was possible to separate

19

[inaudible] chromosomes by [inaudible] and several groups

20

are exploring this procedure again.

21

The pulsed-field gel techniques that were developed

22

by Charles Cantor can separate DNA molecules up to about

23

7 megabases in size.

24

5 times smaller than the smallest human chromosome.

25

developments in this area are marketable, I can't say.

This is still in the order of 4 or
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1

Can I have the next slide, please?

2

This just shows the study that was done several

3

years ago.

This is the chinese hamster karyotype.

4

Can I have the next one, please?

5

And this is after one passed through in a zonal cPntrifuge.
at 3

7

that there is an excellent purification of the smaller chromosomes.

8

This was a study done 15 years ago.

9

that this approach can at least give enrichment for particular

10

runs

, and three different fractions, you can see

6

So I think it's true

sizes of chromosomes, but not purified samples.
Another point, the size of the YAC transformance

11
12

that our group is obtaining, and I think it's a general -- is

13

not representative of the size of the fragments that are

14

in the restriction fragment unless one does presize fractionation.

15

And this could either be due to selective sharing of the

16

larger molecules or some selection in the ligation or transformation

17

step or possibly instability of the larger YAC's in both

18

cells.

I think the latter possibility is not too realistic.
But this would call for research in manipulation

19

20

of large DNA molecules and also in general studies of yeast

21

transformation, ligation and transformation.
Well, another area that-- the size of YAC's is

22
23

determined by pulse-field gel electrophoresis

24

this is the one that I showed you originally.

25

lambda.

For instance,
These are

And the upper gel -- the only difference between
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1

these was the pulse time.

2

And you can see that the gel is spread out between 50kb up

3

to over a megabase.

4

only the bottom three of these chromosomes are resolved,

5

but their spread out over most of the gel.

6

to the 15 seconds, then regions smaller than the smaller

7

chromosome are spread out.

8
9
10

The upper one is 55 seconds pulses.

If one goes to 22 second pulses, then

If one one goes

And so by selecting particular switch times one
can expand different parts of the gel and resolve different
sized YAC's with the yeast chromose.
But as I say, most of our information on [inaudible]

11
12

is empirical, and I think a lot more work is needed to give

13

better understanding of these factors.
One other area that I think calls for research;

14
15

in fact, all of the physical mapping procedures that I know

16

of involve autoradiography of gel blots and using film.

17

a two-dimensional data detector were available which could

18

be just placed on top of the blot

19

are feasible from just talking to physicists -- that this

20

would allow automation and automatic digitation of the data.

21

And it seems to me that this is an area that calls for future

22

research.

23

If

and I think such things

One area that we're quite interested in just strictly

24

for basic reasons, if one had a diploid cell that carried

25

two yeast artificial chromosomes, which are mostly human

Pike Court Reporting

(805)658-7770

152.

1

chromosomes, the question is:

Would they recombine at frequencies

2

normally seen for yeast cells or frequencies normally seen

3

for human cells.

4

miotic recombination frequency between the two species.

5

I think that it would be quite an interesting point to look

6

at.

There's about a 300-fold difference in
And

I haven't the slightest idea which result would occur.

7

Finally, just David Sheldon in my group, just relating

8

to the evolutionary argument, is cloning human genes by functional

9

complimentation of the yeast mutants.

10

of the

11

genes in this case.

12

purine

metabolism genes, human

DR. ARNHEIM:

And has obtained several
purine metabolism

I think the first thing that we can

13

do is just ask if anybody has any questions that they would

14

like to address for our panelists.

15

DR. SALSER:

Maybe it should wait until after we

16

get into the next one, but I'm very interested since these

17

are not representative, and similar problems may occur with

18

the cosmid physical maps; are any of you in the cosmid or

19

the YAC groups thinking about how to overlap your sets of

20

data and piece it together from all of the -- together?

21

DR. HORTIMER:

22

DR. SALSER:

23

DR. ARNHEIM:

24

25

Yes.
Have their thoughts only been frustrating?
That will be discussed in the next

panel.
DR. COX:

They're all at very different levels.
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1

So going from the level of cracking off a whole hunk of chromosome

2

to then making YAC's is

3

at one level that you can well understand.

4

5

DR. SALSER:

and ordering those YAC's -- is

I realize it's not a trivial technical

question that I'm asking.
DR. MORTIMER:

6

I think Maynard Olson has one approach

7

that gets around us by -- such as using size fraction equal

8

our one partial fragments.

9

a representative sample of the total genome by this approach;

I think that's probably obtaining

10

as we try to go for the huge one, something in the order

11

of 300 kb.

12

DR. EVANS:

I think a number of people have shown

13

with yeast that by doing an awful lot of work you can begin

14

to overlap by cosmids by picking them at random, restriction

15

mapping them, putting all of your information into a computer

16

with an appropriate program that will match things up.

17

I think there's no question that that works with

18

a certain limitation.

19

thinking of ways of doing the same thing not requiring such

20

a vast amount of work, number one, which involves analysis

21

of multiple clones once, multiplexing, and now I guess to

22

the George Church sequencing method and then having appropriate

23

programs to sort that out.

24

25

There are a number of people around

And I can think of three or four different groups
in the process of working on those things.
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1

appear to work.

Some of them theoretically will work, but

2

technical limitations such as the Hans Laroff method in using

3

all of the nucleotides are very difficult to overcome.
In my mind, the technical advances that will really

4

5

make that efficient are two-fold.

6

up the process by doing multiplexy.

7

do it rather than people because it's very difficult to convince

8

postdoc's

9

to get graduate students to do it, but robots like that kind

10

One, to be able to speed
Secondly, to have machines

to do that experiment, practically impossible

of thing.
DR. FITCH:

11

As a remark of frivolity,

I was reminded

12

during this conversation of my youth which was preceded

13

Dr. Arnheim's by quite a bit I think.

14

to Fred Allen who routinely visited Allen's Alley, one of

15

whose residents was Falstaff Oppenshaw, the poet laureate

16

of the alley, one of whose poems was entitled, "Alas, Alack,

17

What Is a YAC?"
DR. BOYER:

18

But I was listening

I had a minor question for Walter Fitch.

19

This humanian lactation gene, what's known about its biochemical

20

function?

21

DR. FITCH:

A great deal.

The association between

22

the lysozyme which breaks down the cell walls and bacteria,

23

they happen to be carbohydrates, the cell walls.

24

the lysine breaks a particular bond.

25

And so

In the case of the gene related lactation, what
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1

it's trying to do is to impose the system a recognition of

2

a specific configuration of carbohydrates so as to join them

3

together to make lactose.

4

DR. BOYER:

It's actually the lactose synthetase?

5

DR. FITCH:

Yes.

6

It's not the whole synthetase,

it's a part of it.
DR. ARNHEIM:

7

I'm wondering whether there's anybody

8

from the industrial sector who might want to make a comment

9

concerning what they feel the human genome initiative might

10

terms of their basic, if they have any basic research programs,

11

but in terms of their basic research programs -- what impact

12

they might see.

13

volunteer?

Is there anybody here who would like to

14

[No response.]

15

DR. ARNHEIM:

16

Are there any other additional questions?

17

we're more or less on time, and we can go to the next session.

18

No.

UNIDENTIFIED SPEAKER:

It's not a question.

Otherwise,

But

19

I'm curious.

20

what I just heard is that contrary to what some people feared,

21

it sounds like the Human Genome Project -- technology if

22

it's accelerating, there is also greatly accelerating assisting

23

biological basic research.

24

what I just heard?

25

Do you think as a valid to labor, I think that

DR. ARNHEIM:

Is that a fair conclusion to

Well, certainly, I think a lot of

Pike Court Reporting

(805)658-7770

in

156.

1

us would agree with that conclusion, yes.

2

DR.

FITCH:

3

DR.

COX:

4

I mean it's absolutely necessary.
I would say that that's a very succinct

way of saying what I've tried to say, yes.
DR. ARNHEIM:

5

I'd like to thank the panel.

6

7

Recess 2:20 p.m. to 2:30 p.m.

8
DR. SALSER:

9

I thought it would be good to give

10

everyone about 10 minutes I think we've taken to stretch

11

your legs.

12

But it's time to get underway again.
It's a pleasure to introduce the moderator of our

13

second panel, Tony Carrano.

14

the genetic section at the Lawrence Livermore Laboratories

15

of the Department of Energy and the University of California.

16
17

He is a section leader with

Dr. Carrano also received his Ph.D.

from the University

of California, Berkeley.

18

I've known Tony for a very long time, and I've

19

always been impressed with this group's ability to apply

20

very elegant physical and instrumentation techniques to carry

21

out difficult genetic analyses.

22

In the National Gene Library Project, they used

23

flourescence activated chromosome sorting to make chromosomal

24

assignments for various genes and also to make chromosome-specific

25

human clone banks.
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1

More recently, Tony has been successful in using

2

the ABI, Applied Biosystems, DNA sequencer as a powerful

3

tool for a new purpose, not for sequencing but to automate

4

the creation of ordered sets of cosmid clones to create the

5

so-called physical maps of the human chromosomes just as

6

was discussed in the last talk of the preceding panel.

7

These physical maps are going to make clone by

8

phone an incredibly powerful approach, and that's totally

9

independent of the uses of the main goals of the Genome Project.

10

But they're also, I think, an essential starting point for

11

a well-organized sequence analysis program.

12

Tony is going to introduce his panel, who will

13

consider development of the needed technologies, both hardware

14

and software.

15

DR. CARRANO:

16

be back at UCLA again.

17

Thank you, Winston.

It's good to

As Winston indicated, the charge to our panel is

18

to discuss the development of needed technologies as well

19

as hardware and software.

20

What I thought I'd do to try and set the mood for

21

this is to actually take the biology of the human genome

22

initiatve as we had seen displayed and try and put it against

23

the disciplines and the technologies that might be necessary

24

to get the initiative accomplished.

25

viewgraph sort of sums that up.
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1

The human genome initiative really is at least

2

two projects, two major projects, and separate in terms of

3

the technologies that are needed in a sense.

4

of all, a project of ordering; and, secondly, a project of

5

DNA sequencing.

6

It's, first

We start with human material in the form of a cell

7

and we want to wind up with the genetic code, the DNA sequence.

8

And there are really many steps that we have to go through

9

to get there, and there's many technologies and disciplines

10

involved.

11

For example, as we heard earlier, the human genome

12

is huge.

13

that problem as a whole is extremely difficult, if not impossible,

14

at least with the present state of technology.

15

It's 3 billion base pairs in size.

And to tackle

And so everybody's consensus is that we've got

16

to fractionate this human genome in some way.

17

to break it up naturally into its components, the chromosomes,

18

the 24 different human chromosome types that we have.

19

way is to break it up into yeast-artificial chromosomes.

20

One way is

Another

We've heard about yeast cloning from Bob Mortimer

21

a few minutes ago.

22

methods to separate individual chromosomes.

23

at Livermore and at Los Alamos simultaneously the development

24

of fluorescence activated cell sorting to purify chromosomes.

25

And this basically separates chromosomes on the basis of

The other approach is to use physical
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1

DNA content and DNA base composition.

2

Now, it's an interesting feature because this particular

3

methodology can analyze chromosomes at the rate of several

4

thousand per second and it can separate chromosomes at the

5

rate of 700 per second.

6

several years now -- it works just fine for cloning DNA into

7

certain types of vectors, lambda vectors or cosmid vectors.
But it doesn't provide us enough DNA just yet to

8

9
10

Now this works just fine -- after

clone into systems which require a little more cloning efficiency
such as the yeast-artificial chromosome.

11

For example, we can sort on good days, purifying

12

good days, about 5 million chromosomes of any one type.

13

provides about 1 micrograms worth of DNA equivalent.

14

as I talked with Bob a little bit before at lunchtime, it

15

looks like that to clone into yeast-artificial chromosomes

16

it's going to require about 10 8 chromosomes or 20 times that

17

much DNA, or on good days, 20 good days of actually sorting

18

with the instrumentation.

And

That's sort of a balloon of practicability right

19

20

now.

21

do it another 20 days.

22

there.

23

That

It only gives you one shot.

If you miss you have to

And so right nmJ we're not quite

But there are other mechanical methods that can

24

accompany that such as prepurifying the chromosomes on

25

systems and then using that as an enriched fraction to sort.
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1

2

And all these things can be looked at.
Well, once chromosomes are purified, then one has

3

to then go into the molecular biology genetics and clone

4

these pieces, fractionate the chromosome further and clone

5

the pieces of DNA.

6

And this is an interesting area because we don't

7

have to wait until a project is finished to get something

8

commercialized.

9

right here.

We immediately create a set of consumables

We immediately create a new set of vectors,

10

cloning vectors, which are marketable, are being marketed.

11

We immediately create libraries of specific chromosones which

12

are marketable.

13

that DNA where certain genes are markers for genomes which

14

are marketable.

15

can and are being commercialized right from the very start

16

of the project.

We immediately create from this probes from

So this creates a set of consumables which

17

Once we have these libraries, then one has to put

18

them all back together again, take these little pieces that

19

we've now got separated into little tubes and put them

20

all back together again.

21

So we've actually come a full circle.

22

with an entire chromosome, cut it into pieces and then we

23

want to put it back together again.

24

25

We started

This is a very labor intensive process, and it's
also a process that requires a heavy dose of mathematics
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1

and statistics.

So the mathematicians, staticians and the

2

computations experts get involved in this problem to a very

3

large extent.
We have developed a technology, as Winston just

4

5

mentioned, to automate this process.

6

relies upon not radioactivity but using the fluorescence

7

tag to label these fragments and to analyze them on automated

8

DNA sequencer, which is commercially valuable.

9

a project that we did in collaboration with a group at Applied

10

The present methodology

This was

Biosystems in Foster City, California.

11

With the technology that we have, it allows one

12

to progress at the rate of putting these pieces together,

13

and I believe it's about a million bases per week.

14

still a long way to go to do the whole human genome, but

15

this can be improved further, we think, by at least a factor

16

of 4.

17

There's

Once these pieces are put together, then one can

18

take the probes that are established here and pull out those

19

pieces of DNA that contain the genes of interest, the genes

20

of interest that you're working on which could then be sequenced,

21

that could then be used certainly in diagnostics or the treatment

22

of certain diseases.

23

and human benefit at this end right here.

24

25

And so there's definite commercialization

So what I want to impress upon you here is that
this is really a multi-disciplinary project.
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physics.

2

It involves mathematics.

3

It's not just a biology project.

4

is that groups get together.

5

laboratories, all those components exist.

6

those components exist.

7

them together to talk to get the project done.

8

9

It involves chemistry.

It involves engineering.

1

It involves computer sciences.
And so what it requires

Fortunately, at least the national
At universities

It's a question of how you can get

Now this group is going to address some of the
issues related to these technologies.

And our next speaker

10

up I think will sum up what we're going to talk about I hope.

11

The components of that, I mentioned they're here.

12

going to continue to be here, and they change.

13

rapidly.

14

and libraries may be different than what's marketed six months

15

from now.

16

They're

They change

What's being marketed today in terms of vectors

So it's an ever-changing market.
Mapping I've briefly mentioned.

But an important

17

component of this whole process is robotics, and we're going

18

to hear a little bit about that and how that can -- other

19

technologies in this area can help accelerate this process.

20

DNA sequencing, of course.

We've heard some of

21

that all ready.

22

in what I call the first generation perhaps of DNA sequencing,

23

and I can see at least two more generations coming beyond

24

that right now what's on paper at least.

25

Multiplex is' still in its infancy.

We need the hardware, and we certainly need the
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1

software to be able to put all this information together

2

and to analyze it and to disseminate it.

3

hear a little bit about that as we go along.

4

We're going to

So each of our speakers will address these areas.

5

Our first speaker is going to be in the area of robotics,

6

and that's Dr. Nebojsa Avdalovic.

7

University of Zagreb in Yugoslavia where he got both an M.D.

8

and a Ph.D. degree.

9

in Birmingham, Alabama and then at the Rissler Institute

He graduated from the

He carne to the United States and worked

10

in Pennsylvania.

11

in 1985 in Palo Alto where he's associated with the Spinco

12

Research Department there.

13

robotics in DNA sequencing and mapping and has made contributions

14

in the automation of the Sanger sequencing reactions using

15

vector robot.

16

17

DR. AVDALOVIC:

And he has been working on exploring

I hope I wouldn't murder the English

language the same way he murdered my name.

18

19

And then he carne to Beckman Instruments

I'm going to try in these couple of minutes which
are allocated for my discussion to cover certain topics.

20

Would you please show the first overhead.

21

I would like to address some need for automation

22

in robotic devices, and then I would like to show some examples

23

of what is available today and perhaps what is needed for

24

tomorrow.

25

of the Human Genome Program on certain issues for each goal

And I will address a couple of questions of impact
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1

2

beyond science, or direct science.
If we stripped the past of bare necessities, and

3

you decide to invest more than two days a week in molecular

4

biology, as some speakers mentioned today are investing,

5

and you start really planning your research in trying to

6

address these issues, you will now realize that this is an

7

enormous task.

8

was done by friend and colleague from Lawrence Livermore,

9

Tony Carrano, when he fractionated that task, which is really

10

11

And I think the best introduction of that

an enormous task, into manageable components.
So if I just take two examples for this discussion,

12

the first example I would like to mention is making an order

13

to overlapping libraries.

14

of how you're going to pick up your first clones.

15

do it by hand today.

16

good overlapping library, you need approximately five genome

17

equivalents, that's the minimum of the minimum.

18

approximately 1 million clones.

19

to do it by hand, but you could.

20

this by hand is because we would like to assign parking space

21

in a [inaudible] for each of those clones.

22

you will make this in and duplicate it.

23

I'm not going to go into a discussion
You can

But if you realize that to make a reasonably

This is

It's not such a big task
And the reason we are doing

If you are smart,

If you don't do it in duplicates, about 10 times

24

a month -- microtiter plates.

25

replica clones, if these are by some chance [inaudible] they
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1

would like to make this as replicas, it means 2 times million

2

replica clones, which you will like to screen by certain

3

means.

4

those people like Tony, or some others, who are trying to

5

characterize each and every clone by doing a restriction

6

mapping, either using single or double digest, or using partial

7

digestion maps, it means 1 million -- approximately 1 million

8

clones isolated and labeled for screening.

9

You will also have to isolate DNA for probing.

You can see that this is not an easy task.

And

It

10

will require enormous bookkeeping to start with if you want

11

to have a use.

12

or a device which is capable of reading bar code on your

13

microtiter plates, which will also manipulate those microtiter

14

plates and understand and realize the X/Y relationship in

15

that microtiter plates.

16

So you will have to have robotic devices,

On the other hand, if we would like to do plating

17

or making a very dense restriction map of your clones either

18

on a [inaudible] or on an Agar plate, you will have to have

19

a robotic device which will do it because the desire is to

20

put at least 100 microtiter plates in the same size as is

21

in microtiter plates.

22

reason you would like to do it would be because you want

23

to decrease the amount of possible manipulations in hybridization.

24

25

This cannot be done by hand.

So you will have to read those.

The

You will have

to have an automatic system which will recognize each parking
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1

space of your clone and relate it to your existing data base

2

with your microtiter plates and then play with with regard

3

to retrieval, cataloging and manipulating.
I even didn't mention here the need for a computing

4

5

abilities to make some overlapping clones.

6

addressing this at all.

7

I'm not even

As an example of the trouble with autoradiography or

8

fluorescence, Tony Carrano mentioned a machine made by ABI

9

which was run in conjunction with the University showing

10

good collaboration with industry and the University if you

1,

choose the right partners, and which was vastly approved

12

by ABI.

13

technology and somehow enter those data in the data base.

14

15

They can use restriction mapping and fluorescent

But if you are doing this with autoradiography -- could
I see the next slide, please?

16

This is example of how high-resolution restriction

17

mapping done on C. elegans.

18

fragments, and it's standard in between, which you will have

19

to deal with if you want to enter those data and make overlapping

20

segments.

21

These are the number of restriction

Well, to tell you the truth, somebody said that
this technique might be working.

23

for small genomes.

Well, it might be working

Here, when you are looking in an E. coli

system, you are examining overlaps or relationship 1 clone

25

versus 200 clones in a library.
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1

genome, this is 1 clone versus 2,000 clones, or 200,000 --excuse

2

me -··· clones.

3

In that case, physically you either have to have

4

100,000 times more information to produce that or you have

5

to have 100,000 times bigger fragments.

6

with YAC's if you think you can do that here.

7

enormous problems.

8
9

Well, good luck
So there are

So what I'm trying to tell you is that we have
to have a little more humility in all these aspects because

10

our aspirations at the moment are much higher than our abilities

11

are to do that job.

12

Could you go back to the --

13

So that's a big issue with autoradiography.

14

I

will have similar remarks in analyzing DNA sequencing later.

15

Could I see the next -- thank you.

16

The other example is DNA sequencing.

You have

17

to isolate and purify DNA.

18

showing that the purity of DNA is extremely critical for

19

good results.

20

but it's even more so for fluorescene sequencing, especially

21

if you would like to have a double-standard DNA as a source

22

for your sequencing.

23

are spending more than two days a week in doing the work.

24

25

And there are more and more data

It's not only for radioactive sequencing,

As I say, this all comes from us who

So now when you take a robotic device perhaps and
you say, "I would like to run 100 or more templates per day,

Pike Court Reporting

168.

1

which is possible -- I can show it to you -- is 400 pipetting

2

steps, 100 to 400 loading for electrophoresis.

3

versus 400 regarding this using fluorescent sequencing protoca1

4

where you can combine certain lanes together, or radioactivity

5

where you have to run a lane separately.

I say 100

6

I would like to see you really more than the two

7

days in a row sequencing films of the size 14 by 17 inches

8

carrying 24 templates on it.
It was a good remark of a colleague of mine who

9
10

said that

when I asked him:

"How do you do your sequencing,

11

and do you have any problems?"

12

problems, but I'm changing my technicians."

13

do you change them?"

He said, "No, no specific
I said, "How

He said, "Every 100,000 base pairs."

14

So on the other hand, again, if you would like

15

to read those interesting films automatically, we need a

16

device, and right now we don't have it.

17

it, you will have to shotgun merge 50 to 70,000 base pairs

18

in one day on a small computer, or a big computer if you

19

want.

20

And if you have

I did an exercise, which was an exercise in futility,

21

I cut genome in manageable pieces of 350 base pairs as a

22

source of possible sequencing data and did some manipulation

23

to use single base changes, and then trying to do a base

24

on a computer, and I can tell you this is a very tough task

25

for just 4,000 or 4.1 kilobases of bbi.
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1

Right now I'm trying to do a similar simulation

2

on the EBB lighters which are 170,000 base pairs, and I

3

can visualize what kind of problems one can get on a computer.

4

We just don't have that technology.

5

So what I would like to show to you is a humble

6

approach to the present day needs by showing a robotic workstation

7

which Beckman Instruments has developed and which is successfully

8

being used for DNA sequencing in many laboratories all over

9

the world right now and is capable of addressing both fluorescent

10

sequencing technology and radioactivity protocols.

11

Some of the aspects on that workstation were worked

12

out together with Dr. Lee Hood's laboratory whose colleagues,

13

Wilson and others, have contributed --· and Steve Clark --

14

contributed by designing a nice heater system which now comes

15

with a robotic station.

16

And then I will show you what is in the making

17

with some new aspects of robotic device, and then we can

18

talk about automated electrophoresis and detection which

19

was accomplished very nicely by our colleagues at ABI.

20

I will show you some data with electrophoresis which is a

21

fully automated system.

22

And

So this is a robotic device which has pipetting

23

device tools on the right-hand side.

24

plate on one side, the plate, platform and microtiter plate

25

together with the solutions.
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1

When you look at this scheme you can see that where

2

the tubes are located by pipet tips, microfish tubes carrying

3

the samples of the [inaudible,] and then the heating plate

4

where you can heat inside from 10 to 90 degrees at your desire,

5

and you also have a 4 degrees cooling system.

6

Then you make some patterns for those reactions.

7

And since the time is running you can incubate this very

8

easily at any desired temperature using any enzyme available

9

today.

10

11
12

And this shows the profile of the temperature and
the time which elapsed in doing all these jobs.
This will give you your chance at running [inaudible]

13

to run 24 templates in a run which gives to you approximately

14

about 12,000 base pairs per run on that machine.

15

And this is the approximate result which you see

16

here on the right-hand side where the gel was done by machine.

17

The left-hand side was done manually.

18

is practically no difference.

19

by machine and by hand.

20

This is what is new.

And you can see there

It's the same quality done

This is a side-loader arm

21

which helps you to change those microtiter plates from your

22

workstation so that you can run multiple reactions.

23

are like towers, like hotels with the microtiter plates,

24

or test tubes if you need them, or if you want to have an

25

electrophoresis apparatus on it.too.
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1

So basically this system will allow very high throughput

2

in both sequencing and mapping because the tools are being

3

made which can stamp the [inaudible] both on an agar or on

4

the filter paper, and in this way you can exchange and go

5

through the process with not only one plate but with multiple

6

plates.

7

8

This is one of the towers with different kinds
of consumables on it.

9

This is something to provoke curiosity.

10

of electrophoresis is becoming a reality by using capillary

11

electrophoresis.

12

is not a regular charge mass ratio like you have in a polyacDJlarnide

13

or Agarose system.

14

separate in 10 minutes using [inaudible] gas system from

15

12 to 30 [inaudible]

16

Thank you.

17

I didn't have time to address some impacts, but

18
19

Automation

Where the driving force in an open tube

And this shows the example that you can

in 10 minutes.

we can talk about this later.
DR. CARRANO:

Our next speaker is going to address

20

the area of DNA sequencing, and that is Dr. Norm Whiteley

21

whose from Applied Biosystems.

22

'74 from Harvard University.

23

synthesizers, the DNA [inaudible] and the sequencing.

24

25

DR. WHITELEY:

He received his Ph.D. in
And he's worked on the DNA

I'd like to be in some ways a little

more optimistic about the ease of some of \vhat v'Ve' re about.
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1

to do.

2

there are some aspects of it that are very hard.

3

there are some aspects of it that require a lot of work but

4

are relatively straight forward, try and draw the distinction

5

between research and development as it were.

6

may actually require much more work in terms of man hours

7

and effort and dollars, but it's relatively straight forward.

8
9

Everybody has talked about how hard it is.

I think
I think

Development

It comes back to the little question that Dr. Watson
addressed this morning which is:

How do you get all these

10

good people to do this?

11

How do you get good researchers to do this?

12

key is that you want the good researchers to do the hard

13

creative parts and you want other kinds of people to do the

14

other parts because they like to do it, and they're good

15

at it.

16

I think what he was thinking was:
I think the

In order to sequence very large amounts of DNA,

17

I think everybody has almost totally agreed that we need

18

a lot of automation, whatever the techniques.

19

of this brief talk I'm going to focus on the existing scheme

20

of somehow generating clones doing, if you will, Dideoxy

21

sequencing or perhaps Maxon Gilbert sequencing, electrophoretic

22

analysis of that and conventional data collection.

23

And the rest

At the moment, there's essentially no automation

24

of the clone, and that's the part that I was referring to

25

as very hard.

Part of the slide is what we need and what

Pike Court Reporting

173.

people are working on are global strategies for the mapping

2

und genPrating sequencing clones.

3

a lot.

4

The point has been made

I agree with it.
The other three areas doing the reactions, we just

5

saw a way that's been automated by our colleagues at Beckman.

6

And there's a number of other systems on the horizon, and

7

that's about to truly-- or has really happened.

8

say it's about to

9

I should

truly happen.

The data collection, as you know, our company sells

10

an automated DNA sequencing based on fluorescence.

11

are a number of other DNA sequencers commercial, or in the

12

works, and there are a number of people, and I think some

13

will address it later, who are very interested in automated

14

data analysis.

15

There

The point is, those last three things are, if you

16

will, in the chute.

17

the range of being able to do the. kind of work we are talking

18

about, that the real holdup is the first step, that many

19

people have addressed, that is truly the really hard point.

I think that they are totally within

20

May I have the next overhead, please.

21

To illustrate my point that the others are in the

22

works, this is a huge slide indicating the progress in commercial

23

automated DNA sequencing.

24

you can buy in 1986, or you can buy now, and just in that

25

time from the middle of '86 to the middle of '88, about

This is not -- this is something
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1

two years, the number of bases that can be sequenced, and

2

the accuracy with which they can be sequenced, has improved

3

fairly dramatically, as well as a decrease in the amount

4

of DNA involved.

5

I think that that -- all of that improvements has

6

been based on changes in

7

none of them changes in hardware. That graph will continue

8

for awhile, in terms of improving throughput.

9
10

[inaudible]

changes in software,

If I can have the next slide.
To do a thought experiment -- I am not proposing

11

that someone do this -- to do a thought experiment, you just

12

want to take that fraction of the process and automate it

13

with today's existing commercial, off-the-shelf technology.

14

What would it cost you?

15

you could do about 500 bases a line, and if you were to run

16

it twice a day -- which nobody in a research lab would do

17

because that means coming in in the middle of the night to

18

turn it on the second time -- you can figure that to have

19

a 1x coverage of the human genome is about 750 instrument

20

years, or for 4x coverage, in 12 years that is 250 instruments.

21

That is $23 million of hardware, bought one of, which again,

22

no one would do, and it would take you something like 50

23

people, maybe 100 people, to run those things.

24

25

What would you have to do?

Well,

That is within the scale of the kinds of money
and time the people are talking about.
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1

technology.

2

there that will happen in the next year or two.

3

any doubt, the company that doesn't do it will go out of

4

business, regardless of whether it is us or our competitors.

5

6

Easily there is a factor of three in throughput
Without

So, my point is you really -- this is within the
realm of reasonableness already.

7

May I have the next slide.

8

Now, obviously, if you can get very clever and

9
10

inventive you will do it even better.
The next point is that in actual sequencing reactions,

11

how are they done?

12

we are going to be repetitive.

13

on a large number, when we are talking about something like

14

sequencing the human genome, and you want, obviously, routinely

15

high quality.

16

an academic auspices, or university, or a national lab, or

17

an industry, it is a manufacturing type of operation.

18

again, I raise the word "contract" which offends a number

19

of people, but it is inherently an operation in which you

20

want to define what you are doing well enough that you don't

21

need research scientists to do it.

22

type of people doing it.

23

However clever we get about this strategy,
They are going to be done

Whoever does it, v;hether it is done under

And,

You, in fact, want manufacturing

To use an example, DNA synthesis, a few years ago,

24

was worth a Nobel Prize.

25

and the instruments are made by people who don't have

It is now currently the reagents
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1

college degrees.

2

they work.

3

is that some development scientists, not research scientists,

4

took the time to figure out exactly how to do each step,

5

so that they could do it right every time, and then they

6

hire some people who are very bright and care about their

7

They are made every time, perfectly, consistently,

It is a routine thing.

The reason it is routine

work, that don't know anything about chemistry or biology

8

necessarily, but they know that they need to be careful with

9

what they are doing to execute that every day.

10
11

12

13
14
15
16

17
18
19

20
21

22
23
24

25

quite well.

It works

They are regularly available, and that is the

kind of operation that is totally feasible, even at the scale
we are talking about, if we had the strategy to do it.
Another illustration, about ten years ago I uorked
for a company that made clinical diagnostics, and they made
100 million reagents packs a year, and it is complex chemistry.
The pipettings were done with precision of fraction of microliters,
and those were made at a cost of $.20 to $.30 each.

I don't

think that is inherently a great deal more difficult than
doing the operations that would result in conventional sequencing
strateging today.

However, you can only do that again, if

you know the strategy itself.
The last couple of minutes, I just wanted to address
the other theme that is running here about cooperation within
California and the effects on industry -- I hope there are
still a few of the political people in the audience.
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As a practical matter, industry must cooperate with

1

2

[inaudible].

3

a brief list of those products that I've been involved with.

4

They are DNA products.

5

collaborators.

6

people that I couldn't think of, and I did this off the top

7

of my head.

8
9

The previous speaker referred to it.

This is

And it's a list of California academic

They're industrial collaborators.

There are

There's lots of people outside of California.

But every product that we have -- DNA synthesizer,
DNA sequencer, and

acid extractor, and the mapping

10

that Tony is working on -- has had academic collaboration.

11

It's vital, it's important, and I'm glad people are encouraging

12

it, but it needs to happen, and it really does happen.

13

we're pretty good at it.

I think

The last side is a competitiveness concern specific

14
15

to California.

Competitives really means good people.

It

16

doesn't necessarily just mean good researchers.

17

people in the operation at whatever level they're working.

It means good

We have a lot of advantages here in California.

18

We

19

have great universities.

20

easy to find good people if you have a lot of people to start

21

with.

22

There are a lot of people, so it's

It's a fun place to live for all sorts of reasons.
There are some serious disadvantages that are for

23

the political people in the audience, I think, very important.

24

We lose people because either we're not trying very hard to

25

keep them or because they've got some wonderful new opportunity
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1

to join a start-up company or become a massage therapist or

2

whatever.

Those people leave eagerly.
The other category of people we lose, and we lose

3
~

them frequently, are people who are sad about leaving our

5

company, and they're going some place where they figure their

6

kids can get a better education, where they can afford to live

7

close to where they work, which is a function either of

8

transportation or cost of housing.
We've lost in the last six months people I'm involved

9
10

with, not necessarily ones that work for me, somebody to

11

Indianapolis, somebody to Philadelphia, two people to North

12

Carolina, lost a potential recruit because his wife is a teacher

13

and came out and checked out the schools in the area and

1~

decided they could educate their kids better in Georgia.
So it's a serious problem.

15

It's a daily problem.

16

It's one that people like myself

I like to think of myself

17

as inventive and clever -- but I am concerned about things

18

like that instead of strategies in automation.
The last thing which is both a concern and an

19

20

opportunity, I think, in terms of competitiveness for California

21

is if we could encourage better public understanding of what's

22

going on.

23

and, indeed, for all of us.

2~

bit better idea of what you're doing and maybe appreciate

25

you a little more.

I think that would be an advantage for the state
Your neighbors would have a little
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1

DR. CARRANO:

2

Our next speaker is Tim Hunkapillar.

3

Thank you, Norm.
He's from

Cal Tech.
MR. HUNKAPILLAR:

4

Well, we seem to be bouncing back

5

between what's being optimistic and pessimistic.

6

was optmistic, and I'll say that I'm pessimistic, in the sense

1

of

8

the current level,

9

the data and analyzing the data and this sort of stuff.

10

how hard this problem is.

And Norm

And mine is particularly, at

a computational sort of issue in handling

And one thing we can kind of keep hearing a 3 billion

11

bases and all that sort of stuff.

12

it's an attractible and noble figure.

13

if -- well, the issue is not just that size.

14

the complexity of that data as well as the size of that data,

15

which makes it a significantly different problem.

16

alone is down, forgetting the notion of say 10 to 15 which is

17

like way in the future,

18

bases that are your human genome, more or less complete, you're

19

talking about having an enormous number of other bases.

20

And that sounds --well,
But in reality I think
The issue is

And the size

by the time you have the 3 billion

You're talking about --well, if that's the 3 billion

21

of the single strand

you're talking about having to sequence

22

thousands of clones, of course.

23

of these clones.

24

comes from,

25

that time also a lot of other genomes, or partial genomes, already

You don't have any history

You don't have any record of where this

the annotation of this sequence.
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1

s~quenced.

2

multiple times for comparative analysis.

3

even at that point, which is relatively the foreseeable future,

4

but when you have the first more or less genome of the human

5

now, you will have approximately, say, 100 billion sort of

6

base equivalents of information, whether that's annotation or

7

whether that's bases or whatever.

8
9

You have a lot of pieces of the human genome sequenced

Now,

So it's not unreasonable

that already sort of ranks it as a large data

base by anybody's standards.

There are, in fact,

larger data

10

bases in the world; but, nonetheless, that's a huge amount of

11

information.

12

And I would argue -- I've argued many times on this

13

fact -- that there are problems with that because of its size,

14

because of its complexity that, in fact,

15

sort of paradise for handling it.

16

level and the analytical level.

17

or base equivalents, of course, does not even count the sort

18

of entire literature data bases and the other biological

19

data bases, the NSF sort of ecological data base, stuff like

20

this that all tie back into this sort of stuff where you end

21

up getting terabytes of information eventually.

22

there are not tremendous

That means at the data base
And that 100 billion bases,

Now, nothing we have, either hardware or software

23

or even strategies, come anywhere near approaching this problem.

24

Ancl there's no reason to believe we know how to do it even if

25

we had the money right now.

It's not the issue of "Oh, well,
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1

we just need to build bigger computers or put work stations

2

at everybody's desk."

3

It's not that simple an issue.

It's an issue of rethinking the -- or thinking the

4

process now as to what really are the issues.

5

to do with this data?

6

at a research level how to handle this new paradigm, or construct

7

rew paradigms, with this new model of data.

And start thinking

You have a chromosome that's 250 million bases long.

8

9

How do we manage it?

What do we need

It's not just 250 million a, d,

~·sand

10

all the sort of landmarks.

11

the history of how it was sequenced.

12

are all tied together.

t's in a row.

It's all the context.

It's

It's all

All these sort of things

And as a single sort of data object -- and I could

13
14

be wrong, and I've had this argument with computer scientists

15

but there is no real current sort of model for that.

16

not going to go out into the industry and find somebody that

17

says, "Oh, we've solved that problem.

18

data base system that will do that for you."

19

that actually.

You're

We have a personnel
I've been told

I don't believe it.

So there are issues of research involved here as

20
21

defining these problems.

22

It's a matter of going to NIH, to the DOE, the NSF, or whatever

23

and saying, "He need to do research.

24
25

It's not a matter of just applying.

"

There's no reason to believe right now we know the
approach.

We have to take many approaches and see where they
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1

lead.

And I'm very keen on that notion that there's software

2

approaches to handling these obvious problems and there are

3

hardware.

4

you about it in a second.

5

in that.

I have a keen interest in hardware.

I'll talk to

I have this particular keen interest

Now, this is a very collaborative sort of operation.

6
1

It has to be.

A lot of the sort of stuff we as biologists

8

have used in the past up to this point are both sort of -- while

9

hardware means that we all have our PC's and the lucky ones

10

have a little work station on their desk, and we all have a

11

package of software that was written more often than not by

12

people like me, people who are biologists and thought that

13

they could learn computers.
The level of software, generally-- that doesn't

14
15

mean that there aren't exceptions to this -- but the level of

16

software tools that are available in the world are not

17

state-of-the-art technology.

18

that you're not working on state-of-the-art hardware, you're

19

not even -- at the level of hardware you're using, you're not

20

generally using state-of-the-art software that can take

21

advantage of that hardware.

I mean regardless of the fact

So we're in pretty primitive sort of circumstances

22

23

rignt now in dealing with this data, in managing it, distributing

24

it.

25

at places like GenBank and the NBL people and stuff like this

There are a lot of people -- a lot of effort obviously
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1

that are putting a lot of thought and concern about how to

2

deal at the present time with the data that we have, which is

3

an enormous -- even though it's not 100 billion bytes of data

4

it's an enormous amount of data, again, given its complexity,

5

given the fact that it's being sort of contributed by several

6

thousand people, which is an issue in and of itself.

7

got to keep this thing of complexity in mind.
Now, I have a particular interest.

8

9

So we've

I have a lot of

particular interests, but the one particular interest -- I'll

10

show a quick couple slides of this -- is not a solution.

11

an approach to some of these questions.

12

some of the hardware sort of things that are not using, per se,

13

the computers.

14

It's

We're interested in

The problem with using sort of the general computer

15

model is that the problem is growing you might say logarithmically

16

whereas the speed of computers is not.

17

may be getting a lot faster and a lot cheaper but not at the

18

same rate the problem is growing.

19

up just by relying on the fact that next week you'll have a

20

faster sun on your desk than the week before.

21

to work.

22

The speed of computers

You're not going to keep

It's not going

Just a real quick general notion of what the problem

23

is, one of the bottlenecks is that the notion is on a model

24

with a normal sort of computer architectures that we deal with.

25

If you had data coming in, the data that handled and manipulated
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1

and everything and processed all within the [inaudible] a

2

traditional sort of computer model, the variation on this is,

3

in fact, is to separate out permanent computational question

4

before it gets to the computer.

5

processing and report writing and inferencing and all this

6

sort of stuff that preprocess the data, that you can make

7

simple but very fast.

8

they do them very fast.

9

are essentially the speed of that data transfer, not the speed

10

It's going to do your post

They don't do very many things, but
And you can make those so that they

of your computer.
Now, this is the approach that we are taking.

11

This

12

is the generic notion of how to do this now.

13

have a few collaborations.

14

at U.S.C.

15

multi-disciplinary sort of issues that Mike and I collaborate.

16

We collaborate with computer engineers at JPL and an eventually

17

determined commercial partner as well.

18

units in designing some specialized hardware for dynamic programming

19

avenues that will allow you to compare and search through data

20

bases.

21

We at Cal Tech

One is with Mike Waterman's group

And it's a good paradigm for the sort of collaborative

So there's four essential

Now, we also at Cal Tech, as mentioned by Bob this

22

morning, are collaborating with TRW on an analogous-type system

23

for explicit pattern matching which is the FDF -- TRW/FDF

24

thing.

25

systems for the broader questions of relationships, and the

And both of these systems, both are dynamic programming
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1

n~R

2

based on systolic models.

system for dealing with explicit pattern matching, are

3

Systolic means that you essentially -- you get a

4

lot of little cells, a lot of little tiny cpu's stuck in a

5

row, each one of them does exactly the same thing, and you

6

could have a lot of them.

7

calculation, more or less, and they outbreak by streaming

8

the data, refer to it as systolic because of the pumping.

9

You need to take one byte into the next, into the next, into

10

And what they do, they do one

the next byte, the clock cycle of the computer.

11

So you've got a pumping operation that essentially

12

means that once a day it gets through the [inaudible] it's

13

finished.

14

So you can do it, essentially, as fast as you can read

15

the data.

16

[inaudible].

17

the complexity and the relationships that you'd find, whether

18

it's gaps in insertions or what kind of data is going through

19

there, all this sort of stuff.

20

There's no turning around and thinking about it.

So systolics isn't some generic sort of inherited
It's constant speed which is independent of

The problem with most of this sort of either pattern

21

matching or relational matching sort of schemes now is that

22

you either have huge amounts of membrane or huge [inaudible]

23

process going on that essentially blow up with the length of

24

the data; hence, you can't do them unless you've got a crane

25

sitting on your desk.
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1

And the notion of massive parallelism at the bottom

2

means that you can make these things, essentially, as big as

3

you want to make them.

4

chips in a row, essentially.

5

nevertheless, it's pretty much the model.

6

You just keep putting more and more
I'm simplifying somewhat;

Now, as a paradigm for that, again, the TRW sort of

7

stuff real quick, I'm not going to go through what this is.

8

Well, I'm going to say that it's an actual query going through

9

GenBank.

And I can load into the

FDF system

that is

10

searching things on both the top for the biology, the history,

11

and the sequence.

12

protein and composition and proximity, all this sort of stuff.

13

The sequence has motifs of both DNA and

Now, I can load that in as a query, a single query.

14

Now that means that I can do this query in the time against

15

all of GenBank as fast as I cah GenBank off of my desk.

16

Now, I use this as a cute example; nonetheless, it has

17

limitation.

18

What it does now is significantly noted.

Using systolic sorting systems has tremendous promise

19

in speeding up complex operations.

20

biologists to sit there and make quiries against this huge

21

amount of data in real time.

22

bases even, if this is running at 10 million bases a second,

23

which is a very, very fast disk, you're not going to get it

24

much faster than that, at least for a while, you're still not

25

worried.

It means it allows

Now, of course, at 3 million
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I show this for entertainment value alone.

1

r show

2

that Bob was right this morning about where this technology

3

came from.

4

for where this chip came from.

5

the point that, in fact,

6

in the world.

7

have companies corning to our lab all the time saying, "We have

8

technology.

9

amazing.

10

This was the first slide that TRW ever showed me
But I use it to illustrate

there's an enormous amount of technology

But the notion is that there are people

How can we use it?"

I

And it's actually pretty

And this collaborative effort between industry,

11

between computer scientists, between biologists, between

12

mathematicians can be amazingly productive, and it's something

13

that in California we have a tremendous amount of, so we should

14

encourage it.

15

Thank you.

16

DR. CARRANO:

Our next speaker is Elbert Branscomb

17

from Lawrence Livermore National Laboratory.

18

Ph.D. in theoretical physics.

19

computations at the genome project at Livermore.

20

going to tell us a little bit about hardware and so forth.

21

DR. BRANSCOMB:

Elbert got his

And he's responsible for our
And he's

About a year and half ago at the -- I

22

think it was the second Santa Fe meeting -- Wally Gilbert gave

23

a talk on the Human Genome Project in which he described what

24

biology in the 21st century would be like and emphasized that

25

it would be entirely unlike all the biology that had proceeded
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1

it.

And the picture he drew was of large groups of people

2

sitting in front of large monitors and not getting their hands

3

wet.

4

I think there's no doubt that as several people have said that

5

the biological activity is going to -- biological research is

6

going to see a rather large shift towards people -- towards

7

the task of analyzing a data base, which is rather than having

8

a bunch of data collected by someone who then analyzes it

9

and publishes it, there will be a big shift towards large

And whereas that certainly is not a very pleasant prospect,

10

efforts, industrial efforts, to obtain a large part of the

11

fundamental data base of biology and then that will be a public

12

resource which is analyzed.

13

And that then shifts towards a very heavy burden on

14

data analysis, and it's very likely this will prove to be for

15

the limitations that Tim was just talking about a weight-limiting

16

step in the process.
And part of what I was going to make a few remarks

17
18

about is:

19

And I wanted to just say something about the hardware that's

20

now available.

21

work station can do and what its storage capabilities are.

22

And there's a reliable predicition that about a 10-fold boost

23

in most of those properties will occur within a few years.

21.J.

25

What might we think are the critical problems there?

I was trying to describe what a current good

A typical arrangement for a well-endowed lab is
quite a few of work stations like this slave to a large compute

Pike Court Reporting

189.

1

server over finaudible] which has essentially the powers that

2

work stations will have four years hence.

3

this table will flip and the compute servers will be about

~

10 times bigger.

5

both in hardware and software.

6

And in four years

And it's plain that we will see limitations

I wanted to say a word about the data base.

I don't

7

disagree with the previous speakers about what they will be

8

though, except in some details.

9

very large.

But they are going to be

And the problem is not, however, in the size of

10

the data base.

11

really storage techniques that not very rich people can buy

12

and can store probably all the data we will have in this project

13

10 years hence on a single disk of maybe 200 gigabytes or so,

1~

and that is certainly not the problem.

15

There's just a number of bytes.

There are

I think, in general, we will for most cases be more

16

software limited than we're hardware limited.

17

things that I think that's going to happen to biology is that

18

it will become as compute insatiable as physics.

19

to just mention a few areas in which I think that's going

20

to be the case.

21

One of the

And I wanted

There are the obvious ones about -- in particular,

22

what Tim was just talking about -- involving the sequence

23

analysis, pattern recognition, homology searches, consensus

2~

searches and so on where we have problems at all scales.

25

We don't really know what to doy and we have to figure out
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1

what we should do in principle.

2

it economically, and even when we do, good software is generally

3

not available for reasons having to do with the economics of

4

this problem more than the history of computational science

5

and of the history of the industrial production of computers.

6

We don't [inaudible] for doing

One of the problems that's clearly-- will exhaust

7

all the computational ability

8

the problem of protein folding and predicting protein function

9

from underlying sequence.

for a long time, I think, is

And one of the things that's impressed

10

me about why that's such a profound problem is the fact that

11

the difference between a properly folded and unfolded protein

12

is only a few weak bonds.

13

in many cases to be the result of excluding water access to

14

a very small number of hydrophobic residues, a handful, and

15

that that implies extremely subtle issue about the folding

16

properties, but we are out of our league in trying to compute

17

that straight ahead.

18

will engage us for a long time I think.

19

And, moreover,

that that appears

And it's a very profound problem which

Item No. 4 is an idiosyncratic fantasy of mine and

20

a lot of other people for sure, but in the end of -- or pretty

21

soon after we have gone after genetic analysis, linkage analysis

22

to get where we can in understanding the 3,000 or so most important

23

loci in the catalog, we can then -- we will be empowered and

24

motivated to turn our attention to the more general issues of:

25

How does the genotype orchestrate phenotype?
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And I believe it's arguable, but if we have 1 eM

1

2

VNTR

3

order to get it dense enough to really be functional at

4

1 eM map, with about 70 to 80 percent average heterozygosity,

5

which is apparently what these --what goods the VNTR's deliver,

6

will be in a position to-- and if we can, as I think it's

7

arguable that we -- as I think Charles said earlier -- automate

8

the genetic analysis using these probes, it will be feasible

9

to go a fair way towards genotyping individuals at the l eM

10

11

map, which is characterized by about 5,000 probes in

shot all together.
The fantasy is that we characterize what is the

12

specification of people more or less completely for a complete

13

set of 1 eM VNTR's.

14

been used in some other standard genetic analysis now is

15

that a single 1 eM locus is quite a durable piece of DNA and

16

has, in general, a very respectable history in time.

17

the human population is to one degree or another more or

18

less clonal in single alleles.

19

as having a particular two-point allele,

20

have emphasized the importance of recently, that particular

21

allele will be shared completely by a lot of other people who

22

have the same two-point allele, so that we can in some sense

23

make a rather complete genetic characterization of individuals

24

at that degree of resolution.

25

to look for genotype/phenotype correlations on a population

The advantage of that in principle has

And

So if we characterize someone
Lander and Botstein

And it makes it feasible, I think,
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basis rather than on a kindred basis, and be able to ask a

2
3

very general question.
As Tim emphasized, I think the overpowering problem

4

is that we don't have good software.

We don't have good cheap

5

software to do all these problems.

6

tools in place, though we certainly could,

7

fantasy of having a reasonable, friendly, appropriate and

8

indjvidualized work station which would be -- have common

9

interfaces and be recognizable and talk to everyone and run

We don't have the software
to fulfill Charles'

10

on all sorts of -- talk to everyone in the same language and

11

run on all sorts of hardware.

12

And the critical issue, it seems to me, and an issue

13

where state policy and governmental policy have a very big

14

role is in trying to enforce and further the development of

15

standards which will overcome these problems.

16

matter at a large number of levels in computer design.

17

just tried to indicate a few of the dominant ones here.

18

And the standards
And I

There's the operating system, the window environment,

19

what the windows look like and how do they behave.

You have

20

to sit there and learn a whole new window paradigm every time

21

you sit down at a computer.

22

that talks through the window?

23

for drawing?

24

a Tower of Babel as someone said before.

25

conventions?

What's the visual interface software
What are the graphics conventions

There's very little agreement there.

Pike Court R-eporting

It's really

What are the network

193.

And the last item is one that I think is particularly
2

important and can drive an awful lot of economy here, and that

3

is the prospect of having so-called applications by or near

4

interfaces, which means that you don't have to recompile software

5

to run on one computer or another, but it will run straight

6

across.

7

And there's the prospect now, but stimulated by

8

some's aggression in this field in large part that there will be

9

not one, that's too much to hope for, but maybe five or six

10

such groups of computers that at least within those groups

11

you won't have to cross-compile.

12

that is not, I think,

13

independent so that you can compete vendors against each other,

14

which is important enough, but rather that it would make it

15

economic, much more economic, for people to build software

16

because now it will be -- there will be many, many more customers.

17

And I think that can help us a great deal in getting good software

18

for this problem.

19

enough software development for our problems, particularly if

20

we split ourselves up into lots of groups.

And the big significance of

just that it allows you to be vendor

We are too small a user audience to justify

21

DR. CARRANO:

Thank you, Elbert, catch your breath.

22

Our last speaker is Michael Waterman.

He's a professor

23

of mathematics in biological sciences at the University of

24

Southern California.

25

DR. WATERMAN:

I'm certainly here to speak as a
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1

mathematical scientist.

2

in theoretical physics because I was just told that I have

3

negative time.

~

And I'm glad that my education wasn't

This is supposed to be about hardware and software.

5

And I have a really hard time talking about hardware and

6

software when we don't talk about why we need the hardware

7

and the software.

8

between this session and the next session.

9

run over a little bit of what I think of what the other people

10
11

And so let me -- maybe this is a bridge
So let me just

have said.
Most of what has been talked about today, I think,

12

is data generation.

13

genetic and physical mapping, and they talked about some of

14

the analytical problems entailed therein but not too much.

15

And the reason the analytical problems are interesting, I think,

16

is to get accurate maps in the genetic case and just to decide

17

whether you're going to have your postdoc's

18

years or 50 years on the physical mapping scheme.

19

are worthwhile analyses to perform.

20

People have talked about mapping, both

working five
And those

I think as well there are certainly some

21

hardware/software issues in reading your classical or automated

22

sequencing projects.

23

And that's definitely been talked about.

Tim talked something about after the data is generated

21!

how we're going to manage it.

25

research required there.

He said there was certainly some

And I think there's a point I'd like
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1

2

to make about that.

There's a nucleotide data base as we see it today

3

is called GenBank or NBL's data base, which are almost but

4

not quite the same, and there's a model of sequence that's been

5

published, that's been annotated, .. at least in the literature,

6

and is sort of a final product.

7

I think when we start cruising through genomic

8

sequences, an entirely different model of how to manage the

9

data-- that just hasn't been thought through.

And the management

10

and the access and how we correct stuff after it's out there,

11

whatever percent wrong, is a really interesting problem that

12

people like Cantor are going to have to face.

13

Well, after you've got all this data, I think there's

14

a new piece of action that certainly wasn't around 15 years ago,

15

and that is that you take a look at the sequence and you try

16

to find biological and meaningful patterns and chain.

17

talked about that sort of thing.

18

We

There's one kind of problem -- where's the mathematics

19

or statistics or computer science in this?

20

of problem, if you've got eyes like mine and it's after dark

21

and you're trying to find your way to a specific address in

22

Los Angeles and you pull out the Thomas Guide, it's hard work.

23

Finding your way to an address even when you know, even when

24

you have a map and you know where you are going is hard.

25

that was the Moslim slide that Tim showed basically.
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1

some idea of what they were looking for.

2

What is a lot harder is to find your way around when

3

you don't have a map and you don't know what you're looking

4

for.

5

and a map of New York, what parts look a lot alike?

6

don't know what look alike means.

7

And one of the most exciting versions of it, I think, is

8

predicting protein structure from sequence there.

9

of that.

Or perhaps a better analogy, if you have a map of Los Angeles
Again, you

So that's a hard problem.

It's a version

I think there are a couple of approaches to these

10
11

kinds of problems.

12

does this, buy a great big new Cray

13

it.

14

a lower-scale technology thing, thank goodness, but just new

15

hardware, same old ideas.

16

is getting people to have new ideas.

17

One is to buy a bigger computer.

And NIH

and run the old ideas on

Tim and I are involved in that with generated chips.

It's

And, obviously, what I'm [inaudible]

One of the things as a mathematical scientist interested

18

Ln biology, one of the things that I'm impressed by is how

19

smart biologists are at analyzing their own data.

20

doesn't surprise any biologists, of course.

21

a lot about this, but it requires in the end people who know

22

about both sides of the fence, and there aren't very many of

23

these people around, I don't think.

24
25

Now, that

But you can learn

And that's sort of my pitch today is that

W<'

need-- no one has mentioned education today 1 don't think,
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1

and there are lots of universities here.

We need to train

2

some people who are trained to think in a nontrivial way

3

both about an analytical side of things and about the biological

4

side of things.

5

in each one, some real training.

6

for our universities to come up with these people because they'll

7

be an important part of biology in the end of this and the next

8

century.

And that's -- and I don't mean just two courses
And I think that's a challenge

Thank you.

9
10

DR. CARRANO:

11

I'm going to defer to our moderator here, Winston.

12

DR. SALSER:

13

Well, let's take a few questions and

then a short break.
MR. KISSLER:

14
15

Thank you very much.

I

just wanted to make a statement.

T'm Jerry Kissler.
While this session is going on, there's also another

16

17

session going on on light sources.

Light sources are another

18

technology that rnightbeimportant to this project.

19

a group of people representing basically the same universities

20

and labs that are here working on light sources.

There is

So for any of you who might be interested in compact

21

22

light sources, sort of room-size light sources, at very short

23

close length, there will be a green paper in the back of

24

the room.

25

You might want to check it out.
DR. CARRANO:

Anything else before we turn this back?
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1

MR. BRENNEN:

Thomas Brennen, Genomyx.

2

One of the things that -- is there a unit underway,

3

anything sort of like a biological computer?

When you clone

4

a filter, or something like that, you're actually performing

5

a [inaudible]

6

is there anything -- in other words, as opposed to the sequencing

7

part of it where we have [inaudible].

8

we really need good new technology in the software.

9

there anything like that in progress?

There's a lot of stuff-- biology on silicon,

This is an area where
Is

10

DR. CARRANO:

Who wants to tackle that question?

11

Tom.

12

MR. MARR:

13

There's a group at MIT who has been working on

Tom Marr, Los Alamos.

14

biological materials and how those apply to computing problems.

15

I think they've actually built some prototypes.

16

There's a fellow named Arvin who is a computer

17

scientist whose been working on data flow problems, architectures,

18

who is looking at biological materials as an avenue for

19

implementation.

20

21

22
23
24

25

MR. BRENNEN:

What I meant was actually using biology

as [inaudible) probe on any kind of an actual array.
[At this point, the question went on, but the
reporter was unable to hear the question.]
DR. SALSER:

We're going to take a brief five-minute

break to stretch your legs, and be back here at a quarter till.
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I<ecess

3:40p.m. to 3:53 p.m.

2
DR. SALSER:

3

Before I start the next session, I

4

want to just summarize something from the last session that

5

I was

interested in.
I cornered Tony Carrano, and he has just taken off

6
7

to make his plane, so he won't be able to say it.

8

interested in his project of doing the cosmid overlaps.

9

wasn't clear to me just how far along it was and what the

10

But I was
It

capabilities of the method were as they see it at this point.
And he says that they're starting a project on the

11
12

Chromosome 19 cosmid library that they think that at the rate

13

they're going that they could cover it to a depth of 1 in

14

about a year.

15

on the ABI machine of the restriction digest about two-thirds

16

of the clones they would have analyzed would have an overlap

17

with another member of the set and that about roughly 1 over E

18

of the sequence would be uncovered.

That means that after about a year's sorting

And so in about six months, I guess, he'll be able

19

20

to tell us whether that's working out as they planned.

21

he thinks that they can do it on whole chromosomes.

22

where they're at.

But

And that's

And that is so important, either that or the YAC

23
24

approach,

that I thought it was really useful to summarize

25

the status of that.
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Now I want to introduce the next panel which will

1

2

be moderated by Elizabeth Neufeld.

It turns out that having

3

a Ph.D. from Berkeley was an absolute requirement apparantly

4

for all of today's panel moderators.

5

why that was.

6

the education game earlier than UCLA, not to worry.

And I asked Paul Boyer

And he said that was because Berkeley guarded

Elizabeth has been one of the leaders in studying

7
8

the molecular genetics lysosomal storage diseases.

She

9

served as Chief of the Genetics and Biochemistry Branch of

10

the National Institute of Arthritis, Diabetes, Digestive and

11

Kidney diseases up to 1984.

12

of all those names and came to UCLA as Chair of the Department

13

of Biological Chemistry, which is easier to remember.

And at that point she got tired

Her research accomplishments have been acknowledged

14
15

by a host of scientific awards, which she told me not to

16

go through because it would embarrass her.

17

she was elected to the National

18

recognition of some of her work.

But in 1977

Academy of Sciences in

Dr. Neufeld will introduce her panel which will

19

20

discuss utilization of the data generated by the Genome

21

Project.

22

DR. NEUFELD:

Thank you, Winston.

23

Before I introduce the panelists, I would like to

24

introduce Ellen Philhower who is the stenographer for this

25

meeting.

And she's been assiduously taking notes.
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1

has a very special request of the speakers and the panelists.

2

Jf you have any notes, any transparencies, she would like a

3

copy thereof.

She says that it will make her job much easier.

DR. SALSER:

4

Can I add to that?

If you have copies

5

but you don't want to give them up to her, give them to me

6

and I will xerox them immediately.

7

all around, and you can have your copies and leave them too.

8
9

DR. NEUFELD:

There are xerox machines

Since we are the last panel, we thought

that there might be some issues which have not been touched

10

during the day.

11

at UCLA is going to touch on one such issue, which is:

12

happens when your gene product is not really included in

13

your DNA?

14

And Dr. Simpson, who is a Professor of Biology

DR. SIMPSON:

What

Well, most of my thoughts on this

15

subject have already been mentioned.

16

directly to my one unique thought on this, and that is that

17

I'd like to throw out a cautionary note as to the difficulty

18

in interpretation of raw sequence data that will be generated,

19

the huge amount of raw sequence data, that will be generated

20

in this project.

21

In fact,

So I guess I'll go

I go along with Tim in his thinking that

22

the most practical and the most valuable aspect of this project

23

will come as a result of the effort required to improve the

24

computational aspects.

25

be the development of new Algorisms

I think the most immedate spinoff will
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1

amount of new sequence data and recognize patterns.

2

And in line with that, I think that the most

3

valuable information from the scientific point of view will

4

come from the initial sequencing projects involving the E. coli

5

yeast and Drosophila genomes because there we have a large

6

background of genetic information.

7

testing of hypotheses, which you can't do with a human.
What can we learn from the human data, the human

8

9

We can do experimental

sequence?

Well, we can look for open reading frames.

We can

10

identify known genes by similarity or hemology with genes

11

already in the data base from lower organisms.

12

identify unknown genes that have been previously mapped to

13

precise sites or by prediction of secondary structure or a

14

function of the proteins.

15

We can perhaps

However, in the absence of an experimental genetics

16

approach such inferences are going to be very difficult to make

17

and substantiate.

18

I'd like to add one additional cautionary note stemming

19

from work in my own laboratory, and that is that we either

20

found that in some cases in messenger RNA's in the mitochondria

21

of certain types of protozoa, known as tropatazomes, the

22

nucleotide sequence information encoded in several other

23

messenger RNA's and transcribed from the mitochondria DNA

24

differs from that encoded in the mitochondria DNA.

25

Let me just show this slide.
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1

cartoon just shows what I'm talking about for the nonspecialists

2

here.

3

sequence.

4

RNA sequence we have additional nucleotides, which in our

5

case are all uridines, at specific locations in coding

6

regions which are not present in DNA sequence.

7

uridines there present as thigmodines in the DNA sequence that

8

are not present here.

9

We have a DNA sequence and we have the messenger RNA
And what we found is that in the mature messenger

And we have

The next slide is just an example of this for

10

one particular gene in the mitochondria.

And here is from

11

two different species of these protozoa.

Here is the DNA

12

sequence, and here is the RNA sequence.

13

is that dots indicate uridines that we found in the RNA

14

sequence that are not present in the DNA sequence.

15

these circles indicate thigmadines present in the DNA sequence

16

that are not present in the RNA sequence.

And what you see

And

17

And this is conserved, at least the pattern of

18

the addition of uridines, conserved in these two species

19

that differ by about 100 million years of evolutionary history

20

but the pattern of deletions differs, and they both give

21

rise to exactly

almost the same amino acid sequences.

The next slide -- this just shows how common this

22

23

is.

24

and sequences of which we know.

25

out that this occurs in five genes in this mitrochondria genome.

This just compares the two complete mitochondria genomes
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1

It's not an isolated event with one or two nucleotides.

2

occurs in this gene.

3

15 U's deleted.

4

the indicated number of deletions and additions.

5

[inaudible] it occurs in a very dramatic way in this region

6

here, and now we know this region here, where of 731 nucleotide

7

sequence, 407 are resulting from additional uridines at 145

8

sites and 19 uridines deleted.

There's 29 U's added,

It occurs here, here, here, and here with
And in

So this just shows you -- this is the work of Gene

9

10

There's three here.

lt

Fagan and Ken Stewart, by the way, this last piece of information.

11

So we don't yet understand the mechanism for this,

12

apparently, nontemplated, non-normally-templated sequence

13

information, and we don't know the biological generality of

14

this.

15

always be able to go directly from a DNA sequence to a protein

16

sequence.

But I just want to throw it out to say that you may not

17
18

One should keep this in mind.
DR. NEUFELD:

Does anybody want to comment on

this rather important cautionary note?

19

[No response.]

20

If not, we'll go on to Dr. Esposito who is from

21

the Human Genome Center and is Deputy Director of the Cell

22

an8 Molecular Biology Division at Lawrence Laboratory in

23

Berkeley.

24

to complex human genetic disorders.

25

And he'll talk about the applications of biotechnology

DR. ESPOSITO:

Because the hour is late and time is
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short, and I think most of us have received perhaps more
2

information than we can hopefully deal with, let me assure

3

you that what I want to do is not to talk about the arcane

4

aspects of human genetics and population genetics as it applies

5

to complex human disorders but rather to focus on an issue

6

that arises when we consider the fact that many of the human

7

genetic disorders that are of interest to us are very difficult

8

to study genetically.

9

But as we see the human genome mapping and sequencing

10

project perceived, there is an enormous target of opportunity

11

that develops for California-based biotechnology and pharmaceutical

12

industries, and that is to begin a dialogue, and if I could

13

have the next slide.

14

To begin a dialogue, to start an intent at applying

15

the information to the vast array of very complex human genetic

16

disorders that -- as well as those that are attractable.

17

Now, most of the applications that we've heard

18

about today in mapping refer to wise choices of known simple

19

Mendelian genetic defects in which almost anecdotal analysis

20

of kindreds and pedigrees can lead you to the conclusion that

21

this is a single gene defect.

22

on the part of these investigators.

23

That is a very wise choice

But we know that -- and not only will we be able

24

to proceed to analyze such diseases very carefully, but there

25

are many diseases that are extremely frequent as far as
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1

diseases are concerned.

2

There are many very important human genetic diseases

3

for which we have information that these genes are highly

4

complex, complex in the following sense:

5

more than one genetic locus involved.

6

Two.

There are probably

Complex in the sense that if you have the

7

disease genotype, you don't necessarily get the disease, limited

8

penetrance.

9

I've simply broken down as those associated with the human

And they include a collection of diseases that

10

major HLA.

11

arthritis, multiple sclerosis, and some of them which are

12

complex multi-genic unknown degrees of penetrance -- alzheimer's,

13

epilepsy, asthma, various cancers, schizophrenia, non-insulin

14

dependent diabetes.

15

They include insulin dependent diabetes, rheumatoid

But the interesting thing that has happened in the

16

struggle to understanding complex genetic diseases is that

17

a mathematical apparatus for dealing with such diseases

18

emerged here because in the region of the HLA locus in

19

humans and in other organisms, there is a tremendous degree

20

of polymorphism, genetic polymorphism, which provided markers.

21

So there is a population out there of human geneticists

22

who have the mathematical apparatus in hand.

23

part of the Branscomb fantasy, and I was glad that he mentioned

24

it.

25

very important point to note that we are on the threshold

But I think it's more than a fantasy.
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1

of making an interesting combination between the mathematical

2

apparatus that has evolved to deal with these diseases with

3

the limited amount of genetic information that was available

4

in the emerging map.

5

They are refractory because, as I mentioned, there

6

are multiple disease loci involved.

7

loci involved.

8

necessarily have the disease.

9

difficult to localize.

10

There are many disease

And when you have the genotype, you don't
This makes these diseases

But with the apparatus in hand, that has allowed

11

us to sort out the number of loci involved, the degree of

12

heterogeneity, and make [inaudible) of penetrance; that together

13

with the genetic map will allow us to proceed to other parts

14

of the genome, all of those non-HLA associated diseases which

15

are among the most common human genetic disorders and the most

16

costly to society.

17

And it would seem appropriate that this organization,

18

this loose affiliation or consortium of interested people

19

should reach out to that community and put together some

20

thoughts about how California-based biotechnology could

21

exploit that development.

22

Thank you.

23

DR. NEUFELD:

24

Our next speaker is Dr. Michael Kelly who is President

25

Thank you very much.

of Intelligenetics and will tell us about some computational
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1

aspects.

DR. KELLY:

2

I

just wanted to say that some of the

3

previous speakers depressed me a little bit about the future

4

of computational abilities for the human genome.

5

to be more like the gentleman from ABI and say that we think

6

that there are a few clouds on the horizon, but for the most

7

part I think the sun is shining as far as computational

8

capabilities is concerned for the near future.

9

But I'd like

Today I'd like to talk a little bit about the

10

information generated by the human genome and also the

11

computational needs for the human genome.

12

about that in terms of not about the restriction mapping

13

because I think that was talked about earlier in detail, but

14

more about things such as fragment assembly, the data base

15

hardware and software needs and sequence analysis and

16

specialized data bases that have been generated for the human

17

genome.

18

We'd like to talk

In terms of the computational needs, we have to

19

manage the genetic and the physical maps.

20

the cosmids and the YAC's.

21

of all the sequences that are generated.

22

network communication available worldwide for all the researchers

23

to be able to instantaneously communicate, and we need to analyze

24

the genome and also to look at inter and intrachromosomal

25

interactions.

We have to manage

We need management and analysis
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In terms of fragment assembly, there are a number

1

2

of commercial packages available, and they are quite adequate

3

at analyzing and managing the sequencing of the individual

4

fragments.

5

500 base pair fragments.

We have, as was told to us earlier, we're up to
Now how do we overlap these fragments?

Well, to give you an example of this, and that is

6

7

the proeram GEL.

8

vector sequences so that you can eliminate any of the cosmid

9

sequences included in the sequencing, and also you can

10

It allows you to display and eliminate the

automatically merge these functions.
Surely Intelligenetics will have a program called

11

12

the SymGel out on the PC which will be able to handle over

13

100,000 base pairs.

14

future.

15

in this particular case.

16

us to do millions of base pairs.

And there is no limitation for the

It's only a limitation of the size of the hardware
We have a new Algorisms

that allows

In terms of the generation of all these sequences,

17
18

I'd like to give you some perspective on the growth of GenBank.

19

This is through March of '88.

20

particular time, it was just below 20 million nucleotides,

21

and r,rowing exponentially.

And you can see that it at that

So when Intelligenetics was awarded the contract

22

23

for GenBank, we did an analysis to decide exactly what will

24

be the needs for the next five years since this is a five-year

25

contract.

And on that basis, we started out in 1987 and there
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1

were 15 million nucleotides in the data base at that particular

2

time.

3

that there will be 250 million nucleotides in the data base,

4

but that depends on how fast Dr. Cantor's group and other

5

laboratories move in terms of entering sequences.

6

By 1992 -- and I think this is a little optimistic --

But right now these are the estimates that we have.

7

We will have the capability -- the computer capability -- of

8

the storage of all this data in a relational format, and I'll

9

tell you a little bit more about that later.

10
11

And we estimate

that it will only require about two gigabytes at that time.
There was a previous slide that I think either

12

Tim Hunkapillar or Mike Waterman had that said

13

Branscomb -- that we had -- we need about 1 to 10 gigabytes

14

for the whole human genome.

15

available and software available to access that in a fairly

16

reasonable way.

17

or Elbert

But there is currently hardware

In terms of rapid retrieval, we need to develop a

18

sophisticated network communication with easy access to a

19

PC host-type of system.

20

There is the NSF map which is being developed and will have

21

a fairly wide band width up to 1 megabyte per second, but

22

not every researcher will have access to that currently.

23

And that currently does not exist.

But this is an area where, I think, the NSF and

24

other organizations can take a step in furthering this

25

particular network so that we can access quite rapidly the
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1

information generated.

2

There are natural language communication devices

3

heing generated, both at Intelligenetics and also at Los Alamos

4

among other laboratories for the sequence entry and manipulation.

5

And I'll tell you a little bit more about the software for

6

entry of the data in a little bit.

7

In terms of distribution of the data bases, currently

8

it's released on magnetic tape.

9

two or three reels of magnetic tape to do the whole GenBank

10

release.

11

format, it's about 19

12

not include all the annotation.

13

floppies at the current release.

And right now it takes about

In terms of 1.2 megabyte floppies in compressed
1.2 megabyte floppies, and that does
It's actually about 80

360k

So we have a problem for people using PC's right

14
15

now.

Their arms get tired entering the data.

So what

16

GenBank is going to be doing fairly soon is developing a

17

CD ROM.

18

density.

19

we said 300 in here because we're thinking about adding other

20

data bases to the format as well.

It will be a single entity because we have high-storage
We can store actually close to 500 megabytes, but

21

We are currently under negotiations with PIR and

22

other data bases to try to develop a single system so that

23

it makes it easier for the researcher, but that will require

24

some more negotiations.

25

So this is ideal for the current needs.
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1

costs about $1,000, and it's quite easily accessible from a

2

PC.

3

access times.

4

of this information is dependent upon the time of the type of

5

search done, whether you're doing a straight match, a pattern

6

expansion, a local or a global alignment.

7

type of CPU and the load on that CPU.

8

large VAC's and you have 15 or 20 people on it all doing

9

searches, you can grind it to a halt, and it depends on the

There are some problems with that, however, because of
And so as was stated earlier, the access time

It depends on the

So if you've got a

10

structure of the data base.

11

easily access the portion of the data base that you want to

12

look at and it also depends on the storage medium.

13

this case the CD ROM is a slightly slower mechanism of access

14

of the data.

15

Is it indexed so that you can

And in

But if you want to do an overnight search or something

16

like that, you can do that.

17

Tim Hunkapillar's plea that we have more research done on

18

things like parallel processing and also Mike Waterman's

19

suggestion that we have more education in the area of

20

computational molecular biology.

21

But I would like to second

Now, what about the future directions of the data

22

base?

23

contract, the GenBank contract, in October of '87 the data -- we

24

estimate the data for which GenBank is responsible, not for

25

which European Molecular Biology Laboratory is responsible,

It needs to become more current.
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and GenBank's portion of the overall nucleotide data base
2

represents about two-thirds of the total.

GenBank was somewhere

3

in the range of 80 percent of the data would be in within

4

12 to 14 months of publication.

5

And we recognized that.

And this was totally inadequate.

And there were steps taken by the NIH to improve

6

7

this by providing more resources to allow us to become more

8

current.

9

data -- 80 percent of the data is getting in within five

And as of the last release, we believe that the

10

months.

So there's been a drastic improvement in the currency

11

of the data.

12

much more up to date.

And we expect that trend to continue and become

We want to organize this for more efficient use.

13

14

We will be doing new indexing routines to allow the researchers

15

to access it more rapidly.

16

data bases.

17

structure is being generated mostly through the group at

18

Los Alamos.

19

HGML data base,

20

allow tables and relational linkages to all of the human gene

21

map.

22

We want to develop links to other

And in terms of this, a relational data base

And they are working very closely also with the
and so that the relational structure will

Also, we are developing an author entry set of

23

software.

24

to have the same interface on most computers.

25

working towards that goal so that when the individual researcher

And as Elbert Branscomb was talking about, we need
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1

wants to enter his sequence and annotation information that

2

you will be able to do it with the same format in every type

3

of computer.

~

for both -- it will be on the PC first, and it will be available

5

in the Spring of '89.

6

Macintosh, on the Sun and the VAC systems as we can get that

7

done.

This author entry software will be developed

Also, it will be developed on the

8

And this also, in terms of data bases, is spawning

9

specialized entities that are just coming into the four, and

10

some of these are the cytogenetic map data base, the RFLP map

11

data bases.

12

data base.

13

Roberts' Restriction Enzyme data base, and what we call a

14

Signature Region data base.

15

We already have the Brookhaven Coordinate
VectorBank is a data base of all the plasmids.

In terms of analyzing sequences, as of March there

16

were over 19,000 DNA sequences and over 6,000 protein sequences.

17

And we ought to look at them in terms of their structural and

18

their functional properties.

19

In terms of sequence patterns, we're looking at

20

groups of bases or amino acids associated with a particular

21

function or aspect.

22

tata box and consensus sequences for DNA or proteins.

23

Examples of this, of course, are the

Key Bank is a data base of known sequence patterns.

24

And this has been generated by Intelligenetics as reported

25

in the scientific literature.

Pike Court Reporting

And currently in Key Bank we

215.

1

have over 1300 entries of known structure function-type

2

relationships.

3

they're classified into categories and then indexed.

4

currently have 16 categories of protein keys and 112 categories

5

of nucleic acid keys.

These entries are all fully referenced.

And

And we

Examples of these categories are amino acid modifications,

6
7

signal sites, binding sites, enzyme active and allosteric sites,

8

regulatory regions, binding sites and repeats and ends.
Key Bank was designed for use with the Quest program.

9
10

Quest searches the sequence files for key words and sequence

11

patterns.

12

It retrieves sequences while searching.

13

ambiguities and boolean operators in the patterns and allows

14

patterns to be combined to form complex patterns.

15

It searches the single sequence or many sequences.
It allows use of

There's another program on the PC which does similar

16

things for the protein.

It's called Procyte.

And here is an

17

example of actually delineating.

18

something like 120 individual signatures or patterns that

19

can be delineated on proteins.

20

the next version of PC Gene.

And currently we have

And this will be coming in

21

In summary, we think the Human Genome Project will

22

generate vast numbers of large sequences, cosmids, YAC's and

23

restriction maps.

24

for better distribution, storage, access times and use.

25

we think that new computational tools as well as the existing

The data base growth will generate needs
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1

computational tools will be needed to analyze this data.

2

DR. NEUFELD:

3

I think we'll go on to Dr. Marr who comes from

Thank you very much.

4

Los Alamos Laboratories.

5

on computational aspects.

6

DR. MARR:

And we'll continue this discussion

Unless I have to, I think I'll go ahead

7

and stand here and use what few relevant slides I have

8

left myself.

9

Not knowing who was going to be here or what was

10

going to be discussed, I sort of naively put this set of

11

overheads together.

12

bother going over some of the things that have been discussed

13

here already.

So I think it's clear that I shouldn't

14

Let me just put up one thing that hasn't been clearly

15

pointed out to the group, and that is some of the computational

16

complexities involved with some of the problems that have

17

been discussed here today.

18

If N represents the length of the sequence, and

19

complexity is some index of -- well, in this case -- the time

20

to compute, being proportional to -- in the case of similarity

21

searching -- the length of the sequence squared.

22

looking at some of the real interesting problems that confront

23

us in going over the examining the DNA sequences.

24

25

We start

We see that the problem gets complicated very quickly
as we move from the relatively simple problem of similarity
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1

searching, which is the thing that GenBank is used for on a

2

daily basis.

3

to see what it looks like so they go through and apply some

4

type of searcl, Algorisms

5

be similar to some other pattern that exists in the data base.

6

Somebody sequenced a piece of DNA, and they want

to GenBank, and it shows up to

Well, as we start looking at predicting RNA secondary

7

structure from primary sequence, we see that complexity or

8

time to compute goes up as the cue of the length of the sequence

9

and to the where the most interesting, in my opinion, problems

10

is predicting tertiary structure from primary sequence data.

11

And I don't know what that really scales at, but it's apparently

12

some large number.

13

do this for a tetramer.

Right now it takes one cray, one hour, to

14

And if you think on the average --what's that?

15

DR. SALSER:

16

DR. MARR:

Tetramer of what?
If you take primary sequence and you

17

do a good calculation to come up with tertiary structure, it

18

takes about one cray, one hour.

19

it on PC's, et cetera, but they're not believable structures

20

they end up with.

21

There are simpler ways to do

This is using a Monte Carlo approach to energy

22

minimization in the structure.

23

to do this over a larger piece of DNA, it gets up into many

24

thousands of cray one hours very quickly.

25

So if you think -- if you want

So that's some more numerical view of the complexity
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that we're confronted with.
2

It has come up that what the speakers are doing is

3

viewing this problem from different backgrounds.

4

is in evolutionary biology and system science.

5

challenge that this is really -- or the new things that the

6

DNA technology is opening up to evolutionary biologists, of

1

course, is being able to test hypotheses that we've made

8

glaring assumptions about for many years, that is evolution

9

within populations.

10

My background
And the

Now we can measure gene frequencies, allelic frequencies,

11

in populations by looking at distributions of Jeffry's-type

12

probes in populations.

13

We can apply the DNA technology to very practical wildlife

14

management problems.

15

whooping cranes and tell who is related to whom.

16

if we're going to be doing artificial insemination studies, we

17

shouldn't be pairing brothers and sisters in that situation.

18

So I think the technology in a broader sense opens

We're not involved in doing that.

So we can go in and take blood from
And, therefore,

19

up a whole range of new problems to other types of scientists.

20

And that's what I think is exciting about potential spinoffs.

21

DR. NEUFELD:

Thank you very much.

22

Our last speaker is going to address an issue which

23

I think has been omitted from much of today's discussions; namely,

24

where are we going to get the manpower to do all this computing

25

and biology?
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1

Dr. Steven Dahms is a Professor of

ClH~mistry

at

2

San Diego State University, and he's also the Director of

3

the California State University Program For Education Research

4

in Biotechnology, which is a nice acronym of C-SUPERB.

5

DR. DAHMS:

I'll try and keep my comments brief.

6

This topic doesn't address how or with what the initiative

1

will be conducted, but by whom.

8

biotechnology training programs, both in predoctoral, postdoctoral

9

levels as well as below.

10

It relates directly to

My initial comments will temporarily disregard the

11

mapping and sequencing initiative and will focus instead on

12

current manpower demands and projections in California and

13

training programs in the biotech arena.

14

I do this largely because the new and existing

15

programs have not taken into account the potential initiative

16

to any extent.

17

My initial comments will focus upon the NIH and

18

California.

19

challenged in the Fall of '87 by the U.S. Senate largely to

20

the action of Senator

21

was doing and the biotech arena that involved biotech research

22

and training.

23

NIH has recently addressed the problem.

Chiles

It was

to assess what the NIH

It charged the NIH with supplying an internal

24

analysis to the Senate by the end of January and also with

25

establishing an advisory panel to establish the needs for
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1

2

new training programs and to make recommendations therefore.
The report was submitted to Wyngaarden on February 1st,

3

by Wyngaarden on February 1st to the Senate.

4

appointed and met at the end of March for several day.

5

focused upon specific areas to be developed in the biotech

6

arena on all levels of instruction.

7

It's a matter of public record.

8

discussion on manpower needs on the Ph.D., Masters, Bachelor's

9

level and the Associate Arts' degree level as well from the

10
11

And a panel was
It

I won't go into that.

There was a considerable

11 academic panel members and the six corporate members.
Considerable focus was on the trends of:

What's

12

happening in the next 10 years with regard to faculty replacements

13

in the United States in the sciences?

14

A good example of the problem that exists now is

15

in California is:

What will be happening within the California

16

State University system in the next 10 years where between

17

40 and 60 percent of all faculty will be turning over?

18

With about 20,000 faculty in the system, this means that in

19

the next 10 years about 750 faculty will be hired in chemistry

20

and biology.

21

be occurring in the corporate biotech arena.

At the same time the exponential hirings will

22

Well, finally the report was submitted first to

23

the Senate and eventually it was incorporated into Chiles

24

and was a bill that was entitled "Biotech Competitiveness" and

25

resulted in $2.7 in new money to NIH.
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1

$5 million, but NIH didn't separate it correctly.

It's

2

resulted in 150 new predoctoral trainingships in the biotech

3

arena and a number of postdoctoral and some in the M.D. side

4

as well.
A lot of the discussion focused on the predoctoral

5

6

level.

7

reinterpreting the word predoctoral to mean pro pre level

8

of training programs in the biotech arena below the Ph.D.

9

granting area.

10

And I think in the next year the NIH might be

Moving onto California in particular.

With about

11

20 percent of corporate U.S. biotechnology in San Diego our

12

all Molecular Biology Institute and the State Biotech Program

13

have conducted a survey in that area on the needs for the next

14

five years.

15

800 Bachelor's, 300 Master's and 200 Ph.D.'s in the next

16

five years.

17

You might be surprised that these translate to

A recent committee composed of Salk/Scripps' corporate

18

CEO's have in turn projected a need for at least 200 Associate

19

of Arts degree level individuals for San Diego.

20

a new phenomenon on the west Coast, and it appeared to be

21

popular on the East coast.

22

in California, more and more junior colleges moving into

23

so-called biotechnology training positions to conduct some

24

of these activities.

25

And this is

So I what I think you'll be seeing

We have not completed the survey in the Bay Area,
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It's

1

but the initial figures agree with those in San Diego.

2

clear that we're going to have difficulty meeting those manpower

3

needs between UCSD and San Diego State, and major problems

4

exist.
The impact of the sequencing initiative has not been

5

It's important to realize that not

6

addressed in any surveys.

7

only are manpower needs to be considered for the Ph.D and

8

Masters' and Bachelor's level and below for the initiative

9

but for life thereafter in the life sciences, that is thereafter

10

the sequence initiative is completed.
I think once Dr. Salser gave projections of 4500

11

12

man years.

13

today that assuming a dollar were a base pair, and three

14

billion base pairs, and 8 to 10 man years per $1 million

15

expense, this translates to about 30,000 man years.

16

want to do this over a five-year period, that means 6,000

17

personnel, and that's at 3 billion base pairs, not a 100 billion

18

base pairs, the panel has not evaluated any data of this type

19

to consider where it should be going.

20

far is to project a program within five years that will have

21

1500 Ph.D. trainees in the works.

22

If you take the suggestion by Norman Whiteley earlier

If you

All NIH has done so

Right now this first year there will be 150.

Elementation

23

will take place next year for another 150, plus 300 more.

24

it will be building.

25

So

The 6,000 personnel needed nationally, very conservative
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1

estimates, assuming 10 percent goes to California, that means

2

roughly a 25 percent increase in demand projected in the

3

next five years.

4

could be 10-fold higher due to spinoff technologies and

5

related endeavors.

6

the number of Ph.D.'s and non-Ph.D. 's isn't clear; but, generally,

7

it's about a 5 to 1 ratio of non-Ph.D. 's to Ph.D.'s in this

8

area.

What the real figure is nobody knows.

It

What this translates to in terms of

According to the evaluation, the impact upon the

9
10

manpower pool needs to be conducted in California with about

11

360,000 students in the California State University system

12

and 140 in the U.C., together there's about a 20 percent

13

coverage of higher education in the United States.

14

might be wise for a joint CSU/UC committee to evaluate

15

manpower needs in defining new facilities and new training

16

programs.

17

It

CSU is contributing quite significantly to meet

18

these manpower needs through a modest number of Ph.D.'s that

19

are produced, but in particular to a large number of Masters'

20

and Bachelor's level people that are brought through strong

21

research programs.

22

training programs, non-degree,

23

have been established.

24

and other individuals.

25

There are a number of novel alternate
that in specific biotechnologies

They involved postdoc's, technicians

Biotech training programs at UCSU are in the exponential
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phase resulting in new research programs being established
2

and training programs, but these, I emphasize, have been

3

conducted without new state monies and have impacted existing

4

programs and facilities as much as it has clearly within the

5

uc.

6

I guess there are several take-home lessons.

7

California we're having severe difficulty meeting manpower needs

8

now.

9

not much unless we take action soon.

What will be able to do with the initiative?

In

Probably

Secondly, NIH has not considered the sequencing

10
11

initiative.

12

advisory panel that this be discussed as soon as possible.

It needs to.

And it has been recommended to the

Thirdly, a number of other federal agencies are

13
14

initiating new biotechnology training programs.

And it's

15

clear that there's not much communication taking place between

16

the agencies, and this should be taking place.
Lastly, there was a quotation earlier today, something

17

18

to the effect that "I hope our aspirations don't exceed our

19

abilities."

20

aspirations in the manpower arena are not greater than our

21

abilities to provide it."

I'd modify that somewhat to say, "I hope our

22

Thank you.

23

DR. NEUFELD:

24

DR. SALSER:

25

that is:

Are there questions from the audience?
I have a question for Dr. Kelly, and

Are you planning to support the next computer or
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1

will its unit system be compatible with some software package

2

you're already supplying?

3

DR. KELLY:

4

the next computer.

5

viable as a system.

We are not currently planning on supporting
We are waiting to see when it will be

6

DR. SALSER:

7

DR. KELLY:

Do you have reservations about that?
Yes, only since we've only seen the

8

initial stages of it.

9

will be a viable system.

10

DR. BOYER:

And we're waiting to see whether it

I have a question for Dr. Dahms.

If

11

UCLA -- one of the depressing statistics is the fraction

12

of the entering freshman class that indicate an interest

13

in science and chemistry and biology as a major.

This is

14

down dramatically from what it was a decade ago.

There's only,

15

I think, something about half or 60 percent or as many

16

indicating this interest.

17

I wonder if that's the same trend you have in the

18

state college system.

19

class of freshman is indicating an interest in science as a

20

major.

21

DR. DAHMS:

A much smaller fraction of our entering

I think it's a national phenomenon.

22

clearly been a discussion on the NIH advisory panel level.

23

There's even been discussion of NIH putting money into high

24

school instructor training programs so that they can affect

25

the quality and numbers of students who elect careers in
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1

science.

2

professional societies.

3

that the NSF has not sufficiently addressed.

4

agency that should do it.
DR. AVDALOVIC:

5
6

It's a subject of discussion among a number of
I think it's a national phenomenon
It is the

I have a question and a suggestion

which I didn't have a chance to make during my presentation.

7

We all realize that there is a big problem

8

UNIDENTIFIED SPEAKER:

9

up somewhat.

10

11

You probably should move that

DR. AVDALOVIC:

I didn't want to obstruct you with

the first question.

12

-- is to promote some postdoctoral projects with

13

the interdisciplinary education with emphasis on computer

14

applications because we all see the need for a cross hybridization

15

between molecular biology and computer sciences.

16

What we have here is more a lack of good and

f~esh

17

ideas and approaches than a lack of computational speed.

18

So that could be perhaps one of the proposals for interdisciplinary

19

postdoctoral programs.

20

The question which I had is for Dr. Kelly.

Last

21

month at the human genome meeting in Valencia, Rich Roberts

22

from Cold Spring Harbor raised a very interesting question

23

asking:

24

on computer?

25

might be perhaps faster expedited if we had the access to the

Are there any efforts in the arena of literature
In other words, all these efforts in human genome
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1

rea

[inaudible] through the computer to access to the data

2

like structural analysis, crystalography data and so on.

3

A e there any efforts in that area?

4

something feasible?

5
6

DR. KELLY:

Do you think that is

Could you rephrase that question?

I'm

not quite sure that I understand.

7

DR. AVDALOVIC:

Access to the real articles.

When

8

you retrieve the sequence you get a sequence, but you would

9

like to know what that sequence does.

10

into protein somewhere.

11
12

This is translated

DR. KELLY:

So the complete article in an electronic

form?

13

DR. AVDALOVIC:

14

DR. KELLY:

Yes.

I think there are some indications that

15

people want to put journals on CU ROM.

16

information only would occur through programs such as Quest

17

or other programs such as that where you do key word searches

18

currently.

19

The access to that

There needs to be more research in that area.

And

20

I don't think there is a strong effort to do that.

21

we are not starting to put the abstracts of articles on the

22

system.

23

abstract system, Bionet will be a vehicle for them to look at

24

the abstracts electronically.

25

DR. MARR:

On Rionet

So if individual journals want to have an electronic

I might be able to say something about
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1

that as well.
We've been talking to Dennis Benson at the National

2
3

Library of Medicine.

4

numbers and pull up abstracts out of MedLine from the medical

5

literature.

6

puts significant

7

National Library of Medicine for them to digitize the primary

8

literature, then the technology is there to do it.

9

a little slow right now, but certainly within the next few

10

years high-speed communications networks will be available

11

to support full text retrieval in pointers across network

12

data bases.

13
14

Right now we can take GenBank accession

It's just a question of dollars.

If somebody

a sufficient amount of money into the

It may be

So it's just to point out to funding agencies the
requirement for that.

15

DR. KELLY:

Along with that, there is an experimental

16

program that NLM has generated called IRX that will do a

17

sophisticated type of key word search.

18

19

DR.DAHMS:

Could I comment on your statement about

the postdoctoral training programs?

20

The new program that has just come on line within

21

the past month, the first deadline for application, I think,

22

is January 1.

23

for industry interactions in the predoctoral and postdoctoral

24

level.

25

It would cover that clearly.

It's looking

And if I could provide another comment to Dr. Boyer.
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1

The most recent publications in the National Academy of

2

Science indicate that students make their decision on

3

Pntorinp, a careor in science usually at the latest hy th0

4

lOth grade.

5

made to influence students to elect science as a career.

6

And there are some activities within the state now in the

7

molecular life science arena that are doing this.

8
9

So there is a concerte

effort that has to be

There's a collaborative program between San Francisco
State and Santa Cruz that is bringing high school students

10

through DNA training programs in the summer in an attempt

11

to educate them and affect them to the point of increasing

12

the number of students electing science as a career.

13

DR. NEUFELD:

14

Larry.

15

DR. SIMPSON:

Any other comments?

I'd like to make a comment about

16

commercially available software for analysis of sequences.

17

I realize that by the time it gets to be commercially available,

18

it's certainly not state-of-the-art, but it's what is available

19

to most people out there in the field.

20

And I'd just like to say that most of the packages

21

are foreign sequence unfriendly.

22

understand why, but they try to be self-sufficient and

23

self-contained whereas the user out there, the noncomputer

24

expert who just wants to use and understand the sequences,

25

has to use the best things of this package, the best parts of
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1

that package, and the best parts of that package.

So should

2

be easily able to switch from package to package.

And part

3

of this problem is simple sequence format problems.

4
5

I'd just like to emphasize that this is a major
problem for the user.

6

DR. NEUFELD:

7

DR. SALSER:

Thank you very much.
Well, I thought that the best way

8

to wrap this up would be for me to twist Charles Cantor's

9

arm to give us his overview.

10

with little notice to do that.

11

this over to him.

12

DR. CANTOR:

And he has graciously agreed
And so I'm going to turn

As if you haven't heard enotigh from

13

me already.

14

more than five minutes just summing up what I think are the

15

main things that were said today.

16

What I thought I would do is spend, I hope, no

The title is the Human Genome Projects.

And I would

17

contend that one of the things that you heard today, at least

18

within the United States, is that there is only one project,

19

that DOE and NIH seem very likely to be sufficiently

20

coordinated so that there really is no discord between them.

21

It remains to be seen whether this coordination can be spread

22

internationally.

23

within the U.S.

24

25

Issues.

But I'm optimistic about what's happening

I think there really are two major issues

that we have to keep in mind.
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1

major concern with the biological community that led originally

2

to a lot of oppositjon to the project was the fear that it would

3

sap resources on traditional biological research.

4

that this simply hasn't happened.
And it hasn't happened for two reasons.

5

I think

One,

thus

6

far we've been successful at raising new money for the project,

7

roughly $46 million dollars in totally new money in fiscal

8

'89.

We have to make sure this continues.
Two, the project has been broadened in its definition

9
10

and scope so that it actually encompasses quite a bit of what

11

was traditional, albeit, fairly high-tech biology.

12

it probably is actually providing indirectly additional funding

13

from mainstream biology labs and sapping it.

14

important that we make sure that that be the trend.

And so

I think it's

The second issue that I want to touch on briefly is

15
16

the ethical issue.

17

project are quite considerable.

18

they are quantitative and qualitative.

19

being raised by the Human Genome Project, just the existing

20

issues are being amplified.

21

we face those issues early in the game and up front and deal

22

with them.

23

I think the ethical consequences of this
But from all I've heard,
There are no issues

And I think it's important that

I think Jim Watson mentioned this morning that he

24

plans to use some NIH funds for education.

25

struck by thus far is that the agencies have made -- especially
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DOE and also NIH

small efforts to educate the press.

And

2

if you have very few bucks to spend on education, it seems

3

to me this is probably the best place you could put it right

4

now because if we can get more accurate reporting on what's

5

going on, we will educate a large number of people.

6

those are the key issues.

7

Goals.

I think

It strikes me that there's a remarkable

8

consensus at this point as to what the short-term goals of

9

the project ought to be.

And considering how new the project is,

10

this is very satisfying.

I think we will be mapping.

11

be developing techniques.

12

major hurdle is to try and organize the informanics and

13

computing aspects of the project.

14

where at least nationally, and probably internationally,

15

efforts will be made to try to orchestrate things properly.

16

We will

We all agree that at this stage a

That's clearly the arena

I think we also all agree, although it came very

17

late in today's discussion, that the project today is

18

people limited, and it's likely to be so for quite a considerable

19

time.

20

the Human Genome Project somehow.

21

say about goals.

22

So it's critical to build a training component into
That's what I wanted to

One other thing about goals, you heard an enormous

23

spectrum, especially in this afternoon's session, of optimism

24

and pessimism.

25

actually trying to do the work with their own hands.

I think that's appropriate for people who are
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1

think it's simply a natural part of human nature and science.

2

And as always, I'm in the middle of the road.

3

the optimists are right.

4

right.

5

p;oing.

I don't think

I don't think the pessimists are

This project is going, and it's going to continue

I want to talk about California for a second.

6

I

7

think the simplest thing I can say is that I don't think any

8

other state could put together such a program with only

9

one exception, only people whose home is or will be in this

10

state.

Since the project is people limited, it's destined

11

that California will play a major role in the project so long

12

as it holds all these people.

13

The only bad note is that it's quite clear from

14

what was said this morning that you have to have two jobs

15

to somehow succeed.

16

That's a little taxing to say the least.

I think that one other way that I could just in the

17

process of arranging for a meetin& which will be held in

18

October in San Diego on the Human Genome Project, co-sponsored

19

by Science Magazine and by the Human Genome Organization,

20

and in organizing a meeting, you usually worry about your

21

travel budget.

22

all the people we wanted that we don't have any trouble with

23

our travel budget because so many of them come from California

24

that it's not going to be so bad.

25

And I was very surprised as we began to invite

Finally, let me turn to what I still consider to be
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1

the most difficult challenge with this project, and that is

2

organization.

3

told what to do, and justifiably we resist it.

4

also used to a system in which people sort of individually

5

compete in many research areas, and the person who eets

6

there first almost beautifully gets the awards.

7

We as scientists are simply not used to being
And we're

Those concepts have to change a bit if you're

8

talking about live science.

I mean the physicists have

9

gotten used to the fact that they have 50 or 60 people working

10

on a physics project at a major accelerator center.

11

somehow, even though someone was 50th over, they get a Ph.D.

12

And the biologists haven't dealt with this problem yet of

13

how you coordinate very large efforts and share the credit

14

in an appropriate way.

15

And

And I think a model to this has its strains but

16

also it's successes is the search for the Huntington's disease

17

gene coordinated by the Hereditary Disease Foundation

18

represented by Nancy Wexler who is in the back of the room.

19

That project has been going for four years, and it is

20

coordinating internationally, seven or eight research groups,

21

which have their cooperation and their intentions.

22

But I think it serves as a pretty good local

23

since it's California

24

for biologists to carry out relatively large collaborative

25

research effort and still remain friends.

model for the fact that it's possible
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1

So I think that's what I wanted to say.

I look

2

forward to another meeting of this type, hopefully, with

3

even more optimism.

4

DR. SALSER:

Thank you, Dr. Cantor.

5

you all for participating.

6

as this project goes forward.

And thank

And I hope we see you again

7

8

[Thereupon the hearing was concluded at 5:46p.m.]
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